

=> file medicine cancerlit scisearch biosis embase wpids uspatfull
FILE 'MEDLINE' ENTERED AT 10:02:54 ON 28 AUG 1998
FILE 'CANCERLIT' ENTERED AT 10:02:54 ON 28 AUG 1998
FILE 'SCISEARCH' ENTERED AT 10:02:54 ON 28 AUG 1998
COPYRIGHT (C) 1998 Institute for Scientific Information (ISI) (R)
FILE 'BIOSIS' ENTERED AT 10:02:54 ON 28 AUG 1998
COPYRIGHT (C) 1998 BIOSIS(R)

FILE 'EMBASE' ENTERED AT 10:02:54 ON 28 AUG 1998
COPYRIGHT (C) 1998 Elsevier Science B.V. All rights reserved.
FILE 'WPIDS' ENTERED AT 10:02:54 ON 28 AUG 1998
COPYRIGHT (C) 1998 DERWENT INFORMATION LTD

FILE 'USPATFULL' ENTERED AT 10:02:54 ON 28 AUG 1998
CA INDEXING COPYRIGHT (C) 1998 AMERICAN CHEMICAL SOCIETY (ACS)

=> s 312c2

1 312C2
d 11 1bib ab

L1 ANSWER 1 OF 1 WPIDS COPYRIGHT 1998 DERWENT INFORMATION LTD

ACCESSION NUMBER: 98-159534 [14] WPIDS

DOC. NO. CPI: C98-051555

TITLE: Isolated ***312C2*** T cell gene - used to develop products for treating, e.g. cancers, auto-immune disorders, transplantation rejection and other T cell disorders.

DERWENT CLASS: B04 D16

INVENTOR(S): GORMAN, D M; RANDALL, T D; ZLOTNIK, A

PATENT ASSIGNEE(S): (SCHE) SCHERING CORP

COUNTRY COUNT: 75

PATENT INFORMATION:

PATENT NO KIND DATE WEEK LA PG

WO 9806842 A1 980219 (9814)* EN 71

RW: AT BE CH DE DK EA ES FI FR GB GH GR IE IT KE LS LU MC MW NL

OA PT SD SE SZ UG ZW

W: AL AM AU AZ BA BB BG BR BY CA CN CZ EE GE HU IL IS JP KG KR

KZ LC LK LR LT LV MD MG MK MN MX NO NZ PL RO RU SG SI SK SL

TJ TM TR TT UA UZ VN YU

AU 9740556 A 980306 (9830)

PUBLICATION DETAILS:

PATENT NO KIND APPLICATION DATE

WO 9806842 A1 WO 97-US-13831 970814

AU 9740556 A AU 97-40556 970814

FILING DETAILS:

PATENT NO KIND PATENT NO

AU 9740556 A Based on WO 9806842

PRIORITY APPLN INFO: US 96-27901 961007; US 96-689943 960816

AB WO 9806842 A UPAB: 980406

Pure or recombinant ***312C2*** protein (A) or a conservatively

modified variant is new.

Also claimed are:

(1) an antibody which specifically binds a protein as in (A);

(2) an isolated or recombinant nucleic acid which encodes a

312C2 protein or peptide;

(3) a recombinant nucleic acid comprising a sequence having at

least 70% identity over a stretch of at least 30 nucleotides to a

312C2 nucleic acid sequence as shown;

(4) an expression or replicating vector comprising a nucleic

acid as in (2), and

USE - The ***312C2*** proteins are expressed in the thymus

and are induced on T cells and spleen cells following activation.

Engagement of ***312C2*** stimulates proliferation of T cell

clones, antigen-specific proliferation and cytokine production by

T-cells, and potentiates T cell expansion or apoptosis.

The products can be used in the treatment of conditions

associated with abnormal physiology or development, including

abnormal proliferation, e.g. cancerous conditions or degenerative

conditions. They can be used in the regulation or development of

haematopoietic cells, e.g. lymphoid cells which affect immunological

responses, e.g. autoimmune disorders.

In particular the products can be used to treat rheumatoid

arthritis, systemic lupus erythematosus (SLE), Hashimoto's

autoimmune thyroiditis, as well as acute and chronic inflammatory

responses in which T cell activation, expansion, and/or

immunological T cell memory play an important role. They can also be

used in disorders in which abnormal T cell responses are of

importance, e.g. in a transplantation rejection situation. They can

be used to mediate T cell interactions with other cell types leading

to, e.g. cell proliferation, enhanced cytokine synthesis by the

cells and consequential amplification of T cell proliferation.

The products can also be used to redirect T cell responses,

e.g. towards a Th0/Th1 pathway or towards a Th2 type response.

The products can also be used for detection, diagnosis or drug

screening.

Dwg.00

=> s (t)(cell or t(w)lymphocyte or thymocyte

L2 397502 T(T) CELL OR T(W) LYMPHOCYTE OR THYMOCYTE

=> s receptor

L3 1875287 RECEPTOR

=> s co-stimulat?

L4 4810 CO-STIMULAT?

=> s l2 and l3 and l4

L5 1185 L2 AND L3 AND L4

=> s proliferat? or activat? or divid? or growth

L6 5520103 PROLIFERAT? OR ACTIVAT? OR DIVID? OR GROWTH

=> s l5 and l6

L7 1080 L5 AND L6

=> s antigen(8a)spect? or antigen(8a)target?

L8 194581 ANTIGEN(8A) SPECIF? OR ANTIGEN(8A) TARGET?

=> s l7 and l8

L9 234 L7 AND L8

=> dup rem

ENTER L# LIST OR (END):l9

PROCESSING COMPLETED FOR L9

L10 148 DUP REM L9 (86 DUPLICATES REMOVED)

=> s l10 and ((nucleic(w)acid or dna or cdna or gene or

polynucleotide)(4a)encod?)

L11 52 L10 AND ((NUCLEIC(W) ACID OR DNA OR CDNA OR GENE OR

POLYNU

LCEOTIDE(4A) ENCOD?)

=> d 111 1-52 1bib ab

L11 ANSWER 1 OF 52 MEDLINE
ACCESSION NUMBER: 97054641 MEDLINE
DOCUMENT NUMBER: 97054641
TITLE: ***Antigen*** - ***specific***
targeting of CD28-mediated T cell ***co***
- ***stimulation*** using chimeric single-chain
antibody variable fragment-CD28 ***receptors***

AUTHOR: Alvarez-Vallina L; Hawkins R E

CORPORATE SOURCE: Centre for Protein Engineering, MRC Centre,
Cambridge, GB

SOURCE: EUROPEAN JOURNAL OF IMMUNOLOGY, (1996 Oct) 26
(10)

2304-9.

Journal code: EN5 ISSN: 0014-2980.

PUB. COUNTRY: GERMANY: Germany, Federal Republic of

Journal: Article, (JOURNAL ARTICLE)

LANGUAGE: English

FILE SEGMENT: Priority Journals; Cancer Journals

ENTRY MONTH: 199702

ENTRY WEEK: 19970204

AB T cells require two distinct signals for optimal ***activation***

. One is an ***antigen*** - ***specific*** signal and is

provided by engagement of the T cell ***receptor*** (TCR). The

second is an antigen-independent signal mediated by engagement of

the T cell surface molecule CD28 with members of the B7 family. To

endow CD28 molecules with antibody-type recognition, we have

constructed chimeric single-chain antibody variable fragment

(scFv)-CD28 molecules; following transfection of the ***genes***

encoding such constructs into the Jurkat human T cell line

we show that they are stably expressed as functional cell surface

receptors. These chimeric molecules have no apparent

negative effects on the expression and signaling ability of the

wild-type CD28 and TCR/CD3 molecules. When combined with signaling

via the TCR/CD3 complex, these ***antigen*** - ***specific***

scFv-CD28 chimeric molecules provide signals similar to those

elicited by the cross-linking of the unmodified CD28 molecules.

Furthermore, the generation of double transfectants simultaneously

expressing scFv-CD28 and scFv-CD3 zeta chimeras demonstrates that

antigen - ***specific*** ***co*** - ***stimulatory***

signals can also synergize with signals mediated through chimeric

CD3 zeta chains to secrete maximal levels of interleukin-2. Overall,

our results suggest that optimal, predefined ***antigen*** -

specific ***activation*** of T cells directed by the

specificity of the scFv should be possible.

L11 ANSWER 2 OF 52 WPIDS COPYRIGHT 1998 DERWENT

INFORMATION LTD

ACCESSION NUMBER: 95-131352 [17] WPIDS

DOC. NO. NON-CPI: N95-103189

DOC. NO. CPI: C95-060672

TITLE: Novel ***cDNA*** ***encoding*** human

receptor protein H4-1BB - useful to produce

the protein which is used to treat autoimmune

disease and facilitate organ transplantation.

DERWENT CLASS: B04 D16 S03

INVENTOR(S): KWON, B S

PATENT ASSIGNEE(S): (INDV) UNIV INDIANA FOUND

COUNTRY COUNT: 34

PATENT INFORMATION:

PATENT NO KIND DATE WEEK LA PG

WO 9507984 A1 950323 (9517)* EN 36

RW: AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE

W: AU BY CA CH CN CZ DE DK ES FI GB HU JP KR LT LU LV NL NO

NZ RU SE SI SK UA

AU 9477294 A 950403 (9529)

EP 719329 A1 960703 (9631) EN

R: AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE

JP 06503911 W 970422 (9726) 35

NZ 273838 A 970922 (9745)

APPLICATION DETAILS:

PATENT NO KIND APPLICATION DATE

WO 9507984 A1
AU 94-77294 A
EP 94-928141 940915
WO 94-928141 940915
JP 09503911 W
NZ 94-273838 940915
WO 94-928141 940915

FILING DETAILS:

PATENT NO KIND PATENT NO
AU 9477294 A Based on WO 9507984
JP 719329 A1 Based on WO 9507984
JP 09503911 W Based on WO 9507984
NZ 273838 A Based on WO 9507984

PRIORITY APPLN INFO: US 93-122796 930916
AB WO 9507984 A UPAB: 950508
A ***cDNA*** (I) ***encoding*** for human ***receptor***
protein H4-1BB is new

USE - The use of H4-1BB to block H4-1BB ligand (H4-1BBL) finding has practical applic. in the suppression of the immune system during organ transplantation. The MAb against H4-1BB can be used to enhance T-cell ***proliferation*** by treating T-cells that have expressed ***receptor*** protein H4-1BB with the anti-H4-1BB MAb. Tumours transfected with H4-1BB may be capable of delivering ***antigen*** ***specific*** signals as well as the ***co*** ***stimulatory*** signals and can be killed by human cytotoxic ***T*** ***lymphocytes***
Dwg/05

L11 ANSWER 3 OF 52 USPATFULL
ACCESSION NUMBER: 1998-98602 USPATFULL
TITLE: Gene coded for interleukin-2 polypeptide, recombinant DNA carrying the said gene, a living cell line possessing the recombinant DNA, and method for producing interleukin-2 using the said cell

INVENTOR(S): Taniguchi, Tadatsugu, Tokyo, Japan
Muramatsu, Masami, Tokorozawa, Japan
Sugano, Haruo, Tokyo, Japan
Matsui, Hiroshi, Yokohama, Japan
Kashima, Nobukazu, Yokohama, Japan
Hamuro, Junji, Yokohama, Japan

PATENT ASSIGNEE(S): Ajinomoto Co., Inc., Tokyo, Japan (non-U.S. corporation)

NUMBER DATE

PATENT INFORMATION: US 5795777 980818
APPLICATION INFO.: US 96-621057 960322 (8)
RELATED APPLN. INFO.: Continuation of Ser. No. US 95-516563, filed on 18 Aug 1995 which is a continuation of Ser. No. US 91-814049, filed on 26 Dec 1991, now patented, Pat. No. US 5620868 which is a continuation of Ser. No. US 89-332364, filed on 3 Apr 1989, now abandoned which is a continuation of Ser. No. US 87-36309, filed on 7 Apr 1987, now abandoned which is a continuation of Ser. No. US 83-463496, filed on 3 Feb 1983, now patented, Pat. No. US 4738927

NUMBER DATE

PRIORITY INFORMATION: JP 82-51122 820331
JP 82-82509 820518
JP 82-219518 821215
JP 82-229619 821224
JP 82-234607 821227
JP 82-230371 821229

DOCUMENT TYPE: Utility
PRIMARY EXAMINER: Martineil, James
LEGAL REPRESENTATIVE: Oblon, Spivak, McClelland, Maier & Neustadt, P.C.
NUMBER OF CLAIMS: 18

EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 11 Drawing Figure(s); 10 Drawing Page(s)
LINE COUNT: 1523
AB A gene coded for a polypeptide which possesses interleukin-2 is isolated, and connected with a vector DNA which is capable of replicating in a prokaryotic or eucaryotic cell at a position downstream of a promoter gene in the vector obtaining a recombinant DNA, with which the cell is transformed to produce interleukin-2.

L11 ANSWER 4 OF 52 USPATFULL
ACCESSION NUMBER: 1998-98795 USPATFULL
TITLE: ***Gene*** ***encoding*** interleukin-2 polypeptide, recombinant ***DNA*** carrying the gene, a living cell line possessing the recombinant DNA and method for producing interleukin-2 using the cell

INVENTOR(S): Taniguchi, Tadatsugu, Tokyo, Japan
Muramatsu, Masami, Tokorozawa, Japan
Sugano, Haruo, Tokyo, Japan
Matsui, Hiroshi, Yokohama, Japan
Kashima, Nobukazu, Yokohama, Japan
Ajinomoto Co. Inc., Tokyo, Japan (non-U.S. corporation)

NUMBER DATE

PATENT INFORMATION: US 5795769 980818
APPLICATION INFO.: US 95-516563 950818 (8)
RELATED APPLN. INFO.: Continuation of Ser. No. US 91-814049, filed on 26 Dec 1991, now patented, Pat. No. US 5260868 which is a continuation of Ser. No. US 89-332364, filed on 3 Apr 1989, now abandoned which is a continuation of Ser. No. US 87-36309, filed on 7 Apr 1987, now abandoned which is a continuation of Ser. No. US 83-463496, filed on 3 Feb 1983, now patented, Pat. No. US 4738927

NUMBER DATE

PRIORITY INFORMATION: JP 82-51122 820331
JP 82-82509 820518
JP 82-219518 821215
JP 82-229619 821224
JP 82-234607 821227
JP 82-230371 821229

DOCUMENT TYPE: Utility
PRIMARY EXAMINER: Martineil, James
LEGAL REPRESENTATIVE: Oblon, Spivak, McClelland, Maier & Neustadt, P.C.

NUMBER OF CLAIMS: 4

EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 10 Drawing Figure(s); 10 Drawing Page(s)
AB A gene coded for a polypeptide which possesses interleukin-2 is isolated, and connected with a vector DNA which is capable of replicating in a prokaryotic or eucaryotic cell at a position downstream of a promoter gene in the vector obtaining a recombinant DNA, with which the cell is transformed to produce interleukin-2.

L11 ANSWER 5 OF 52 USPATFULL
ACCESSION NUMBER: 1998-95405 USPATFULL
TITLE: Secreted protein, BA3.1, and polynucleotides encoding same

INVENTOR(S): Bowman, Michael, 50 Aldrich Rd., Canton, MA, United States 02021

NUMBER DATE

PATENT INFORMATION: US 5792628 980811
APPLICATION INFO.: US 97-818163 970314 (8)
DOCUMENT TYPE: Utility
PRIMARY EXAMINER: Grimes, Eric
ASSISTANT EXAMINER: Longton, Enrique D.
LEGAL REPRESENTATIVE: Brown, Scott A.
NUMBER OF CLAIMS: 13

EXEMPLARY CLAIM: 1
LINE COUNT: 1440
AB A novel secreted protein, BA3.1, is disclosed. Polynucleotides encoding BA3.1 are also provided.

L11 ANSWER 6 OF 52 USPATFULL
ACCESSION NUMBER: 1998-86944 USPATFULL
TITLE: Secreted proteins and polynucleotides encoding them

INVENTOR(S): Jacobs, Kenneth, Newton, MA, United States
McCoy, John M., Reading, MA, United States
LaValle, Edward R., Tewksbury, MA, United States
Rade, Lisa A., Acton, MA, United States
Merberg, David, Acton, MA, United States
Treacy, Maurice, Chestnut Hill, MA, United States
Spaulding, Vikki, Billerica, MA, United States
PATENT ASSIGNEE(S): Genetics Institute, Inc., Cambridge, MA, United States (U.S. corporation)

NUMBER DATE

PATENT INFORMATION: US 5786465 980728
APPLICATION INFO.: US 96-721489 960927 (8)
RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 96-686878, filed on 26 Jul 1996

DOCUMENT TYPE: Utility

PRIMARY EXAMINER: Walsh, Stephen
ASSISTANT EXAMINER: Kaufman, Claire M.
LEGAL REPRESENTATIVE: Brown, Scott A.; DesRosier, Thomas J.
NUMBER OF CLAIMS: 20
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 2 Drawing Figure(s); 2 Drawing Page(s)
LINE COUNT: 1564
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Novel polynucleotides and the proteins encoded thereby are disclosed.

L11 ANSWER 7 OF 52 USPATFULL

ACCESSION NUMBER: 1998-75403 USPATFULL
TITLE: MYPPPY variants of CTLA4 and uses thereof

INVENTOR(S): Linsley, Peter S., Seattle, WA, United States
Ledbetter, Jeffrey A., Seattle, WA, United States
Peach, Robert, Edmonds, WA, United States
PATENT ASSIGNEE(S): Bristol-Myers Squibb Company, Princeton, NJ, United States (U.S. corporation)

NUMBER DATE

PATENT INFORMATION: US 5773253 980630
APPLICATION INFO.: US 95-505058 950721 (8)
RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 94-228208, filed on 15 Apr 1994 which is a continuation-in-part of Ser. No. US 93-8898, filed on 22 Jan 1993

DOCUMENT TYPE: Utility

PRIMARY EXAMINER: Spector, Lorraine M.
ASSISTANT EXAMINER: Lazar-Wesley, Eliane
LEGAL REPRESENTATIVE: Mandel & Adriano
NUMBER OF CLAIMS: 17
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 10 Drawing Figure(s); 9 Drawing Page(s)
LINE COUNT: 1493

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention provides CTLA4 mutant molecules as ligands for the B7 antigen. Methods are provided for expressing CTLA4 mutant molecules as soluble, functional molecules, for preparing CTLA4 mutant fusion proteins, and for using these soluble molecules to regulate T cell interactions and immune responses mediated by such interactions.

L11 ANSWER 8 OF 52 USPATFULL

ACCESSION NUMBER: 1998-75369 USPATFULL
TITLE: Method to identify compounds which modulate ICAM-related protein interactions

INVENTOR(S): Gallatin, W. Michael, Seattle, WA, United States
Vazeux, Rosemary, Seattle, WA, United States
PATENT ASSIGNEE(S): ICOS Corporation, Bothell, WA, United States

(U.S. corporation)

NUMBER DATE

PATENT INFORMATION: US 5773218 980630
APPLICATION INFO.: US 95-462882 950607 (8)
RELATED APPL. INFO.: Division of Ser. No. US 94-286754, filed on 5 Aug 1994 which is a continuation-in-part of Ser. No. US 93-102852, filed on 5 Aug 1993, now abandoned which is a continuation-in-part of Ser. No. US 93-9266, filed on 22 Jan 1993, now abandoned And Ser. No. US 92-894061, filed on 5 Jun 1992, now abandoned which is a continuation-in-part of Ser. No. US 92-889724, filed on 26 May 1992, now abandoned which is a continuation-in-part of Ser. No. US 92-827689, filed on 27 Jan 1992, now abandoned

DOCUMENT TYPE: Utility

PRIMARY EXAMINER: Allen, Marianne P.

ASSISTANT EXAMINER: Brown, Karen E.

LEGAL REPRESENTATIVE: Marshall, O'Toole, Gerstein, Murray & Borun

NUMBER OF CLAIMS: 2

EXEMPLARY CLAIM: 1

NUMBER OF DRAWINGS: 39 Drawing Figure(s); 34 Drawing Page(s)

LINE COUNT: 5498

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB ***DNA*** sequences ***encoding*** a novel human intercellular adhesion molecule polypeptide (designated "ICAM-R") and variants thereof are disclosed along with methods and materials for production of the same by recombinant procedures. Binding molecules specific for ICAM-R and variants thereof are also disclosed as useful in both the isolation of ICAM-R from natural cellular sources and the modulation of ligand/ ***receptor*** binding biological activities of ICAM-R.

L11 ANSWER 9 OF 52 USPATEFULL

ACCESSION NUMBER: 1998:72709 USPATEFULL

TITLE: ICAM-related protein fragments

INVENTOR(S): Gallatin, W. Michael, Seattle, WA, United States

Vazeux, Rosemay, Seattle, WA, United States

PATENT ASSIGNEE(S): ICOS Corporation, Bothell, WA, United States

(U.S. corporation)

NUMBER DATE

PATENT INFORMATION: US 5770686 980623
APPLICATION INFO.: US 95-474368 950607 (8)
RELATED APPL. INFO.: Division of Ser. No. US 95-425870, filed on 20 Apr 1995, now abandoned which is a continuation of Ser. No. US 93-102852, filed on 5 Aug 1993, now abandoned which is a continuation-in-part of Ser. No. US 93-9266, filed on 22 Jan 1993, now abandoned which is a continuation-in-part of Ser. No. US 92-894061, filed on 5 Jun 1992, now abandoned which is a continuation-in-part of Ser. No. US 92-889724, filed on 26 May 1992, now abandoned which is a continuation-in-part of Ser. No. US 92-827689, filed on 27 Jan 1992, now abandoned

NUMBER DATE

PRIORITY INFORMATION: WO 93-US787 930126
DOCUMENT TYPE: Utility
PRIMARY EXAMINER: Walsh, Stephen
ASSISTANT EXAMINER: Brown, Karen E.
LEGAL REPRESENTATIVE: Marshall, O'Toole, Gerstein, Murray & Borun
NUMBER OF CLAIMS: 5
EXEMPLARY CLAIM: 2,4
NUMBER OF DRAWINGS: 38 Drawing Figure(s); 30 Drawing Page(s)
LINE COUNT: 3927

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB ***DNA*** sequences ***encoding*** a novel human intercellular adhesion molecule polypeptide (designated "ICAM-R") and variants thereof are disclosed along with methods and materials for production of the same by recombinant procedures. Binding molecules specific for ICAM-R and variants thereof are

also disclosed as useful in both the isolation of ICAM-R from natural cellular sources and the modulation of ligand/ ***receptor*** binding biological activities of ICAM-R.

L11 ANSWER 10 OF 52 USPATEFULL

ACCESSION NUMBER: 1998:68988 USPATEFULL

TITLE: Use of Interleukin-4 ***receptors*** to inhibit biological responses mediated by interleukin-4

INVENTOR(S): Mosley, Bruce, Seattle, WA, United States

Cosman, David J., Seattle, WA, United States

Park, Linda, Seattle, WA, United States

Bednmann, M. Patricia, Poulsbo, WA, United States

March, Carl J., Seattle, WA, United States

Izderda, Rejean, Seattle, WA, United States

PATENT ASSIGNEE(S): Immunex Corporation, Seattle, WA, United States

(U.S. corporation)

NUMBER DATE

PATENT INFORMATION: US 5767065 980616
APPLICATION INFO.: US 95-466324 950606 (8)
RELATED APPL. INFO.: Division of Ser. No. US 93-94669, filed on 20 Jul 1993, now patented, Pat. No. US 5599905 which is a division of Ser. No. US 90-480694, filed on 14 Feb 1990 which is a continuation-in-part of Ser. No. US 89-370924, filed on 23 Jun 1989, now abandoned which is a continuation-in-part of Ser. No. US 89-326156, filed on 20 Mar 1989, now abandoned which is a continuation-in-part of Ser. No. US 89-319438, filed on 2 Mar 1989, now abandoned which is a continuation-in-part of Ser. No. US 88-285047, filed on 31 Oct 1988, now abandoned

DOCUMENT TYPE: Utility

PRIMARY EXAMINER: Draper, Garnette D.

LEGAL REPRESENTATIVE: Anderson, Kathryn A.; Wight, Christopher L.

NUMBER OF CLAIMS: 21

EXEMPLARY CLAIM: 1

NUMBER OF DRAWINGS: 37 Drawing Figure(s); 21 Drawing Page(s)

LINE COUNT: 2668

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Mammalian Interleukin-4 ***receptor*** proteins find use in inhibiting biological activities of IL-4. A method for suppressing an IL-4-dependent immune or inflammatory response in a mammal, including a human, by administering an effective amount of soluble IL-4 ***receptor*** (sIL-4R) and a suitable diluent or carrier.

L11 ANSWER 11 OF 52 USPATEFULL

ACCESSION NUMBER: 1998:65363 USPATEFULL

TITLE: Method of making MHC-peptide complexes using metal chelate affinity chromatography

INVENTOR(S): Nag, Bishwajit, Pacifica, CA, United States

PATENT ASSIGNEE(S): Amgen, Inc., Redwood City, CA, United States

(U.S. corporation)

NUMBER DATE

PATENT INFORMATION: US 5763585 980609
APPLICATION INFO.: US 94-227372 940414 (8)
RELATED APPL. INFO.: Continuation-in-part of Ser. No. US 93-136216, filed on 13 Oct 1993, now abandoned
DOCUMENT TYPE: Utility
PRIMARY EXAMINER: Caputa, Anthony C.
LEGAL REPRESENTATIVE: Townsend and Townsend and Crew LLP
NUMBER OF CLAIMS: 11
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 14 Drawing Figure(s); 8 Drawing Page(s)
LINE COUNT: 1761

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention provides a method for the purification and characterization of MHC-peptide complexes useful in ameliorating immunological disorders, such as, for example, autoimmune diseases, allergic responses and transplant responses. The method disclosed is a one-step method based on the use of metal chelate affinity chromatography to separate the MHC-peptide complexes of

interest from both uncomplexed MHC molecules and other endogenous MHC-peptide bound complexes.

L11 ANSWER 12 OF 52 USPATEFULL

ACCESSION NUMBER: 1998:61171 USPATEFULL

TITLE: Immunogenic LHRH peptide constructs and synthetic

universal immune stimulators for vaccines

INVENTOR(S): Ladd, Anna Elfin, Brooklyn, NY, United States

Wang, Chang Yi, Cold Spring Harbor, NY, United States

Zamb, Timothy Joseph, Stony Brook, NY, United States

States

Patent Assignee(S): United Biomedical, Inc., Hauppauge, NY, United States (U.S. corporation)

NUMBER DATE

PATENT INFORMATION: US 5759551 980602

WO 9425060 941110

APPLICATION INFO.: US 95-446692 951226 (8)

WO 94-US4832 940428

951226 PCT 371 date

951226 PCT 102(e) date

RELATED APPL. INFO.: Division of Ser. No. US 95-488351, filed on 7 Jun 1995

DOCUMENT TYPE: Utility

PRIMARY EXAMINER: Smith, Lynette F.

LEGAL REPRESENTATIVE: Morgan & Finnegan, LLP

NUMBER OF CLAIMS: 15

EXEMPLARY CLAIM: 1

NUMBER OF DRAWINGS: 37 Drawing Figure(s); 37 Drawing Page(s)

LINE COUNT: 3752

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB This invention relates to immunogenic luteinizing hormone releasing hormone (LHRH) peptides that lead to suppression of LHRH activity in males or females. When male rats are immunized with these peptides, serum testosterone drops and androgen-dependent organs atrophy significantly. These peptides are useful for inducing infertility and for treating prostatic hyperplasia, androgen-dependent carcinoma, prostatic carcinoma and testicular carcinoma in males. In females, the peptides are useful for treating endometriosis, benign uterine tumors, recurrent functional ovarian cysts and (severe) premenstrual syndrome as well as prevention or treatment of estrogen-dependent breast cancer. The subject peptides contain a helper T cell epitope and have LHRH at the C terminus. The helper T cell epitope aids in stimulating the immune response against LHRH. The peptides, optionally contain an invasion domain which acts as a general immune stimulator. In another aspect this invention relates to immunogenic synthetic peptides having an invasion domain, a helper T cell epitope and a peptide hapten and methods of using these peptides to treat disease or provide protective immunity. The peptide haptens of the invention include LHRH, amylin, gastrin, gastrin releasing peptide, IgE CH4 peptide, Chlamydia MOMP peptides, HIV V3 peptides and Plasmodium berghei.

L11 ANSWER 13 OF 52 USPATEFULL

ACCESSION NUMBER: 1998:47964 USPATEFULL

TITLE: Methods and materials for the induction of T cell

energy

INVENTOR(S): de Boer, Mark, Beverwijk, Netherlands

Conroy, Leah B., Pacifica, CA, United States

PATENT ASSIGNEE(S): Chiron Corporation, Emeryville, CA, United States

(U.S. corporation)

NUMBER DATE

PATENT INFORMATION: US 5747034 980505

APPLICATION INFO.: US 94-200716 940218 (8)

RELATED APPL. INFO.: Continuation-in-part of Ser. No. US 93-15147, filed on 9 Feb 1993 which is a

continuation-in-part of Ser. No. US 92-910222, filed on 9 Jul 1992, now patented, Pat. No. US 5397703

DOCUMENT TYPE: Utility

PRIMARY EXAMINER: Loring, Susan A.

LEGAL REPRESENTATIVE: Pochopien, Donald J.; Saveriede, Paul B.;

Blackburn, Robert P.
NUMBER OF CLAIMS: 17
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 24 Drawing Figure(s); 13 Drawing Page(s)
LINE COUNT: 2155
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Anti-B7-1 antibodies or other B7-1 ligands may be used to prevent or treat a T-cell-mediated immune system disease in a patient or to induce ***antigen*** - ***specific*** tolerance.

The anti-B7-1 antibodies may be used to cause T cell anergy, treat allograft transplant rejection, treat graft versus host disease, and prevent or treat rheumatoid arthritis. An immunosuppressive agent is co-administered with the antibody.

L11 ANSWER 14 OF 52 USPATFULL
ACCESSION NUMBER: 1998-30871 USPATFULL
TITLE: Induction of ***antigen*** - ***specific***
I - ***lymphocyte*** responses by stimulation with peptide loaded MHC class I molecules on antigen processing defective mammalian cell lines
INVENTOR(S): Meisler, Cornelis J. M., Haarlem, Netherlands
Kast, Wybo M., Leiden, Netherlands
PATENT ASSIGNEE(S): Rijksuniversiteit Leiden, Leiden, Netherlands (non-U.S. corporation)
Seed Capital Investments (SCI) B.V., Utrecht, Netherlands (non-U.S. corporation)

NUMBER DATE
PATENT INFORMATION: US 5731160 980324
APPLICATION INFO: US 92-888943 920526 (7)
DOCUMENT TYPE: Utility
PRIMARY EXAMINER: Capata, Anthony C.
LEGAL REPRESENTATIVE: Hoffmann & Baron, LLP
NUMBER OF CLAIMS: 10
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 11 Drawing Figure(s); 9 Drawing Page(s)
LINE COUNT: 1222
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Induction of an ***antigen*** - ***specific*** - ***lymphocyte*** response in a ***I*** - ***lymphocyte*** culture, e.g. a primary cytotoxic ***I*** - ***lymphocyte*** (CTL) response, by leading antigen-presenting vehicles which carry empty MHC molecules with an antigen-derived T-cell-immunogenic MHC-binding peptide, culturing ***I*** - ***lymphocytes*** in the presence of the peptide-loaded ***antigen*** - presenting vehicles under ***specific*** - ***lymphocyte*** - response-inducing conditions. Optionally, an ***antigen*** - ***specific*** - ***lymphocyte*** is isolated from the resulting culture and cultured. The process can be used for preparing CTL which are ***specific*** for viral or other foreign ***antigens***, or CTL which are ***specific*** for autologous peptides. The process can also be used for the identification of peptides that are capable of binding to MHC and inducing a T cell response.

L11 ANSWER 15 OF 52 USPATFULL
ACCESSION NUMBER: 1998-28196 USPATFULL
TITLE: Secreted proteins and polynucleotides encoding them
INVENTOR(S): Jacobs, Kenneth, Newton, MA, United States
McCoy, John M., Reading, MA, United States
LaValle, Edward R., Tewksbury, MA, United States
Racie, Lisa A., Acton, MA, United States
Merberg, David, Acton, MA, United States
Treacy, Maurice, Chestnut Hill, MA, United States
Evans, Cheryl, Brookline, MA, United States
Spaulding, Vikki, Billerica, MA, United States
PATENT ASSIGNEE(S): Genetics Institute, Inc., Cambridge, MA, United States (U.S. corporation)

NUMBER DATE
PATENT INFORMATION: US 5728819 980317
APPLICATION INFO: US 96-691641 960802 (8)

DOCUMENT TYPE: Utility
PRIMARY EXAMINER: Walsh, Stephen
ASSISTANT EXAMINER: Kaufman, Claire M.
LEGAL REPRESENTATIVE: Brown, Scott A.; DesRosier, Thomas J.
NUMBER OF CLAIMS: 21
EXEMPLARY CLAIM: 1
LINE COUNT: 1864
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Novel polynucleotides and the proteins encoded thereby are disclosed.

L11 ANSWER 16 OF 52 USPATFULL
ACCESSION NUMBER: 1998-25081 USPATFULL
TITLE: Inhibition of II synthesis
INVENTOR(S): Humphreys, Robert E., Acton, MA, United States
Xu, Minzhen, Northborough, MA, United States
PATENT ASSIGNEE(S): University of Massachusetts, Boston, MA, United States (U.S. corporation)

NUMBER DATE
PATENT INFORMATION: US 5726020 980310
APPLICATION INFO: US 96-661627 960611 (8)
DOCUMENT TYPE: Utility
PRIMARY EXAMINER: Elliott, George C.
ASSISTANT EXAMINER: McGarry, Sean
LEGAL REPRESENTATIVE: Farrell, Kevin M.
NUMBER OF CLAIMS: 23
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 1 Drawing Figure(s); 1 Drawing Page(s)
LINE COUNT: 824
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Disclosed are expressible reverse gene constructs, and oligonucleotides, which are characterized by the ability to hybridize with an II mRNA molecule, thereby inhibiting translation of the II mRNA molecule. These compositions are referred to generally as inhibitors of II expression. Also disclosed are MHC class II-positive antigen presenting cells containing an inhibitor of II expression. A particularly important class of MHC class II-positive antigen presenting cells are malignant MHC class II-positive antigen presenting cells (e.g., leukemia, lymphoma and melanoma). Also disclosed are methods which results in the display of an autodeterminant peptide, in association with an MHC class II protein, on the surface of an MHC class II-positive ***antigen*** presenting cell. In such methods, a ***specific*** inhibitor of II synthesis is introduced into an MHC class II-positive ***antigen*** presenting cell. The ***specific*** inhibitor functions, directly or indirectly, through the formation of a duplex molecule with mRNA encoding II. The formation of the duplex molecule functions to inhibit II synthesis at the translational level. Also disclosed are therapeutic methods for the treatment of malignancy in an MHC class II-positive antigen presenting cell, and autodeterminant peptides which are isolated from an MHC class II-positive antigen presenting cell.

L11 ANSWER 17 OF 52 USPATFULL
ACCESSION NUMBER: 1998-22079 USPATFULL
TITLE: Secreted proteins and polynucleotides encoding them
INVENTOR(S): Jacobs, Kenneth, Newton, MA, United States
McCoy, John M., Reading, MA, United States
LaValle, Edward R., Tewksbury, MA, United States
Racie, Lisa A., Acton, MA, United States
Merberg, David, Acton, MA, United States
Treacy, Maurice, Chestnut Hill, MA, United States
Spaulding, Vikki, Billerica, MA, United States
PATENT ASSIGNEE(S): Genetics Institute, Inc., Cambridge, MA, United States (U.S. corporation)

NUMBER DATE
PATENT INFORMATION: US 5723315 980303
APPLICATION INFO: US 96-702344 960823 (8)
DOCUMENT TYPE: Utility
PRIMARY EXAMINER: Walsh, Stephen
ASSISTANT EXAMINER: Kaufman, Claire M.

LEGAL REPRESENTATIVE: Brown, Scott A.; Sprunger, Suzanne A.; DesRosier, Thomas J.
NUMBER OF CLAIMS: 20
EXEMPLARY CLAIM: 1
LINE COUNT: 2437
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Novel polynucleotides and the proteins encoded thereby are disclosed.

L11 ANSWER 18 OF 52 USPATFULL
ACCESSION NUMBER: 1998-21893 USPATFULL
TITLE: Compositions and methods for use of IL-12 as an adjuvant
INVENTOR(S): Scott, Phillip, Swarthmore, PA, United States
Trinchieri, Giorgio, Wynewood, PA, United States
PATENT ASSIGNEE(S): The Trustees of the University of Pennsylvania, Philadelphia, PA, United States (U.S. corporation)
The Wistar Institute of Anatomy & Biology, Philadelphia, PA, United States (U.S. corporation)

NUMBER DATE
PATENT INFORMATION: US 5723127 980303
APPLICATION INFO: US 96-621493 960325 (8)
RELATED APPL. INFO: Division of Ser. No. US 94-265087, filed on 17 Jun 1994, now patented, Pat. No. US 5571515 which is a continuation-in-part of Ser. No. US 94-29282, filed on 18 Apr 1994, now abandoned
DOCUMENT TYPE: Utility
PRIMARY EXAMINER: Smith, Lynette F.
LEGAL REPRESENTATIVE: Howson and Howson
NUMBER OF CLAIMS: 8
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 13 Drawing Figure(s); 7 Drawing Page(s)
LINE COUNT: 1293
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Improved vaccine compositions and methods of making same are provided, which vaccines are characterized by an antigen from a pathogen and an effective adjuvant amount of Interleukin-12. These IL-12 adjuvanted vaccines are capable of increasing the vaccinated host's cell mediated immune response to provide an increased and protective immune response to the pathogen. Also disclosed are methods for vaccinating hosts by administering a vaccine containing an antigen from a pathogenic microorganism and co-administering an adjuvant amount of IL-12. Vaccines or therapeutic compositions directed against a cancer may also be adjuvanted with IL-12 according to this invention.

L11 ANSWER 19 OF 52 USPATFULL
ACCESSION NUMBER: 1998-17059 USPATFULL
TITLE: Transgenic animal model for autoimmune diseases
INVENTOR(S): Harian, David M., Potomac, MD, United States
June, Carl H., Rockville, MD, United States
PATENT ASSIGNEE(S): The United States of America as represented by the Secretary of the Navy, Washington, DC, United States (U.S. government)

NUMBER DATE
PATENT INFORMATION: US 5718883 980217
APPLICATION INFO: US 94-197790 940217 (8)
RELATED APPL. INFO: Continuation-in-part of Ser. No. US 93-48042, filed on 14 Apr 1993, now abandoned
DOCUMENT TYPE: Utility
PRIMARY EXAMINER: Campbell, Bruce R.
LEGAL REPRESENTATIVE: Spevack, A. David; Mandragouras, Amy E.; Lahive & Codfield, LLP
NUMBER OF CLAIMS: 19
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 32 Drawing Figure(s); 11 Drawing Page(s)
LINE COUNT: 1941
AB A transgenic animal, whose germ cells and somatic cells contain a transgene including a ***DNA*** sequence ***encoding*** a

CD28 ligand and a tissue-specific promoter operably linked to the DNA sequence, wherein the tissue-specific promoter effects expression of the CD28 ligand in cells of a specific tissue of the animal is disclosed. This animal serves as a transgenic model for specific autoimmune diseases.

L11 ANSWER 20 OF 52 USPATFULL
ACCESSION NUMBER: 1998:14915 USPATFULL
TITLE: Interleukin-4 ***receptors***
Antibodies that are immunoreactive with
INVENTOR(S): Mosley, Bruce, Seattle, WA, United States
Cosman, David J., Seattle, WA, United States
Park, Linda, Seattle, WA, United States
Beckmann, M. Patricia, Poulsbo, WA, United States
March, Carl J., Seattle, WA, United States
Izterdia, Rejan, Seattle, WA, United States
PATENT ASSIGNEE(S): Immunex Corporation, Seattle, WA, United States
(U.S. corporation)

NUMBER DATE

PATENT INFORMATION: US 5717072 980210
APPLICATION INFO.: US 95-465169 950605 (8)
RELATED APPL. INFO.: Division of Ser. No. US 93-94689, filed on 20 Jul 1993, now patented, Pat. No. US 5599905 which is a division of Ser. No. US 90-480694, filed on 14 Feb 1990 which is a continuation-in-part of Ser. No. US 89-370924, filed on 23 Jun 1989, now abandoned which is a continuation-in-part of Ser. No. US 89-326156, filed on 20 Mar 1989, now abandoned which is a continuation-in-part of Ser. No. US 89-319438, filed on 2 Mar 1989, now abandoned which is a continuation-in-part of Ser. No. US 88-265047, filed on 31 Oct 1988, now abandoned

DOCUMENT TYPE: Utility
PRIMARY EXAMINER: Feise, Lila
ASSISTANT EXAMINER: Reeves, Julie E.
NUMBER OF CLAIMS: 6
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 38 Drawing Figure(s); 22 Drawing Page(s)
LINE COUNT: 2553
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Mammalian antibodies that are immunoreactive with Interleukin-4 ***receptor*** proteins, ***DNAs*** and expression vectors ***encoding*** mammalian IL-4 ***receptors***, and processes for producing mammalian IL-4 ***receptors*** as products of cell culture, as well as antibodies that are immunoreactive with IL-4 ***receptors***. A method for suppressing an IL-4-dependent immune or inflammatory response in a mammal, including a human, involves administering an effective amount of soluble IL-4 ***receptor*** (sIL-4R) and a suitable diluent or carrier.

L11 ANSWER 21 OF 52 USPATFULL
ACCESSION NUMBER: 1998:12125 USPATFULL
TITLE: Antibodies that are immunoreactive with interleukin-7
INVENTOR(S): Namen, Anthony E., Seattle, WA, United States
Goodwin, Raymond G., Seattle, WA, United States
Lupton, Stephen D., Seattle, WA, United States
Mochizuki, Diane Y., Seattle, WA, United States
PATENT ASSIGNEE(S): Sterling Winthrop, Inc., New York, NY, United States (U.S. corporation)

NUMBER DATE

PATENT INFORMATION: US 5714585 980203
APPLICATION INFO.: US 94-231205 940421 (8)
RELATED APPL. INFO.: Division of Ser. No. US 92-957649, filed on 6 Oct 1992, now patented, Pat. No. US 5328988 which is a continuation of Ser. No. US 90-511438, filed on 13 Apr 1990, now abandoned which is a division of Ser. No. US 88-255209, filed on 7 Oct 1988, now patented, Pat. No. US 4965195 which is a continuation-in-part of Ser. No. US 87-113566, filed on 26 Oct 1987, now abandoned

DOCUMENT TYPE: Utility
PRIMARY EXAMINER: Eisenschank, Frank C.
LEGAL REPRESENTATIVE: Davis, William J.
NUMBER OF CLAIMS: 6
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 8 Drawing Figure(s); 7 Drawing Page(s)
LINE COUNT: 1963
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Antibodies that are immunoreactive with interleukin-7 (IL-7) proteins are provided. The anti-IL-7 antibodies may be polyclonal or monoclonal. Certain embodiments are directed to antibodies that are immunoreactive with human IL-7.

L11 ANSWER 22 OF 52 USPATFULL
ACCESSION NUMBER: 1998:9379 USPATFULL
TITLE: Chimeric ***receptor*** molecules for delivery of ***co*** - ***stimulatory*** signals
INVENTOR(S): Roberts, Margo R., San Francisco, CA, United States
PATENT ASSIGNEE(S): Cell Genesys, Inc., Foster City, CA, United States (U.S. corporation)

NUMBER DATE

PATENT INFORMATION: US 5712149 980127
APPLICATION INFO.: US 95-383749 950203 (8)
DOCUMENT TYPE: Utility
PRIMARY EXAMINER: Uim, John
LEGAL REPRESENTATIVE: Sughrue, Mion, Zinn, Macpeak & Seas, PLLC
NUMBER OF CLAIMS: 25
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 5 Drawing Figure(s); 3 Drawing Page(s)
LINE COUNT: 1722
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention is directed to novel chimeric ***co*** - ***stimulatory*** ***receptor*** proteins and ***DNA*** sequences ***encoding*** these proteins. The chimeric ***receptors*** comprise at least three domains in a single chain molecule: an extracellular ligand binding domain, a transmembrane domain and a cytoplasmic ***co*** - ***stimulatory*** effector function signaling domain that acts synergistically with an effector function signal in the host cell. Novel hybrid ***co*** - ***stimulatory*** ***receptor*** proteins include a second cytoplasmic effector function signaling domain. The invention further relates to expression cassettes containing the ***nucleic*** ***acids*** ***encoding*** the novel chimeric ***receptors***, to host cells expressing the novel chimeric ***receptors*** and to methods of using the ***receptors*** to ***co*** - ***stimulate*** effector functions in the cells and for using cells expressing the ***receptors*** for treatment of cancer, disease and viral infections.

L11 ANSWER 23 OF 52 USPATFULL
ACCESSION NUMBER: 1998:4755 USPATFULL
TITLE: Secreted proteins and polynucleotides encoding them
INVENTOR(S): Jacobs, Kenneth, Newton, MA, United States
McCoy, John M., Reading, MA, United States
LaValle, Edward R., Tewksbury, MA, United States
Racie, Lisa A., Acton, MA, United States
Merberg, David, Acton, MA, United States
Treacy, Maurice, Chestnut Hill, MA, United States
Evans, Cheryl, Brookline, MA, United States
Spaulding, Vicki, Billerica, MA, United States
PATENT ASSIGNEE(S): Genetics Institute, Inc., Cambridge, MA, United States (U.S. corporation)

NUMBER DATE

PATENT INFORMATION: US 5708157 980113
APPLICATION INFO.: US 96-686878 960726 (8)
DOCUMENT TYPE: Utility
PRIMARY EXAMINER: Walsh, Stephen
ASSISTANT EXAMINER: Kaufman, Claire M.
LEGAL REPRESENTATIVE: Brown, Scott A.; Sprunger, Suzanne A.;

DesRosier, Thomas J.
NUMBER OF CLAIMS: 21
EXEMPLARY CLAIM: 1
LINE COUNT: 3204
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Novel polynucleotides and the proteins encoded thereby are disclosed.

L11 ANSWER 24 OF 52 USPATFULL
ACCESSION NUMBER: 1998:1443 USPATFULL
TITLE: Use of interleukin-7 to stimulate ***proliferation*** of hematopoietic cell precursors
INVENTOR(S): Namen, Anthony E., Seattle, WA, United States
Goodwin, Raymond G., Seattle, WA, United States
Lupton, Stephen D., Seattle, WA, United States
Mochizuki, Diane Y., Seattle, WA, United States
PATENT ASSIGNEE(S): Sterling Winthrop Inc., New York, NY, United States (U.S. corporation)

NUMBER DATE

PATENT INFORMATION: US 5705149 980106
APPLICATION INFO.: US 95-446908 950522 (8)
RELATED APPL. INFO.: Division of Ser. No. US 94-231205, filed on 21 Apr 1994 which is a division of Ser. No. US 92-957649, filed on 6 Oct 1992, now patented, Pat. No. US 5328988 which is a continuation of Ser. No. US 90-511438, filed on 13 Apr 1990, now abandoned which is a division of Ser. No. US 88-255209, filed on 7 Oct 1988, now patented, Pat. No. US 4965195 which is a continuation of Ser. No. US 87-113566, filed on 26 Oct 1987, now abandoned

DOCUMENT TYPE: Utility
PRIMARY EXAMINER: Uim, John
ASSISTANT EXAMINER: Mertz, Prema
LEGAL REPRESENTATIVE: Davis, William J.
NUMBER OF CLAIMS: 10
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 8 Drawing Figure(s); 7 Drawing Page(s)
LINE COUNT: 2052
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Mammalian Interleukin-7 proteins (IL-7s), ***DNAs*** and expression vectors ***encoding*** mammalian IL-7s, and processes for producing mammalian IL-7s as products of cell culture, including recombinant systems, are disclosed.

L11 ANSWER 25 OF 52 USPATFULL
ACCESSION NUMBER: 97:104313 USPATFULL
TITLE: Chimeric ***receptor*** molecules for delivery of ***co*** - ***stimulatory*** signals
INVENTOR(S): Roberts, Margo R., San Francisco, CA, United States
PATENT ASSIGNEE(S): Cell Genesys, Inc., Foster City, CA, United States (U.S. corporation)

NUMBER DATE

PATENT INFORMATION: US 5686281 971111
APPLICATION INFO.: US 95-455860 950531 (8)
RELATED APPL. INFO.: Continuation of Ser. No. US 95-383749, filed on 3 Feb 1995

DOCUMENT TYPE: Utility
PRIMARY EXAMINER: Uim, John
LEGAL REPRESENTATIVE: Sughrue, Mion, Zinn, Macpeak & Seas, PLLC
NUMBER OF CLAIMS: 11
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 5 Drawing Figure(s); 3 Drawing Page(s)
LINE COUNT: 1627
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention is directed to novel chimeric ***co*** - ***stimulatory*** ***receptor*** proteins and ***DNA*** sequences ***encoding*** these proteins. The chimeric ***receptors*** comprise at least three domains in a single

chain molecule: an extracellular ligand binding domain, a transmembrane domain and a cytoplasmic domain, which synergistically with an effector function signal in the host cell. Novel hybrid ***co***, ***stimulatory***, ***receptor*** domain. The invention further relates to expression cassettes containing the ***nucleic***, ***acids***, ***encoding*** the novel chimeric ***receptors***, to host cells expressing the novel chimeric ***receptors***, and to methods of using the ***receptors*** to ***co***, ***stimulate*** effector functions in the cells and for using cells expressing the ***receptors*** for treatment of cancer, disease and viral infections.

L11 ANSWER 26 OF 52 USPATFULL
ACCESSION NUMBER: 97/78562 USPATFULL
TITLE: ICAM-related protein
INVENTOR(S): Galliani, W. Michael, Seattle, WA, United States
Vazeux, Rosemary, Seattle, WA, United States
PATENT ASSIGNEE(S): ICOS Corporation, Bothell, WA, United States
(U.S. corporation)

NUMBER DATE

PATENT INFORMATION: US 5663293, 970902
APPLICATION INFO: US 95-433010 950503 (8)
RELATED APPL. INFO: Continuation of Ser. No. US 93-9266, filed on 22 Jan 1993, now abandoned which is a continuation-in-part of Ser. No. US 92-894081, filed on 5 Jun 1992, now abandoned which is a continuation-in-part of Ser. No. US 92-889724, filed on 26 May 1992, now abandoned which is a continuation-in-part of Ser. No. US 92-827689, filed on 27 Jan 1992, now abandoned

DOCUMENT TYPE: Utility

PRIMARY EXAMINER: Ulin, John
ASSISTANT EXAMINER: Brown, Karen E
LEGAL REPRESENTATIVE: Marshall, O'Toole, Gerstein, Murray & Borun
NUMBER OF CLAIMS: 16
EXEMPLARY CLAIM: 16

NUMBER OF DRAWINGS: 29 Drawing Figure(s); 23 Drawing Page(s)
LINE COUNT: 2834

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB ***DNA*** sequences ***encoding*** a novel human intercellular adhesion molecule polypeptide (designated "ICAM-R") and variants thereof are disclosed along with methods and materials for production of the same by recombinant procedures. Binding molecules specific for ICAM-R and variants thereof are also disclosed as useful in both the isolation of ICAM-R from natural cellular sources and the modulation of ligand/receptor binding biological activities of ICAM-R.

L11 ANSWER 27 OF 52 USPATFULL

ACCESSION NUMBER: 97/70713 USPATFULL
TITLE: Method of using interleukin-4
INVENTOR(S): Lee, Frank, Palo Alto, CA, United States
Yokota, Takashi, Palo Alto, CA, United States
Arai, Ken-ichi, Palo Alto, CA, United States
Mosmann, Timothy, Atherton, CA, United States
Rennick, Donna, Los Altos, CA, United States
PATENT ASSIGNEE(S): Schering Corporation, Kenilworth, NJ, United States (U.S. corporation)

NUMBER DATE

PATENT INFORMATION: US 5656266, 970812
APPLICATION INFO: US 95-468734 950606 (8)
RELATED APPL. INFO: Division of Ser. No. US 94-221551, filed on 1 Apr 1994, now abandoned which is a continuation of Ser. No. US 93-27601, filed on 5 Mar 1993, now abandoned which is a continuation of Ser. No. US 92-854771, filed on 20 Mar 1992, now abandoned which is a continuation of Ser. No. US 90-615902, filed on 20 Nov 1990, now abandoned which is a division of Ser. No. US 86-808215, filed on 17 Sep 1986, now patented, Pat. No. US 5017691 which

is a continuation-in-part of Ser. No. US 86-081553, filed on 3 Jul 1986, now abandoned which is a continuation-in-part of Ser. No. US 86-943958, filed on 25 Mar 1986, now patented, Pat. No. US 5552304 which is a continuation-in-part of Ser. No. US 85-799688, filed on 19 Nov 1985, now abandoned

DOCUMENT TYPE: Utility

PRIMARY EXAMINER: Jagannathan, Vasu S.
ASSISTANT EXAMINER: Kemmerer, Elizabeth C.
LEGAL REPRESENTATIVE: Lunn, Paul G.; Foulke, Cynthia L.; Gould, James M.

NUMBER OF CLAIMS: 1

EXEMPLARY CLAIM: 1

NUMBER OF DRAWINGS: 33 Drawing Figure(s); 24 Drawing Page(s)

LINE COUNT: 2854

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Mammalian proteins and mutants thereof, designated interleukin-4s (IL-4s), are provided which exhibit both B cell ***growth*** factor activity and T cell ***growth*** factor activity. Compounds of the invention include native human and murine IL-4s, mutants thereof, and nucleic acids which are effectively homologous to disclosed cDNAs, and/or which are capable of coding for mammalian IL-4s and their mutants.

L11 ANSWER 28 OF 52 USPATFULL

ACCESSION NUMBER: 97/68346 USPATFULL
TITLE: Secreted proteins and polynucleotides encoding them

INVENTOR(S): Jacobs, Kenneth, Newton, MA, United States
McCoy, John M., Reading, MA, United States
LaValle, Edward R., Tewksbury, MA, United States
Racie, Lisa A., Acton, MA, United States
Merberg, David, Acton, MA, United States
Treacy, Maurice, Chestnut Hill, MA, United States
Spaulding, Vikki, Billerica, MA, United States
PATENT ASSIGNEE(S): Genetics Institute, Inc., Cambridge, MA, United States (U.S. corporation)

NUMBER DATE

PATENT INFORMATION: US 5654173, 970805

APPLICATION INFO: US 96-702080 960823 (8)

DOCUMENT TYPE: Utility

PRIMARY EXAMINER: Jagannathan, Vasu S.

ASSISTANT EXAMINER: Lathrop, Brian

LEGAL REPRESENTATIVE: Brown, Scott A.; DesRosier, Thomas J.

NUMBER OF CLAIMS: 14

EXEMPLARY CLAIM: 1

LINE COUNT: 1685

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Novel polynucleotides and the proteins encoded thereby are disclosed.

L11 ANSWER 29 OF 52 USPATFULL

ACCESSION NUMBER: 97/61556 USPATFULL
TITLE: Immortalized dendritic cells
INVENTOR(S): MacKay, Vivian L., Seattle, WA, United States
Moore, Emma E., Seattle, WA, United States
PATENT ASSIGNEE(S): ZymoGenetics, Inc., Seattle, WA, United States (U.S. corporation)

NUMBER DATE

PATENT INFORMATION: US 5648219, 970715

APPLICATION INFO: US 95-479882 950607 (8)

DOCUMENT TYPE: Utility

PRIMARY EXAMINER: Chan, Christina Y.

ASSISTANT EXAMINER: VanderVegt, F. Pierre

LEGAL REPRESENTATIVE: Sawislak, Deborah A.; Parker, Gary E.; Leith, Debra K.

NUMBER OF CLAIMS: 15

EXEMPLARY CLAIM: 4

NUMBER OF DRAWINGS: 1 Drawing Figure(s); 1 Drawing Page(s)

LINE COUNT: 1020

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention provides an immature dendritic cell line

derived from p53 ***growth*** suppressor gene deficient animals. The immature dendritic cell line may be induced to become an ***activated*** dendritic cell line that will stimulate T-cells to ***proliferate***. The cell line is useful for presentation of antigens involved in autoimmune disease and analysis of peptides that produce a T-cell response.

L11 ANSWER 30 OF 52 USPATFULL

ACCESSION NUMBER: 97/47272 USPATFULL
TITLE: Compositions and methods for the detection, quantitation and purification of ***antigen***, ***specific*** T cells

INVENTOR(S): Altman, John D., San Carlos, CA, United States
McHeyzer-Williams, Michael G., Menlo Park, CA, United States

United States

Patent Assignee(s): Davis, Mark M., Alherton, CA, United States
The Board of Trustees of the Leland Stanford Junior University, Stanford, CA, United States
(U.S. corporation)

NUMBER DATE

PATENT INFORMATION: US 5635363, 970603

APPLICATION INFO: US 95-396220 950228 (8)

DOCUMENT TYPE: Utility

PRIMARY EXAMINER: Saunders, David

LEGAL REPRESENTATIVE: Sherwood, Pamela J.Fish & Richardson P.C.

NUMBER OF CLAIMS: 16

EXEMPLARY CLAIM: 1

NUMBER OF DRAWINGS: 8 Drawing Figure(s); 2 Drawing Page(s)

LINE COUNT: 1049

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB T cells are ***specifically*** labeled according to their ***antigen*** ***receptor*** by binding of a multimeric binding complex. The complex is prepared with major histocompatibility complex protein subunits having a homogeneous population of peptides bound in the antigen presentation site. The multimeric MHC-antigen complex forms a stable structure with T cells, thereby allowing for the labeling, identification and separation of specific T cells.

L11 ANSWER 31 OF 52 USPATFULL

ACCESSION NUMBER: 97/31611 USPATFULL

TITLE: Human anti-Fas IgG1 monoclonal antibodies

INVENTOR(S): Lynch, David H., Bainbridge Island, WA, United States

States

Alderson, Mark R., Bainbridge Island, WA, United States

States

Patent Assignee(s): Immunex Corporation, Seattle, WA, United States
(U.S. corporation)

NUMBER DATE

PATENT INFORMATION: US 5620889, 970415

APPLICATION INFO: US 94-322805 941013 (8)

RELATED APPL. INFO: Continuation-in-part of Ser. No. US 93-159003, filed on 29 Nov 1993, now abandoned which is a continuation-in-part of Ser. No. US 93-136817, filed on 14 Oct 1993, now abandoned

DOCUMENT TYPE: Utility

PRIMARY EXAMINER: Loring, Susan A.

NUMBER OF CLAIMS: 25

EXEMPLARY CLAIM: 1

NUMBER OF DRAWINGS: 14 Drawing Figure(s); 10 Drawing Page(s)

LINE COUNT: 1698

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention provides a panel of monoclonal antibodies and binding proteins which ***specifically*** bind to human Fas ***antigen***. Some of the antibodies and binding proteins are capable of stimulating T cell ***proliferation***, inhibiting binding of anti-Fas CH-11 monoclonal antibody to cells expressing Fas antigen, blocking anti-Fas CH-11 monoclonal antibody-mediated lysis of cells, and blocking Fas ligand-mediated lysis of cells. The invention also provides for therapeutic compositions comprising the monoclonal antibodies.

L11 ANSWER 32 OF 52 USPATFULL

ACCESSION NUMBER: 97-31590 USPATFULL
TITLE: Gene coded for interleukin-2 polypeptide recombinant DNA carrying the said gene, a living cell line possessing the recombinant DNA, and said method for producing interleukin-2 using the said cell

INVENTOR(S): Taniguchi, Tadatsugu, Tokyo, Japan
Muramatsu, Masami, Tokorozawa, Japan
Sugano, Haruo, Tokyo, Japan
Matsui, Hiroshi, Yokohama, Japan
Kashima, Nobukazu, Yokohama, Japan
Hamuro, Junji, Yokohama, Japan

PATENT ASSIGNEE(S): Ajinomoto Co., Inc., Tokyo, Japan (non-U.S. corporation)
Japanese Foundation for Cancer Research, Tokyo, Japan (non-U.S. corporation)

NUMBER DATE
PATENT INFORMATION: US 5620868 970415
APPLICATION INFO: US 91-814049 911226 (7)
DISCLAIMER DATE: 20050419
RELATED APPLN. INFO.: Continuation of Ser. No. US 89-332364, filed on 3 Apr 1989, now abandoned which is a continuation of Ser. No. US 87-36309, filed on 7 Apr 1987, now abandoned which is a continuation of Ser. No. US 83-463496, filed on 3 Feb 1983, now patented, Pat. No. US 4738927

NUMBER DATE
PRIORITY INFORMATION: JP 82-51122 820331
JP 82-82509 820518
JP 82-129518 821215
JP 82-229619 821224
JP 82-234607 821227
JP 82-230371 821229

DOCUMENT TYPE: Utility
PRIMARY EXAMINER: Martini, James
LEGAL REPRESENTATIVE: Obion, Spivak, McClelland, Maier & Neustadt, P.C.

NUMBER OF CLAIMS: 1
EXEMPLARY CLAIM: 11 Drawing Figure(s); 10 Drawing Page(s)
NUMBER OF DRAWINGS: 1434
LINE COUNT: 2652
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A gene coded for a polypeptide which possesses interleukin-2 is isolated, and connected with a vector DNA which is capable of replicating in a prokaryotic or eucaryotic cell at a position downstream of a promoter gene in the vector obtaining a recombinant DNA, with which the cell is transformed to produce interleukin-2.

11 ANSWER 33 OF 52 USPATFULL
ACCESSION NUMBER: 97-22653 USPATFULL
TITLE: Cloning and recombinant production of vespid venom phospholipases, and immunological therapies based thereon

INVENTOR(S): King, Te P., New York, NY, United States
PATENT ASSIGNEE(S): The Rockefeller University, New York, NY, United States (U.S. corporation)

NUMBER DATE
PATENT INFORMATION: US 5612209 970318
APPLICATION INFO: US 95-385745 950208 (8)
RELATED APPLN. INFO.: Continuation of Ser. No. US 93-31400, filed on 11 Mar 1993, now abandoned

DOCUMENT TYPE: Utility
PRIMARY EXAMINER: Wax, Robert A.
ASSISTANT EXAMINER: Saidha, Tekchand
LEGAL REPRESENTATIVE: Klauber & Jackson
EXEMPLARY CLAIM: 22
NUMBER OF DRAWINGS: 7 Drawing Figure(s); 7 Drawing Page(s)
LINE COUNT: 1852
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention is directed to ***nucleic***
acids, ***encoding*** vespid venom phospholipases, or fragments thereof, recombinant vectors comprising such nucleic acids, and host cells containing the recombinant vectors. The invention is further directed to expression of such nucleic acids to produce recombinant vespid venom phospholipases, or recombinant fragments, derivatives or analogs thereof. Such recombinant products are useful for diagnosis of allergy and for therapeutic treatment of allergy. In specific embodiments, the present invention provides ***nucleic***, ***acids***, ***encoding***, and complete nucleotide and amino acids sequences for, vespid venom phospholipase A1, for example, Dolichovespula maculata phospholipase A sub.1 and Vespusula vulgaris phospholipase A1.

L11 ANSWER 34 OF 52 USPATFULL
ACCESSION NUMBER: 97-10123 USPATFULL
TITLE: Interleukin-4 ***receptors***
INVENTOR(S): Mosley, Bruce, Seattle, WA, United States
Cosman, David J., Seattle, WA, United States
Park, Linda, Seattle, WA, United States
Bednarek, M. Patricia, Poussbo, WA, United States
March, Carl J., Seattle, WA, United States
Idzerda, Rejean, Seattle, WA, United States

PATENT ASSIGNEE(S): Immunex Corporation, Seattle, WA, United States (U.S. corporation)

NUMBER DATE
PATENT INFORMATION: US 5599905 970204
APPLICATION INFO: US 93-94669 930720 (8)
RELATED APPLN. INFO.: Division of Ser. No. US 90-480694, filed on 14 Feb 1990 which is a continuation-in-part of Ser. No. US 89-370924, filed on 23 Jun 1989, now abandoned which is a continuation-in-part of Ser. No. US 89-326156, filed on 20 Mar 1989, now abandoned which is a continuation-in-part of Ser. No. US 89-319438, filed on 2 Mar 1989, now abandoned which is a continuation-in-part of Ser. No. US 88-265047, filed on 19 Oct 1988, now abandoned

DOCUMENT TYPE: Utility
PRIMARY EXAMINER: Walsh, Stephen G.
ASSISTANT EXAMINER: Ulin, John D.
NUMBER OF CLAIMS: 21
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 38 Drawing Figure(s); 22 Drawing Page(s)
LINE COUNT: 2652
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Mammalian Interleukin-4 ***receptor*** proteins, ***DNAs*** and expression vectors ***encoding*** mammalian IL-4 ***receptors***, as products of cell culture, are disclosed. A method for suppressing an IL-4-dependent immune or inflammatory response in a mammal, including a human, by administering an effective amount of soluble IL-4 ***receptor*** (sIL-4R) and a suitable diluent or carrier.

L11 ANSWER 35 OF 52 USPATFULL
ACCESSION NUMBER: 97-6049 USPATFULL
TITLE: Method of refolding human IL-13
INVENTOR(S): Cupepper, Janice, Mountain View, CA, United States
McKenzie, Andrew, Redwood City, CA, United States
Dang, Warren, San Jose, CA, United States
Zurawski, Gerard, Redwood City, CA, United States

PATENT ASSIGNEE(S): Schering Corporation, Kenilworth, NJ, United States (U.S. corporation)

NUMBER DATE
PATENT INFORMATION: US 5596072 970121
APPLICATION INFO: US 93-12543 930201 (8)
RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 92-933416, filed on 21 Aug 1992, now abandoned

DOCUMENT TYPE: Utility
PRIMARY EXAMINER: Draper, Garnette D.

ASSISTANT EXAMINER: Spector, Lorraine M.
LEGAL REPRESENTATIVE: Ching, Edwin P.
NUMBER OF CLAIMS: 10
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 288 Drawing Figure(s); 61 Drawing Page(s)
LINE COUNT: 4619
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB ***Nucleic***, ***acids***, ***encoding*** human IL-13, and purified IL-13 proteins and fragments thereof. Antibodies, both polyclonal and monoclonal, are also provided. Methods of using the compositions for both diagnostic and therapeutic utilities are provided.

L11 ANSWER 36 OF 52 USPATFULL
ACCESSION NUMBER: 97-3726 USPATFULL
TITLE: Nucleic acid and recombinant production of vespid venom hyaluronidase
INVENTOR(S): King, Te P., New York, NY, United States
PATENT ASSIGNEE(S): The Rockefeller University, New York, NY, United States (U.S. corporation)

NUMBER DATE
PATENT INFORMATION: US 5593877 970114
APPLICATION INFO: US 94-180209 940111 (8)
RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 93-31400, filed on 11 Mar 1993, now abandoned

DOCUMENT TYPE: Utility
PRIMARY EXAMINER: Walsh, Stephen G.
LEGAL REPRESENTATIVE: Klauber & Jackson
NUMBER OF CLAIMS: 12
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 15 Drawing Figure(s); 13 Drawing Page(s)
LINE COUNT: 2479
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention is directed to ***nucleic***
acids, ***encoding*** vespid venom enzymes, or fragments thereof, recombinant vectors comprising such nucleic acids, and host cells containing the recombinant vectors. The invention is further directed to expression of such nucleic acids to produce recombinant vespid venom enzymes, or recombinant fragments, derivatives or analogs thereof. Such recombinant products are useful for diagnosis of allergy and for therapeutic treatment of allergy. In specific embodiments, the present invention provides ***nucleic***, ***acids***, ***encoding***, and complete nucleotide and amino acids sequences for, vespid venom phospholipase, for example, Dolichovespula maculata phospholipase and Vespusula vulgaris phospholipase, and vespid venom hyaluronidase, for example, Dolichovespula maculata hyaluronidase.

L11 ANSWER 37 OF 52 USPATFULL
ACCESSION NUMBER: 97-1355 USPATFULL
TITLE: Monoclonal antibodies that bind interleukin-15
INVENTOR(S): Anderson, Dirk M., Seattle, WA, United States
Giri, Judith G., Seattle, WA, United States

PATENT ASSIGNEE(S): Immunex Corporation, Seattle, WA, United States (U.S. corporation)

NUMBER DATE
PATENT INFORMATION: US 5591630 970107
APPLICATION INFO: US 94-300903 940906 (8)
RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 94-236919, filed on 6 May 1994, now abandoned

DOCUMENT TYPE: Utility
PRIMARY EXAMINER: Hutzell, Paula K.
LEGAL REPRESENTATIVE: Perkins, Patricia Anne
NUMBER OF CLAIMS: 5
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 2 Drawing Figure(s); 2 Drawing Page(s)
LINE COUNT: 1601
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB There are disclosed interleukin-15 ***receptor*** (IL-15R) proteins, ***DNAs*** and expression vectors ***encoding*** IL-15R, and processes for producing IL-15R as products of

recombinant cell cultures. Also disclosed are monoclonal antibodies that bind interleukin-15 ***receptors***

L11 ANSWER 38 OF 52 USPATFULL
ACCESSION NUMBER: 96-111346 USPATFULL
TITLE: B7IG fusion protein
INVENTOR(S): Linsley, Peter S., Seattle, WA, United States
Dammle, Nalin K., Renton, WA, United States
Brady, William, Bothell, WA, United States
PATENT ASSIGNEE(S): Bristol-Myers Squibb Co., Seattle, WA, United States (U.S. corporation)

NUMBER DATE
PATENT INFORMATION: US 5580756 961203
APPLICATION INFO.: US 94-219518 940329 (8)
RELATED APPLN. INFO.: Division of Ser. No. US 91-722101, filed on 27 Jun 1991 which is a continuation-in-part of Ser. No. US 90-547980, filed on 2 Jul 1990, now abandoned which is a continuation-in-part of Ser. No. US 90-498949, filed on 26 Mar 1990, now abandoned

DOCUMENT TYPE: Utility
PRIMARY EXAMINER: Adams, Donald E.
LEGAL REPRESENTATIVE: Merchant, Gould, Smith, Edell, Weller & Schmidt
NUMBER OF CLAIMS: 3
EXEMPLARY CLAIM: 1
LINE COUNT: 2405

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention identifies the B7 antigen as a ligand that is reactive with the CD28 ***receptor*** on T cells. Fragments and derivatives of the B7 antigen and CD28 ***receptor*** including fusion proteins having amino acid sequences corresponding to the extracellular domains of B7 or CD28 joined to amino acid sequences encoding portions of human immunoglobulin C gamma 1, are described. Methods are provided for using B7 antigen, its fragments and derivatives, as well as antibodies and other molecules reactive with B7 antigen and/or the CD28 ***receptor***, to regulate CD28 positive T cell responses, and immune responses mediated by T cells. The invention also includes an assay method for detecting ligands reactive with cellular ***receptors*** mediating intercellular adhesion.

L11 ANSWER 39 OF 52 USPATFULL
ACCESSION NUMBER: 96-106593 USPATFULL
TITLE: Antibodies to the slam protein expressed on ***activated*** T cells
INVENTOR(S): Aversa, Gregorio, Palo Alto, CA, United States
Chang, Chia-Chun J., San Jose, CA, United States
Cocks, Benjamin G., Mountain View, CA, United States
de Vries, Jan E., Los Altos, CA, United States
PATENT ASSIGNEE(S): Schering Corporation, Kenilworth, NJ, United States (U.S. corporation)

NUMBER DATE
PATENT INFORMATION: US 5576423 961119
APPLICATION INFO.: US 94-348792 941202 (8)
DOCUMENT TYPE: Utility
PRIMARY EXAMINER: Nuckar, Christine M.
ASSISTANT EXAMINER: Reeves, Julie E.
LEGAL REPRESENTATIVE: Ching, Edwin P.
NUMBER OF CLAIMS: 26
EXEMPLARY CLAIM: 1
LINE COUNT: 2811
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Purified ***genes*** which ***encode*** a T cell surface antigen from a mammal, reagents related thereto including purified proteins, ***specific*** antibodies, and ***nucleic*** acids*** ***encoding*** said ***antigen***. Methods of using said reagents and diagnostic kits are also provided.

L11 ANSWER 40 OF 52 USPATFULL

ACCESSION NUMBER: 96-101287 USPATFULL
TITLE: Compositions and methods for use of IL-12 as an adjuvant
INVENTOR(S): Scott, Phillip, Swarthmore, PA, United States
Trinchieri, Giorgio, Wynnwood, PA, United States
PATENT ASSIGNEE(S): The Wistar Institute of Anatomy & Biology, Philadelphia, PA, United States (U.S. corporation)
The Trustees of the University of Pennsylvania, Philadelphia, PA, United States (U.S. corporation)

NUMBER DATE
PATENT INFORMATION: US 5571515 961105
APPLICATION INFO.: US 94-265087 940617 (8)
RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 94-229282, filed on 18 Apr 1994, now abandoned
DOCUMENT TYPE: Utility
PRIMARY EXAMINER: Smith, Lynette R. F.
LEGAL REPRESENTATIVE: Howson and Howson
NUMBER OF CLAIMS: 3
EXEMPLARY CLAIM: 1
LINE COUNT: 1214

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Improved vaccine compositions and methods of making the compositions are provided, which vaccines are characterized by an antigen from a pathogen and an effective adjuvanting amount of interleukin-12 (IL-12). These IL-12 adjuvanted vaccines are capable of increasing the vaccinated host's cell mediated immune response to provide an increased and protective immune response to the pathogen. Also disclosed are methods for vaccinating hosts by administering a vaccine containing an antigen from a pathogenic microorganism and co-administering an adjuvanting amount of IL-12. Vaccines or therapeutic compositions directed against a cancer may also be adjuvanted with IL-12 according to this invention.

L11 ANSWER 41 OF 52 USPATFULL
ACCESSION NUMBER: 96-67750 USPATFULL
TITLE: Soluble and its use in B cell stimulation
INVENTOR(S): Aruffo, Alejandro, Edmonds, WA, United States
Hollenbaugh, Diane, Seattle, WA, United States
Lodbetter, Jeffrey A., Seattle, WA, United States
PATENT ASSIGNEE(S): Bristol-Myers Squibb Company, Seattle, WA, United States (U.S. corporation)

NUMBER DATE
PATENT INFORMATION: US 5540926 960730
APPLICATION INFO.: US 92-940605 920904 (7)
DOCUMENT TYPE: Utility
PRIMARY EXAMINER: Allen, Marianne P.
ASSISTANT EXAMINER: Spector, L.
LEGAL REPRESENTATIVE: Pennie & Edmonds
NUMBER OF CLAIMS: 18
EXEMPLARY CLAIM: 1
LINE COUNT: 1350
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to soluble ligands for the B-cell antigen, CD40, and, in particular, to human gp39 protein and soluble ligands derived therefrom which may be used in methods of promoting B-cell ***proliferation***.

L11 ANSWER 42 OF 52 USPATFULL
ACCESSION NUMBER: 96-50801 USPATFULL
TITLE: Signal transduction via CD28
INVENTOR(S): Rudd, Christopher E., Cambridge, MA, United States
Kanteti, Prasad, Boston, MA, United States
PATENT ASSIGNEE(S): Dana-Farber Cancer Institute, Inc., Boston, MA, United States (U.S. corporation)

NUMBER DATE

PATENT INFORMATION: US 5525503 960611

APPLICATION INFO.: US 93-128971 930928 (8)
DOCUMENT TYPE: Utility
PRIMARY EXAMINER: Ziska, Suzanne E.
LEGAL REPRESENTATIVE: Fish & Richardson
NUMBER OF CLAIMS: 2
EXEMPLARY CLAIM: 1
LINE COUNT: 1056

CAS INDEXING IS AVAILABLE FOR THIS PATENT
AB Disclosed are compositions and methods of blocking T cell signal transduction by introducing into a T cell a peptide comprising a PI 3-kinase-binding-sequence which decreases the association of PI 3-kinase with CD28. Also disclosed are compositions and methods of amplifying T cell ***activation*** by introducing into a T cell, a plurality of modified T cell surface proteins, the cytoplasmic tail of which comprises a plurality of copies of a PI 3-kinase-binding-sequence.

L11 ANSWER 43 OF 52 USPATFULL
ACCESSION NUMBER: 96-46143 USPATFULL
TITLE: CD28IG fusion protein
INVENTOR(S): Linsley, Peter S., Seattle, WA, United States
Dammle, Nalin K., Renton, WA, United States
Brady, William, Bothell, WA, United States
PATENT ASSIGNEE(S): Bristol-Myers Squibb Company, Seattle, WA, United States (U.S. corporation)

NUMBER DATE
PATENT INFORMATION: US 5521288 960528
APPLICATION INFO.: US 94-219116 940329 (8)
RELATED APPLN. INFO.: Division of Ser. No. US 91-722101, filed on 27 Jun 1991, now abandoned which is a continuation-in-part of Ser. No. US 90-547980, filed on 2 Jul 1990, now abandoned which is a continuation-in-part of Ser. No. US 90-498949, filed on 26 Mar 1990, now abandoned

DOCUMENT TYPE: Utility
PRIMARY EXAMINER: Adams, Donald E.
LEGAL REPRESENTATIVE: Merchant, Gould, Smith, Edell, Weller & Schmidt
NUMBER OF CLAIMS: 2
EXEMPLARY CLAIM: 1
LINE COUNT: 2425
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention identifies the B7 antigen as a ligand that is reactive with the CD28 ***receptor*** on T cells. Fragments and derivatives of the B7 antigen and CD28 ***receptor*** including fusion proteins having amino acid sequences corresponding to the extracellular domains of B7 or CD28 joined to amino acid sequences encoding portions of human immunoglobulin C gamma 1, are described. Methods are provided for using B7 antigen, its fragments and derivatives, and the CD28 ***receptor***, its fragments and derivatives, as well as antibodies and other molecules reactive with B7 antigen and/or the CD28 ***receptor***, to regulate CD28 positive T cell responses, and immune responses mediated by T cells. The invention also includes an assay method for detecting ligands reactive with cellular ***receptors*** mediating intercellular adhesion.

L11 ANSWER 44 OF 52 USPATFULL
ACCESSION NUMBER: 95-103247 USPATFULL
TITLE: MHC class II-peptide conjugates useful in ameliorating autoimmunity
INVENTOR(S): Sharma, Suresh D., Los Altos, CA, United States
Clark, Brian R., Redwood City, CA, United States
Lerch, Bernard L., Palo Alto, CA, United States
PATENT ASSIGNEE(S): Amgen, Inc., Redwood City, CA, United States (U.S. corporation)

NUMBER DATE
PATENT INFORMATION: US 5468481 951121
APPLICATION INFO.: US 92-863293 920414 (7)
DISCLAIMER DATE: 20060714
RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 91-650840,

filed on 23 Apr 1991, now patented, Pat. No. US 5260422 which is a continuation-in-part of Ser. No. US 90-576084, filed on 30 Aug 1990, now patented, Pat. No. US 5130297 which is a continuation of Ser. No. US 88-210594, filed on 23 Jun 1988, now abandoned And a continuation-in-part of Ser. No. US 90-635840, filed on 28 Dec 1990, now patented, Pat. No. US 5284935 which is a continuation-in-part of Ser. No. US 89-367751, filed on 21 Jun 1989, now patented, Pat. No. US 5194425

DOCUMENT TYPE: Utility
PRIMARY EXAMINER: Kim, Kay K. A.
ASSISTANT EXAMINER: Cunningham, T.
LEGAL REPRESENTATIVE: Townsend and Townsend and Crew
NUMBER OF CLAIMS: 22
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 35 Drawing Figure(s); 26 Drawing Page(s)
LINE COUNT: 2266
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention is directed to complexes consisting essentially of an isolated MHC component and an autoantigenic peptide associated with the antigen binding site of the MHC component. These complexes are useful in treating autoimmune disease.

L11 ANSWER 45 OF 52 USPATFULL
ACCESSION NUMBER: 9525014 USPATFULL
TITLE: Interleukin-2 polypeptides
INVENTOR(S): Taniguchi, Tadatsugu, Yokohama, Tokyo, United States
Muramatsu, Masami, Yokohama, Tokorozawa, United States
Sugano, Haruo, Yokohama, Tokyo, United States
Matsui, Hiroshi, Yokohama, Yokohama, United States
Kashima, Nobukazu, Yokohama, Yokohama, United States
Hamuro, Junji, Yokohama, JPX, United States
PATENT ASSIGNEE(S): Ajinomoto Co., Inc., Tokyo, Japan (non-U.S. corporation)
Japanese Foundation For Cancer Research, Tokyo, Japan (non-U.S. corporation)

NUMBER DATE
PATENT INFORMATION: US 5399669 950321
APPLICATION INFO.: US 93-96842 930726 (8)
RELATED APPLN. INFO.: Continuation of Ser. No. US 90-631228, filed on 21 Dec 1990, now abandoned which is a continuation of Ser. No. US 89-356653, filed on 17 May 1989, now abandoned which is a continuation of Ser. No. US 87-33792, filed on 3 Apr 1987, now abandoned which is a continuation of Ser. No. US 83-463496, filed on 3 Feb 1983, now patented, Pat. No. US 4738927

NUMBER DATE
PRIORITY INFORMATION: JP 82-51122 820331
JP 82-82509 820518
JP 82-218518 821215
JP 82-228619 821224
JP 82-234607 821227
JP 82-230371 821229
DOCUMENT TYPE: Utility
PRIMARY EXAMINER: Draper, Garnette D.
ASSISTANT EXAMINER: Spector, Lorraine M.
LEGAL REPRESENTATIVE: Obion, Spivak, McClelland, Maier & Neustadt
NUMBER OF CLAIMS: 3
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 11 Drawing Figure(s); 15 Drawing Page(s)
LINE COUNT: 1476
CAS INDEXING IS AVAILABLE FOR THIS PATENT
AB Recombinantly produced interleukin-2 exhibits human IL-2 activity, has a molecular weight of about 15,000 daltons, is activity stable at a pH of 2-9 and is resistant to elevated temperatures. The

recombinant IL-2 has the principal biological activity of human IL-2, promotion of ***proliferation*** of cytotoxic ***lymphocytes***.

L11 ANSWER 46 OF 52 USPATFULL
ACCESSION NUMBER: 9458629 USPATFULL
TITLE: Extracellular matrix protein adherent T cells
INVENTOR(S): Haberman, Allan B., Somerville, MA, United States
PATENT ASSIGNEE(S): Trustees of Tufts College, Medford, MA, United States (U.S. corporation)

NUMBER DATE
PATENT INFORMATION: US 5354686 941011
APPLICATION INFO.: US 93-21220 930223 (8)
DISCLAIMER DATE: 20100223
RELATED APPLN. INFO.: Division of Ser. No. US 90-525512, filed on 18 May 1990, now patented, Pat. No. US 5188959 which is a continuation-in-part of Ser. No. US 89-414131, filed on 28 Sep 1989, now abandoned

DOCUMENT TYPE: Utility
PRIMARY EXAMINER: Elliott, George C.
LEGAL REPRESENTATIVE: Choate, Hall & Stewart
NUMBER OF CLAIMS: 7
EXEMPLARY CLAIM: 1
LINE COUNT: 2174
AB Substantially purified mature T cells, including .alpha..beta. T cells and .gamma..delta. T cells, are capable of binding to an extracellular matrix protein, particularly to one or more of a collagen, a fibronectin, a laminin, a fibrinogen, or a proteoglycan. Also, compositions including the substantially purified ECM binding mature T cells, for use in adoptive immunotherapy in a subject. Also, methods for treating a condition in a mammal, including administering to the mammal an effective quantity of the substantially purified ECM binding mature T cells, and treatment methods using the compositions. Also, methods for increasing the proportion, in a cell population, of substantially purified ECM binding mature T cells. Also, a method for assessing the likelihood that a mixture of cells contains ***activated*** T cells capable of localizing to a site in vivo, wherein an extracellular matrix protein is present at the site, in which greater binding of T cells to an extracellular matrix protein on a support in vivo indicates a greater likelihood that a mixture of cells contains ***activated*** T cells capable of localizing to the site in vivo.

L11 ANSWER 47 OF 52 USPATFULL
ACCESSION NUMBER: 9450237 USPATFULL
TITLE: Interleukin-7
INVENTOR(S): Namen, Anthony E., Seattle, WA, United States
Goodwin, Raymond G., Seattle, WA, United States
Lipton, Stephen D., Seattle, WA, United States
Mochizuki, Diane Y., Seattle, WA, United States
PATENT ASSIGNEE(S): Immunex Corporation, Seattle, WA, United States (U.S. corporation)

NUMBER DATE
PATENT INFORMATION: US 5328988 940712
APPLICATION INFO.: US 92-957649 921006 (7)
RELATED APPLN. INFO.: Continuation of Ser. No. US 90-511438, filed on 13 Apr 1990, now abandoned which is a division of Ser. No. US 89-255209, filed on 7 Oct 1989, now patented, Pat. No. US 4965195 And a continuation-in-part of Ser. No. US 87-113566, filed on 26 Oct 1987, now abandoned

DOCUMENT TYPE: Utility
PRIMARY EXAMINER: Draper, Garnette D.
NUMBER OF CLAIMS: 4
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 8 Drawing Figure(s); 8 Drawing Page(s)
LINE COUNT: 1706
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Mammalian Interleukin-7 proteins (IL-7s). ***DNAs*** and expression vectors ***encoding*** mammalian IL-7s, and processes for producing mammalian IL-7s as products of cell culture, including recombinant systems, are disclosed.

L11 ANSWER 48 OF 52 USPATFULL
ACCESSION NUMBER: 9393911 USPATFULL
TITLE: MHC conjugates useful in ameliorating autoimmune
INVENTOR(S): Clark, Brian R., Redwood City, CA, United States
Sharma, Somesh D., Los Altos, CA, United States
Lerch, L. Bernard, Palo Alto, CA, United States
PATENT ASSIGNEE(S): Anergic, Inc., Redwood City, CA, United States (U.S. corporation)

NUMBER DATE
PATENT INFORMATION: US 5260422 931109
APPLICATION INFO.: US 91-690840 910423 (7)
RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 90-576084, filed on 30 Aug 1990, now patented, Pat. No. US 5130297 which is a continuation of Ser. No. US 88-210594, filed on 23 Jun 1988, now abandoned

DOCUMENT TYPE: Utility
PRIMARY EXAMINER: Nucker, Christine M.
ASSISTANT EXAMINER: Cunningham, T.
LEGAL REPRESENTATIVE: Townsend and Townsend Kourie and Crew
NUMBER OF CLAIMS: 21
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 22 Drawing Figure(s); 23 Drawing Page(s)
LINE COUNT: 1711
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention is directed to complexes consisting essentially of an isolated MHC component and an autoantigenic peptide associated with the antigen binding site of the MHC component. These complexes are useful in treating autoimmune disease.

L11 ANSWER 49 OF 52 USPATFULL
ACCESSION NUMBER: 9314491 USPATFULL
TITLE: Extracellular matrix protein adherent T cells
INVENTOR(S): Haberman, Allan B., Somerville, MA, United States
PATENT ASSIGNEE(S): Trustees of Tufts College, Medford, MA, United States (U.S. corporation)

NUMBER DATE
PATENT INFORMATION: US 5188959 930223
APPLICATION INFO.: US 90-525512 900518 (7)
RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 89-414131, filed on 28 Sep 1989, now abandoned

DOCUMENT TYPE: Utility
PRIMARY EXAMINER: Lacey, David L.
ASSISTANT EXAMINER: Elliott, George C.
LEGAL REPRESENTATIVE: Choate, Hall & Stewart
NUMBER OF CLAIMS: 22
EXEMPLARY CLAIM: 2
LINE COUNT: 2225
AB Substantially purified mature T cells, including .alpha..beta. T cells and .gamma..delta. T cells, are capable of binding to an extracellular matrix protein, particularly to one or more of a collagen, a fibronectin, a laminin, a fibrinogen, or a proteoglycan. Also, compositions including the substantially purified ECM binding mature T cells, for use in adoptive immunotherapy in a subject. Also, methods for treating a condition in a mammal, including administering to the mammal an effective quantity of the substantially purified ECM binding mature T cells, and treatment methods using the compositions. Also, methods for increasing the proportion, in a cell population, of substantially purified ECM binding mature T cells. Also, a method for assessing the likelihood that a mixture of cells contains ***activated*** T cells capable of localizing to a site in vivo, wherein an extracellular matrix protein is present at the site, in which greater binding of T cells to an extracellular matrix protein on a support in vivo indicates a greater likelihood that a mixture of cells contains ***activated*** T cells capable of localizing to the site in vivo.

L11 ANSWER 50 OF 52 USPATFULL
ACCESSION NUMBER: 9140676 USPATFULL
TITLE: Mammalian interleukin-4

INVENTOR(S): Lee, Frank, Palo Alto, CA, United States
Yokota, Takashi, Palo Alto, CA, United States
Arai, Ken-ichi, Palo Alto, CA, United States
Mosmann, Timothy, Atherton, CA, United States
Rennick, Donna, Los Altos, CA, United States
PATENT ASSIGNEE(S): Schering Corporation, Madison, NJ, United States
(U.S. corporation)

NUMBER DATE
PATENT INFORMATION: US 5017691 910521
APPLICATION INFO: US 86-908215 860917 (6)
DISCLAIMER DATE: 20080507
RELATED APPL. INFO.: Continuation-in-part of Ser. No. US 86-881553,
filed on 3 Jul 1986, now abandoned which is a
continuation-in-part of Ser. No. US 86-843958,
filed on 25 Mar 1986 which is a
continuation-in-part of Ser. No. US 85-795668,
filed on 19 Nov 1985, now abandoned

DOCUMENT TYPE: Utility
PRIMARY EXAMINER: Teskin, Robin
ASSISTANT EXAMINER: Ellis, Joan
LEGAL REPRESENTATIVE: Macavicz, Stephen C.
NUMBER OF CLAIMS: 9
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 4 Drawing Figure(s); 3 Drawing Page(s)
LINE COUNT: 2748
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Mammalian proteins and mutants thereof, designated interleukin-4s
(IL-4s), are provided which exhibit both B cell ***growth***
factor activity and T cell ***growth*** factor activity.
Compounds of the invention include native human and murine IL-4s,
mutants thereof, and nucleic acids which are effectively
homologous to disclosed cDNAs, and/or which are capable of coding
for mammalian IL-4s and their mutants.

L11 ANSWER 51 OF 52 USPATFULL
ACCESSION NUMBER: 90-81722 USPATFULL
TITLE: Interleukin-7
INVENTOR(S): Namen, Anthony E., Seattle, WA, United States
Goodwin, Raymond G., Seattle, WA, United States
Lipton, Stephen D., Seattle, WA, United States
Mochizuki, Diane Y., Seattle, WA, United States
PATENT ASSIGNEE(S): Immunex Corp., Seattle, WA, United States (U.S.
corporation)

NUMBER DATE
PATENT INFORMATION: US 4965195 901023
APPLICATION INFO: US 85-255209 881007 (7)
RELATED APPL. INFO.: Continuation-in-part of Ser. No. US 87-113566,
filed on 26 Oct 1987

DOCUMENT TYPE: Utility
PRIMARY EXAMINER: Wiseman, Thomas G.
ASSISTANT EXAMINER: Ellis, Joan
NUMBER OF CLAIMS: 17
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 7 Drawing Figure(s); 7 Drawing Page(s)
LINE COUNT: 1714
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Mammalian interleukin-7 proteins (IL-7s), ***DNAs*** and
expression vectors ***encoding*** mammalian IL-7s, and
processes for producing mammalian IL-7s as products of cell
culture, including recombinant systems, are disclosed.

L11 ANSWER 52 OF 52 USPATFULL
ACCESSION NUMBER: 88-24371 USPATFULL
TITLE: Gene coded for interleukin-2 polypeptide,
recombinant DNA carrying the said gene, a living
cell line possessing the recombinant DNA, and
method for producing interleukin-2 using the said
cell

INVENTOR(S): Taniguchi, Tadatsugu, Tokyo, Japan
Muramatsu, Masami, Tokorozawa, Japan
Sugano, Haruo, Tokyo, Japan
Matsui, Hiroshi, Yokohama, Japan
Kashima, Nobukazu, Yokohama, Japan

Hamuro, Junji, Yokohama, Japan
PATENT ASSIGNEE(S): Ajinomoto Co. Inc., Tokyo, Japan (non-U.S.
corporation)

NUMBER DATE
PATENT INFORMATION: US 4738927 880419
APPLICATION INFO: US 83-463496 830203 (6)

NUMBER DATE
PRIORITY INFORMATION: JP 82-51122 820331
JP 82-82509 820518
JP 82-219518 821215
JP 82-229619 821224
JP 82-234607 821227
JP 82-230371 821229
DOCUMENT TYPE: Utility
PRIMARY EXAMINER: Martiniell, James
LEGAL REPRESENTATIVE: Olson, Fisher, Spivak, McClelland & Maier
NUMBER OF CLAIMS: 24
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 11 Drawing Figure(s); 9 Drawing Page(s)
LINE COUNT: 1478
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A gene coded for a polypeptide which possesses interleukin-2
activity is isolated, and connected with a vector DNA which is
capable of replicating in a procarcyotic or eucaryotic cell at a
position downstream of a promoter gene in the vector obtaining a
recombinant DNA, with which the cell is transformed to produce
interleukin-2.

=> s (2 and 6) and (nucleic)acid or dna or cdna or gene or
polynucleotide(4a)encod(7)

L12 4465 (L2 AND L6) AND ((NUCLEIC(W) ACID OR DNA OR CDNA OR
GENE OR POLYNUCLEOTIDE(4A) ENCOD?)

=> dup rem

ENTER L# LIST OR (END);112

L13 2656 DUP REM L12 (1809 DUPLICATES REMOVED)

=> s i13 and extracell?

L14 666 L13 AND EXTRACELL?

=> s i0 and extracell?

L15 53 L0 AND EXTRACELL?

=> dup rem

ENTER L# LIST OR (END);115

PROCESSING COMPLETED FOR L15

L16 46 DUP REM L15 (7 DUPLICATES REMOVED)

=> s i11 and extracell?

L17 41 L11 AND EXTRACELL?

=> s i11 and (intracell)? or cytoplasm?)

L18 48 L11 AND (INTRACELL? OR CYTOPLASM?)

=> s i11 and label?

L19 44 L11 AND LABEL?

=> s i11 and kit

L20 26 L11 AND KIT

=> d i20 1-26 ibib ab

L20 ANSWER 1 OF 26 USPATFULL
ACCESSION NUMBER: 1988-95405 USPATFULL
TITLE: Secreted protein, BA3.1, and polynucleotides
encoding same
INVENTOR(S): Bowman, Michael, 50 Aldrich Rd., Canton, MA,
United States 02021

NUMBER DATE
PATENT INFORMATION: US 5792628 980811
APPLICATION INFO: US 97-818163 970314 (8)
DOCUMENT TYPE: Utility
PRIMARY EXAMINER: Grimes, Eric
ASSISTANT EXAMINER: Longton, Enrique D.
LEGAL REPRESENTATIVE: Brown, Scott A.
NUMBER OF CLAIMS: 13
EXEMPLARY CLAIM: 1
LINE COUNT: 1440
AB A novel secreted protein, BA3.1, is disclosed. Polynucleotides
encoding BA3.1 are also provided.

L20 ANSWER 2 OF 26 USPATFULL
ACCESSION NUMBER: 1998-88944 USPATFULL
TITLE: Secreted proteins and polynucleotides encoding
them
INVENTOR(S): Jacobs, Kenneth, Newton, MA, United States
McCoy, John M., Reading, MA, United States
Lavallee, Edward R., Tewksbury, MA, United States
Racie, Lisa A., Acton, MA, United States
Merberg, David, Acton, MA, United States
Treacy, Maurice, Chestnut Hill, MA, United States
Spaulding, Vikki, Billerica, MA, United States
PATENT ASSIGNEE(S): Genetics Institute, Inc., Cambridge, MA, United
States (U.S. corporation)

NUMBER DATE

PATENT INFORMATION: US 5786465 980728
APPLICATION INFO: US 96-721489 960827 (8)
RELATED APPL. INFO.: Continuation-in-part of Ser. No. US 96-686878,
filed on 26 Jul 1996

DOCUMENT TYPE: Utility
PRIMARY EXAMINER: Walsh, Stephen
ASSISTANT EXAMINER: Kaufman, Claire M.
LEGAL REPRESENTATIVE: Brown, Scott A.; DesRosier, Thomas J.
NUMBER OF CLAIMS: 20
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 2 Drawing Figure(s); 2 Drawing Page(s)
LINE COUNT: 1564
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Novel polynucleotides and the proteins encoded thereby are
disclosed.

L20 ANSWER 3 OF 26 USPATFULL
ACCESSION NUMBER: 1998-75369 USPATFULL
TITLE: Method to identify compounds which modulate
ICAM-related protein interactions
INVENTOR(S): Gallatin, W. Michael, Seattle, WA, United States
PATENT ASSIGNEE(S): ICOS Corporation, Bothell, WA, United States
(U.S. corporation)

NUMBER DATE

PATENT INFORMATION: US 5773218 980630
APPLICATION INFO: US 95-482882 950607 (8)
RELATED APPL. INFO.: Division of Ser. No. US 94-286754, filed on 5 Aug
1994, which is a continuation-in-part of Ser. No.
US 93-102852, filed on 5 Aug 1993, now abandoned
which is a continuation-in-part of Ser. No. US
93-9266, filed on 22 Jan 1993, now abandoned And
Ser. No. US 92-894061, filed on 5 Jun 1992, now
abandoned which is a continuation-in-part of Ser.
No. US 92-889724, filed on 26 May 1992, now
abandoned which is a continuation-in-part of Ser.
No. US 92-827689, filed on 27 Jan 1992, now

abandoned
DOCUMENT TYPE: Utility
PRIMARY EXAMINER: Allen, Marianne P.
ASSISTANT EXAMINER: Brown, Karen E.
LEGAL REPRESENTATIVE: Marshall, O'Toole, Gerstein, Murray & Borun
NUMBER OF CLAIMS: 2
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 39 Drawing Figure(s); 34 Drawing Page(s)
LINE COUNT: 5498
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB ***DNA*** sequences ***encoding*** a novel human intercellular adhesion molecule polypeptide (designated "ICAM-R") and variants thereof are disclosed along with methods and materials for production of the same by recombinant procedures. Binding molecules specific for ICAM-R and variants thereof are also disclosed as useful in both the isolation of ICAM-R from natural cellular sources and the modulation of ligand/receptor*** binding biological activities of ICAM-R.

L20 ANSWER 4 OF 26 USPATFULL
ACCESSION NUMBER: 1998:72709 USPATFULL
TITLE: ICAM-related protein fragments
INVENTOR(S): Gallatin, W. Michael, Seattle, WA, United States
Vazeux, Rosemary, Seattle, WA, United States
PATENT ASSIGNEE(S): ICOS Corporation, Bothell, WA, United States (U.S. corporation)

NUMBER DATE

PATENT INFORMATION: US 5770686 980623
APPLICATION INFO.: US 95-474368 950607 (8)
RELATED APPLN. INFO.: Division of Ser. No. US 95-425870, filed on 20 Apr 1995, now abandoned which is a continuation of Ser. No. US 93-102952, filed on 5 Aug 1993, now abandoned which is a continuation-in-part of Ser. No. US 93-9266, filed on 22 Jan 1993, now abandoned which is a continuation-in-part of Ser. No. US 92-894061, filed on 5 Jun 1992, now abandoned which is a continuation-in-part of Ser. No. US 92-889724, filed on 26 May 1992, now abandoned which is a continuation-in-part of Ser. No. US 92-827689, filed on 27 Jan 1992, now abandoned

NUMBER DATE

PRIORITY INFORMATION: WO 93-US787 930126
DOCUMENT TYPE: Utility
PRIMARY EXAMINER: Walsh, Stephen
ASSISTANT EXAMINER: Brown, Karen E.
LEGAL REPRESENTATIVE: Marshall, O'Toole, Gerstein, Murray & Borun
NUMBER OF CLAIMS: 5
EXEMPLARY CLAIM: 2, 4
NUMBER OF DRAWINGS: 38 Drawing Figure(s); 30 Drawing Page(s)
LINE COUNT: 3927
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB ***DNA*** sequences ***encoding*** a novel human intercellular adhesion molecule polypeptide (designated "ICAM-R") and variants thereof are disclosed along with methods and materials for production of the same by recombinant procedures. Binding molecules specific for ICAM-R and variants thereof are also disclosed as useful in both the isolation of ICAM-R from natural cellular sources and the modulation of ligand/receptor*** binding biological activities of ICAM-R.

L20 ANSWER 5 OF 26 USPATFULL
ACCESSION NUMBER: 1998:65363 USPATFULL
TITLE: Method of making MHC-peptide complexes using metal chelate affinity chromatography
INVENTOR(S): Nag, Bishwajit, Pacifica, CA, United States
PATENT ASSIGNEE(S): Anergis, Inc., Redwood City, CA, United States (U.S. corporation)

NUMBER DATE

PATENT INFORMATION: US 5763585 980509
APPLICATION INFO.: US 94-227372 940414 (8)

Conroy, Leah B., Pacifica, CA, United States
PATENT ASSIGNEE(S): Chiron Corporation, Emeryville, CA, United States (U.S. corporation)

NUMBER DATE

PATENT INFORMATION: US 5747034 980505
APPLICATION INFO.: US 94-200716 940218 (8)
RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 93-15147, filed on 9 Feb 1993 which is a continuation-in-part of Ser. No. US 92-910222, filed on 9 Jul 1992, now patented, Pat. No. US 5397703

DOCUMENT TYPE: Utility
PRIMARY EXAMINER: Loring, Susan A.
LEGAL REPRESENTATIVE: Pochopien, Donald J.; Savereide, Paul B.; Blackburn, Robert P.
NUMBER OF CLAIMS: 17
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 24 Drawing Figure(s); 13 Drawing Page(s)
LINE COUNT: 2155
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Anti-B7-1 antibodies or other B7-1 ligands may be used to prevent or treat a T-cell-mediated immune system disease in a patient or to induce ***antigen*** - ***specific*** tolerance.
The anti-B7-1 antibodies may be used to cause T cell anergy, treat allograft transplant rejection, treat graft versus host disease, and prevent or treat rheumatoid arthritis. An immunosuppressive agent is co-administered with the antibody.

L20 ANSWER 8 OF 26 USPATFULL
ACCESSION NUMBER: 1998:28196 USPATFULL
TITLE: Secreted proteins and polynucleotides encoding them
INVENTOR(S): Jacobs, Kenneth, Newton, MA, United States
McCoy, John M., Reading, MA, United States
LaValle, Edward R., Tewksbury, MA, United States
Racie, Lisa A., Acton, MA, United States
Merberg, David, Acton, MA, United States
Treacy, Maurice, Chestnut Hill, MA, United States
Evans, Cheryl, Brookline, MA, United States
Spaulding, Vikki, Billerica, MA, United States
PATENT ASSIGNEE(S): Genetics Institute, Inc., Cambridge, MA, United States (U.S. corporation)

NUMBER DATE

PATENT INFORMATION: US 5728819 980317
APPLICATION INFO.: US 96-691641 960802 (8)
DOCUMENT TYPE: Utility
PRIMARY EXAMINER: Walsh, Stephen
ASSISTANT EXAMINER: Kaufman, Claire M.
LEGAL REPRESENTATIVE: Brown, Scott A.; DesRosier, Thomas J.
NUMBER OF CLAIMS: 21
EXEMPLARY CLAIM: 1
LINE COUNT: 1864
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Novel polynucleotides and the proteins encoded thereby are disclosed.

L20 ANSWER 9 OF 26 USPATFULL
ACCESSION NUMBER: 1998:22079 USPATFULL
TITLE: Secreted proteins and polynucleotides encoding them
INVENTOR(S): Jacobs, Kenneth, Newton, MA, United States
McCoy, John M., Reading, MA, United States
LaValle, Edward R., Tewksbury, MA, United States
Racie, Lisa A., Acton, MA, United States
Merberg, David, Acton, MA, United States
Treacy, Maurice, Chestnut Hill, MA, United States
Spaulding, Vikki, Billerica, MA, United States
PATENT ASSIGNEE(S): Genetics Institute, Inc., Cambridge, MA, United States (U.S. corporation)

NUMBER DATE

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 93-136216, filed on 13 Oct 1993, now abandoned
DOCUMENT TYPE: Utility
PRIMARY EXAMINER: Caputa, Anthony C.
LEGAL REPRESENTATIVE: Townsend and Crew LLP
NUMBER OF CLAIMS: 11
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 14 Drawing Figure(s); 8 Drawing Page(s)
LINE COUNT: 1761
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention provides a method for the purification and characterization of MHC-peptide complexes useful in ameliorating immunological disorders, such as, for example, autoimmune diseases, allergic responses and transplant responses. The method disclosed is a one-step method based on the use of metal chelate affinity chromatography to separate the MHC-peptide complexes of interest from both uncomplexed MHC molecules and other endogenous MHC-peptide bound complexes.

L20 ANSWER 6 OF 26 USPATFULL
ACCESSION NUMBER: 1998:61171 USPATFULL
TITLE: Immunogenic LHRH peptide constructs and synthetic universal immune stimulators for vaccines
INVENTOR(S): Ladd, Anna Elfin, Brooklyn, NY, United States
Wang, Chang Yi, Cold Spring Harbor, NY, United States
Zamb, Timothy Joseph, Stony Brook, NY, United States
PATENT ASSIGNEE(S): United Biomedical, Inc., Huppauge, NY, United States (U.S. corporation)

NUMBER DATE

PATENT INFORMATION: US 5759551 980602
APPLICATION INFO.: US 95-446592 951226 (8)
WO 94-25060 941110
WO 94-US4832 940426
951226 PCT 371 date
951226 PCT 102(e) date

RELATED APPLN. INFO.: Division of Ser. No. US 95-488351, filed on 7 Jun 1995

DOCUMENT TYPE: Utility
PRIMARY EXAMINER: Smith, Lynette F.
LEGAL REPRESENTATIVE: Morgan & Finnegan, LLP
NUMBER OF CLAIMS: 15
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 37 Drawing Figure(s); 37 Drawing Page(s)
LINE COUNT: 3752
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB This invention relates to immunogenic luteinizing hormone releasing hormone (LHRH) peptides that lead to suppression of LHRH activity in males or females. When male rats are immunized with these peptides, serum testosterone drops and androgen-dependent organs atrophy significantly. These peptides are useful for inducing infertility and for treating prostatic hyperplasia, androgen-dependent carcinoma, prostatic carcinoma and testicular carcinoma in males. In females, the peptides are useful for treating endometriosis, benign uterine tumors, recurrent functional ovarian cysts and (severe) premenstrual syndrome as well as prevention or treatment of estrogen-dependent breast cancer. The subject peptides contain a helper T cell epitope and have LHRH at the C terminus. The helper T cell epitope aids in stimulating the immune response against LHRH. The peptides, optionally contain an invasion domain which acts as a general immune stimulator. In another aspect this invention relates to immunogenic synthetic peptides having an invasion domain, a helper T cell epitope and a peptide hapten and methods of using these peptides to treat disease or provide protective immunity. The peptide haptens of the invention include LHRH, amylin, gastrin, gastrin releasing peptide, IgE CH4 peptide, Chlamydia MOMP peptides, HIV V3 peptides and Plasmodium berghai.

L20 ANSWER 7 OF 26 USPATFULL
ACCESSION NUMBER: 1998:47964 USPATFULL
TITLE: Methods and materials for the induction of T cell anergy
INVENTOR(S): de Boer, Mark, Beverwijk, Netherlands

PATENT INFORMATION: US 5723315 980303
APPLICATION INFO.: US 96-702344 960823 (8)
DOCUMENT TYPE: Utility
PRIMARY EXAMINER: Walsh, Stephen
ASSISTANT EXAMINER: Kaufman, Claire M.
LEGAL REPRESENTATIVE: Brown, Scott A.; Sprunger, Suzanne A.; DesRosier, Thomas J.
NUMBER OF CLAIMS: 20
EXEMPLARY CLAIM: 1
LINE COUNT: 2437
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Novel polynucleotides and the proteins encoded thereby are disclosed.

L20 ANSWER 10 OF 26 USPATFULL
ACCESSION NUMBER: 1998:17059 USPATFULL
TITLE: Transgenic animal model for autoimmune diseases
INVENTOR(S): Harlan, David M.; Potomac, MD, United States
June, Carl H.; Rockville, MD, United States
PATENT ASSIGNEE(S): The United States of America as represented by the Secretary of the Navy, Washington, DC, United States (U.S. government)
NUMBER DATE
PATENT INFORMATION: US 5718883 980217
APPLICATION INFO.: US 94-197790 940217 (8)
RELATED APPL. INFO.: Continuation-in-part of Ser. No. US 93-48042, filed on 14 Apr 1993, now abandoned
DOCUMENT TYPE: Utility
PRIMARY EXAMINER: Campell, Bruce R.
LEGAL REPRESENTATIVE: Spevack, A. David; Mandragouras, Amy E. Lahive &

NUMBER OF CLAIMS: 19
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 32 Drawing Figure(s); 11 Drawing Page(s)
LINE COUNT: 1941
AB A transgenic animal, whose germ cells and somatic cells contain a transgene including a "DNA" sequence "encoding" a CD28 ligand and a tissue-specific promoter operably linked to the DNA sequence, wherein the tissue-specific promoter effects expression of the CD28 ligand in cells of a specific tissue of the animal is disclosed. This animal serves as a transgenic model for specific autoimmune diseases.

L20 ANSWER 11 OF 26 USPATFULL
ACCESSION NUMBER: 1998:12125 USPATFULL
TITLE: Antibodies that are immunoreactive with interleukin-7
INVENTOR(S): Namen, Anthony E.; Seattle, WA, United States
Goodwin, Raymond G.; Seattle, WA, United States
Lupton, Stephen D.; Seattle, WA, United States
Mochizuki, Diane Y.; Seattle, WA, United States
PATENT ASSIGNEE(S): Sterling Winthrop, Inc., New York, NY, United States (U.S. corporation)
NUMBER DATE

PATENT INFORMATION: US 5714585 980203
APPLICATION INFO.: US 94-231205 940421 (8)
RELATED APPL. INFO.: Division of Ser. No. US 92-957649, filed on 6 Oct 1992, now patented, Pat. No. US 5328988 which is a continuation of Ser. No. US 90-511438, filed on 13 Apr 1990, now abandoned which is a division of Ser. No. US 88-255209, filed on 7 Oct 1988, now patented, Pat. No. US 4965195 which is a continuation-in-part of Ser. No. US 87-113566, filed on 26 Oct 1987, now abandoned
DOCUMENT TYPE: Utility
PRIMARY EXAMINER: Eisenschank, Frank C.
LEGAL REPRESENTATIVE: Davis, William J.
NUMBER OF CLAIMS: 6
EXEMPLARY CLAIM: 1
LINE COUNT: 1963

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Antibodies that are immunoreactive with interleukin-7 (IL-7) proteins are provided. The anti-IL-7 antibodies may be polyclonal or monoclonal. Certain embodiments are directed to antibodies that are immunoreactive with human IL-7.

L20 ANSWER 12 OF 26 USPATFULL
ACCESSION NUMBER: 1998:9379 USPATFULL
TITLE: Chimeric "receptor" molecules for delivery of "co" - "stimulatory" signals
INVENTOR(S): States
PATENT ASSIGNEE(S): Cell Genesys, Inc., Foster City, CA, United States (U.S. corporation)

PATENT INFORMATION: US 5712149 980127
APPLICATION INFO.: US 95-383749 950203 (8)
DOCUMENT TYPE: Utility
PRIMARY EXAMINER: Uim, John
LEGAL REPRESENTATIVE: Sughrue, Mton, Zinn, Macpeak & Seas, PLLC
NUMBER OF CLAIMS: 25
EXEMPLARY CLAIM: 1
LINE COUNT: 1722
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB "stimulatory" "receptor" proteins and "DNA" sequences "encoding" these proteins. The chimeric "receptors" comprise at least three domains in a single chain molecule: an extracellular ligand binding domain, a transmembrane domain and a cytoplasmic "stimulatory" effector function signaling domain that acts synergistically with an effector function signal in the host cell. Novel hybrid "co" - "stimulatory" "receptor" proteins include a second cytoplasmic effector function signaling domain. The invention further relates to expression cassettes containing the "nucleic" "acids" "encoding" the novel chimeric "receptors", to host cells expressing the novel chimeric "receptors", and to methods of using the "receptors" to "stimulate" effector functions in the cells and for using cells expressing the "receptors" for treatment of cancer, disease and viral infections.

L20 ANSWER 13 OF 26 USPATFULL
ACCESSION NUMBER: 1998:4755 USPATFULL
TITLE: Secreted proteins and polynucleotides encoding them
INVENTOR(S): Jacobs, Kenneth, Newton, MA, United States
McCoy, John M.; Reading, MA, United States
LaValle, Edward R.; Tewksbury, MA, United States
Racie, Lisa A.; Acton, MA, United States
Merberg, David, Acton, MA, United States
Tracy, Maurice, Chestnut Hill, MA, United States
Evans, Cheryl, Brookline, MA, United States
PATENT ASSIGNEE(S): Genetics Institute, Inc., Cambridge, MA, United States (U.S. corporation)

PATENT INFORMATION: US 5708157 980113
APPLICATION INFO.: US 96-698878 960726 (8)
DOCUMENT TYPE: Utility
PRIMARY EXAMINER: Walsh, Stephen
ASSISTANT EXAMINER: Kaufman, Claire M.
LEGAL REPRESENTATIVE: Brown, Scott A.; Sprunger, Suzanne A.; DesRosier, Thomas J.
NUMBER OF CLAIMS: 21
EXEMPLARY CLAIM: 1
LINE COUNT: 3204
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Novel polynucleotides and the proteins encoded thereby are disclosed.

NUMBER DATE
PATENT INFORMATION: US 5708157 980113
APPLICATION INFO.: US 96-698878 960726 (8)
DOCUMENT TYPE: Utility
PRIMARY EXAMINER: Walsh, Stephen
ASSISTANT EXAMINER: Kaufman, Claire M.
LEGAL REPRESENTATIVE: Brown, Scott A.; Sprunger, Suzanne A.; DesRosier, Thomas J.
NUMBER OF CLAIMS: 21
EXEMPLARY CLAIM: 1
LINE COUNT: 3204
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Novel polynucleotides and the proteins encoded thereby are disclosed.

disclosed.

L20 ANSWER 14 OF 26 USPATFULL
ACCESSION NUMBER: 1998:1443 USPATFULL
TITLE: Use of interleukin-7 to stimulate "proliferation" of hematopoietic cell precursors
INVENTOR(S): Namen, Anthony E.; Seattle, WA, United States
Goodwin, Raymond G.; Seattle, WA, United States
Lupton, Stephen D.; Seattle, WA, United States
Mochizuki, Diane Y.; Seattle, WA, United States
PATENT ASSIGNEE(S): Sterling Winthrop, Inc., New York, NY, United States (U.S. corporation)

NUMBER DATE
PATENT INFORMATION: US 5705149 980106
APPLICATION INFO.: US 95-446908 950522 (6)
RELATED APPL. INFO.: Division of Ser. No. US 94-231205, filed on 21 Apr 1994 which is a division of Ser. No. US 92-957649, filed on 6 Oct 1992, now patented, Pat. No. US 5328988 which is a continuation of Ser. No. US 90-511438, filed on 13 Apr 1990, now abandoned which is a division of Ser. No. US 88-255209, filed on 7 Oct 1988, now patented, Pat. No. US 4965195 which is a continuation of Ser. No. US 87-113566, filed on 26 Oct 1987, now abandoned
DOCUMENT TYPE: Utility
PRIMARY EXAMINER: Uim, John
ASSISTANT EXAMINER: Mertz, Prema
LEGAL REPRESENTATIVE: Davis, William J.
NUMBER OF CLAIMS: 10
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 8 Drawing Figure(s); 7 Drawing Page(s)
LINE COUNT: 2052
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Mammalian Interleukin-7 proteins (IL-7s), "DNAs" and expression vectors "encoding" mammalian IL-7s, and processes for producing mammalian IL-7s as products of cell culture, including recombinant systems, are disclosed.

L20 ANSWER 15 OF 26 USPATFULL
ACCESSION NUMBER: 97:104313 USPATFULL
TITLE: Chimeric "receptor" molecules for delivery of "co" - "stimulatory" signals
INVENTOR(S): Roberts, Margo R., San Francisco, CA, United States
PATENT ASSIGNEE(S): Cell Genesys, Inc., Foster City, CA, United States (U.S. corporation)
NUMBER DATE
PATENT INFORMATION: US 5686281 971111
APPLICATION INFO.: US 95-455860 950531 (8)
RELATED APPL. INFO.: Continuation of Ser. No. US 95-383749, filed on 3 Feb 1995
DOCUMENT TYPE: Utility
PRIMARY EXAMINER: Uim, John
LEGAL REPRESENTATIVE: Sughrue, Mton, Zinn, Macpeak & Seas, PLLC
NUMBER OF CLAIMS: 11
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 5 Drawing Figure(s); 3 Drawing Page(s)
LINE COUNT: 1627
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention is directed to novel chimeric "stimulatory" "receptor" proteins and "DNA" sequences "encoding" these proteins. The chimeric "receptors" comprise at least three domains in a single chain molecule: an extracellular ligand binding domain, a transmembrane domain and a cytoplasmic "stimulatory" effector function signaling domain that acts synergistically with an effector function signal in the host cell. Novel hybrid "co" - "stimulatory" "receptor" proteins include a second cytoplasmic effector function signaling domain. The invention further relates to expression cassettes

disclosed.

containing the ***nucleic*** ***acids*** ***encoding***
the novel chimeric ***receptors***, to host cells expressing
the novel chimeric ***receptors*** and to methods of using the
receptors to ***co*** - ***simulate*** effector
functions in the cells and for using cells expressing the
receptors for treatment of cancer, disease and viral
infections.

L20 ANSWER 16 OF 26 USPATFULL
ACCESSION NUMBER: 97:78562 USPATFULL
TITLE: ICAM-related protein
INVENTOR(S): Gallatin, W. Michael, Seattle, WA, United States
PATENT ASSIGNEE(S): Vazeux, Rosemary, Seattle, WA, United States
(U.S. corporation)

NUMBER DATE
PATENT INFORMATION: US 5663293 970902
APPLICATION INFO.: US 95-433010 950503 (8)
RELATED APPLN. INFO.: Continuation of Ser. No. US 93-9266, filed on 22
Jan 1993, now abandoned which is a
continuation-in-part of Ser. No. US 92-894061,
filed on 5 Jun 1992, now abandoned which is a
continuation-in-part of Ser. No. US 92-869724,
filed on 26 May 1992, now abandoned which is a
continuation-in-part of Ser. No. US 92-827689,
filed on 27 Jan 1992, now abandoned

DOCUMENT TYPE: Utility
PRIMARY EXAMINER: Ulin, John
ASSISTANT EXAMINER: Brown, Karen E.
LEGAL REPRESENTATIVE: Marshall, O'Toole, Gerstein, Murray & Borun
NUMBER OF CLAIMS: 16
EXEMPLARY CLAIM: 16
NUMBER OF DRAWINGS: 29 Drawing Figure(s); 23 Drawing Page(s)
LINE COUNT: 2834

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB ***DNA*** sequences ***encoding*** a novel human
intercellular adhesion molecule polypeptide (designated "ICAM-R")
and variants thereof are disclosed along with methods and
materials for production of the same by recombinant procedures.
Binding molecules specific for ICAM-R and variants thereof are
also disclosed as useful in both the isolation of ICAM-R from
natural cellular sources and the modulation of ligand/
receptor binding biological activities of ICAM-R.

L20 ANSWER 17 OF 26 USPATFULL
ACCESSION NUMBER: 97:68346 USPATFULL
TITLE: Secreted proteins and polynucleotides encoding
them

INVENTOR(S): Jacobs, Kenneth, Newton, MA, United States
McCoy, John M., Reading, MA, United States
LaValle, Edward R., Tewksbury, MA, United States
Rade, Lisa A., Acton, MA, United States
Merberg, David, Acton, MA, United States
Treacy, Maurice, Chestnut Hill, MA, United States
Spaulding, Vikki, Billerica, MA, United States
PATENT ASSIGNEE(S): Genetics Institute, Inc., Cambridge, MA, United
States (U.S. corporation)

NUMBER DATE
PATENT INFORMATION: US 5654173 970805
APPLICATION INFO.: US 96-702080 960823 (8)
DOCUMENT TYPE: Utility
PRIMARY EXAMINER: Jagannathan, Vasu S.
ASSISTANT EXAMINER: Lethrop, Brian
LEGAL REPRESENTATIVE: Brown, Scott A.; DesRosier, Thomas J.
NUMBER OF CLAIMS: 14
EXEMPLARY CLAIM: 14
LINE COUNT: 1685

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Novel polynucleotides and the proteins encoded thereby are
disclosed.

L20 ANSWER 18 OF 26 USPATFULL
ACCESSION NUMBER: 97:61556 USPATFULL

TITLE: Immortalized dendritic cells
INVENTOR(S): MacKey, Vivian L., Seattle, WA, United States
Moore, Emma E., Seattle, WA, United States
PATENT ASSIGNEE(S): ZymoGenetics, Inc., Seattle, WA, United States
(U.S. corporation)

NUMBER DATE
PATENT INFORMATION: US 5648219 970715
APPLICATION INFO.: US 95-479882 950607 (8)
DOCUMENT TYPE: Utility
PRIMARY EXAMINER: Chan, Christina Y.
ASSISTANT EXAMINER: Vandevogt, F. Pierre
LEGAL REPRESENTATIVE: Sawistak, Deborah A.; Parker, Gary E.; Leith,
Debra K.

NUMBER OF CLAIMS: 15
EXEMPLARY CLAIM: 4
NUMBER OF DRAWINGS: 1 Drawing Figure(s); 1 Drawing Page(s)
LINE COUNT: 1020
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention provides an immature dendritic cell line
derived from p53 ***growth*** suppressor gene deficient
animals. The immature dendritic cell line may be induced to become
an ***activated*** dendritic cell line that will stimulate
T-cells to ***proliferate***. The cell line is useful for
presentation of antigens involved in autoimmune disease and
analysis of peptides that produce a T-cell response.

L20 ANSWER 19 OF 26 USPATFULL
ACCESSION NUMBER: 97:22653 USPATFULL
TITLE: Cloning and recombinant production of vespid
venom phospholipases, and immunological therapies
based thereon
INVENTOR(S): King, Te P., New York, NY, United States
PATENT ASSIGNEE(S): The Rockefeller University, New York, NY, United
States (U.S. corporation)

NUMBER DATE
PATENT INFORMATION: US 5612209 970318
APPLICATION INFO.: US 95-385745 950208 (8)
RELATED APPLN. INFO.: Continuation of Ser. No. US 93-31400, filed on 11
Mar. 1993, now abandoned

DOCUMENT TYPE: Utility
PRIMARY EXAMINER: Wax, Robert A.
ASSISTANT EXAMINER: Saidha, Tekchand
LEGAL REPRESENTATIVE: Klauber & Jackson
NUMBER OF CLAIMS: 22
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 7 Drawing Figure(s); 7 Drawing Page(s)
LINE COUNT: 1852

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention is directed to ***nucleic***
acids ***encoding*** vespid venom phospholipases, or
fragments thereof, recombinant vectors comprising such nucleic
acids, and host cells containing the recombinant vectors. The
invention is further directed to expression of such nucleic acids
to produce recombinant vespid venom phospholipases, or recombinant
fragments, derivatives or analogs thereof. Such recombinant
products are useful for diagnosis of allergy and for therapeutic
treatment of allergy. In specific embodiments, the present
invention provides ***nucleic*** ***acids***
encoding, and complete nucleotide and amino acids
sequences for, vespid venom phospholipase A1, for example,
Dolichovespula maculata phospholipase A sub. 1 and Vespula vulgaris
phospholipase A1.

L20 ANSWER 20 OF 26 USPATFULL
ACCESSION NUMBER: 97:6049 USPATFULL
TITLE: Method of refofing human IL-13
INVENTOR(S): Culpepper, Janice, Mountain View, CA, United
States
McKenzie, Andrew, Redwood City, CA, United States
Dang, Warren, San Jose, CA, United States
Zurewski, Gerard, Redwood City, CA, United States
PATENT ASSIGNEE(S): Schering Corporation, Kenilworth, NJ, United
States (U.S. corporation)

NUMBER DATE
PATENT INFORMATION: US 5596072 970121
APPLICATION INFO.: US 93-12543 930201 (8)
RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 92-933416,
filed on 21 Aug 1992, now abandoned

DOCUMENT TYPE: Utility
PRIMARY EXAMINER: Draper, Gamette D.
ASSISTANT EXAMINER: Spector, Lorraine M.
LEGAL REPRESENTATIVE: Ching, Edwin P.
NUMBER OF CLAIMS: 10
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 288 Drawing Figure(s); 61 Drawing Page(s)
LINE COUNT: 4619

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB ***Nucleic*** ***acids*** ***encoding*** human IL-13,
and purified IL-13 proteins and fragments thereof. Antibodies,
both polyclonal and monoclonal, are also provided. Methods of
using the compositions for both diagnostic and therapeutic
utilities are provided.

L20 ANSWER 21 OF 26 USPATFULL
ACCESSION NUMBER: 97:3726 USPATFULL
TITLE: Nucleic acid and recombinant production of vespid
venom hyaluronidase
INVENTOR(S): King, Te P., New York, NY, United States
PATENT ASSIGNEE(S): The Rockefeller University, New York, NY, United
States (U.S. corporation)

NUMBER DATE
PATENT INFORMATION: US 5593877 970114
APPLICATION INFO.: US 94-180209 940111 (8)
RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 93-31400,
filed on 11 Mar. 1993, now abandoned

DOCUMENT TYPE: Utility
PRIMARY EXAMINER: Walsh, Stephen G.
LEGAL REPRESENTATIVE: Klauber & Jackson
NUMBER OF CLAIMS: 12
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 15 Drawing Figure(s); 13 Drawing Page(s)
LINE COUNT: 2479

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention is directed to ***nucleic***
acids ***encoding*** vespid venom enzymes, or
fragments thereof, recombinant vectors comprising such nucleic
acids, and host cells containing the recombinant vectors. The
invention is further directed to expression of such nucleic acids
to produce recombinant vespid venom enzymes, or recombinant
fragments, derivatives or analogs thereof. Such recombinant
products are useful for diagnosis of allergy and for therapeutic
treatment of allergy. In specific embodiments, the present
invention provides ***nucleic*** ***acids***
encoding, and complete nucleotide and amino acids
sequences for, vespid venom phospholipase, for example,
Dolichovespula maculata phospholipase and Vespula vulgaris
phospholipase, and vespid venom hyaluronidase, for example,
Dolichovespula maculata hyaluronidase.

L20 ANSWER 22 OF 26 USPATFULL
ACCESSION NUMBER: 96:106593 USPATFULL
TITLE: Antibodies to the siam protein expressed on
activated T cells
INVENTOR(S): Aversa, Gregorio, Palo Alto, CA, United States
Chang, Chie-Chun J., San Jose, CA, United States
Cocks, Benjamin G., Mountain View, CA, United
States
de Vries, Jan E., Los Altos, CA, United States
PATENT ASSIGNEE(S): Schering Corporation, Kenilworth, NJ, United
States (U.S. corporation)

NUMBER DATE
PATENT INFORMATION: US 5576423 961119
APPLICATION INFO.: US 94-348792 941202 (8)
DOCUMENT TYPE: Utility

PRIMARY EXAMINER: Nucker, Christine M.
ASSISTANT EXAMINER: Reeves, Julie E.
LEGAL REPRESENTATIVE: Ching, Edwin P.
NUMBER OF CLAIMS: 26
EXEMPLARY CLAIM: 1
LINE COUNT: 2811
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Purified "genes" which "encode" a T cell surface antigen from a mammal, reagents related thereto including purified proteins, "specific" antibodies, and "nucleic" "acids" "encoding" said "nucleic" "Methods of using said reagents and diagnostic "kits" are also provided.

L20 ANSWER 23 OF 26 USPATFULL
ACCESSION NUMBER: 96-50801 USPATFULL
TITLE: Signal transduction via CD28
INVENTOR(S): Rudd, Christopher E., Cambridge, MA, United States
PATENT ASSIGNEE(S): Dana-Farber Cancer Institute, Inc., Boston, MA, United States (U.S. corporation)

NUMBER DATE
PATENT INFORMATION: US 5525503 960611
APPLICATION INFO.: US 93-128971 930928 (8)
DOCUMENT TYPE: Utility
PRIMARY EXAMINER: Ziska, Suzanne E.
LEGAL REPRESENTATIVE: Fish & Richardson
EXEMPLARY CLAIM: 2
NUMBER OF DRAWINGS: 10 Drawing Figure(s); 7 Drawing Page(s)
LINE COUNT: 1056
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Disclosed are compositions and methods of blocking T cell signal transduction by introducing into a T cell a peptide comprising a P1 3-kinase-binding-sequence which decreases the association of P1 3-kinase with CD28. Also disclosed are compositions and methods of amplifying T cell "activation" by introducing into a T cell, a plurality of modified T cell surface proteins, the cytoplasmic tail of which comprises a plurality of copies of a P1 3-kinase-binding-sequence.

L20 ANSWER 24 OF 26 USPATFULL
ACCESSION NUMBER: 95-103247 USPATFULL
TITLE: MHC class II-peptide conjugates useful in ameliorating autoimmunity
INVENTOR(S): Sharma, Somesh D., Los Altos, CA, United States
Clark, Brian R., Redwood City, CA, United States
Lerch, Bernard L., Palo Alto, CA, United States
PATENT ASSIGNEE(S): Amgen, Inc., Redwood City, CA, United States (U.S. corporation)

NUMBER DATE
PATENT INFORMATION: US 5468481 951121
APPLICATION INFO.: US 92-869293 920414 (7)
DISCLAIMER DATE: 20090714
RELATED APPL. INFO.: Continuation-in-part of Ser. No. US 91-690840, filed on 23 Apr 1991, now patented, Pat. No. US 5260422 which is a continuation-in-part of Ser. No. US 90-576084, filed on 30 Aug 1990, now patented, Pat. No. US 5130297 which is a continuation of Ser. No. US 88-210594, filed on 23 Jun 1988, now abandoned And a continuation-in-part of Ser. No. US 90-635840, filed on 28 Dec 1990, now patented, Pat. No. US 5284935 which is a continuation-in-part of Ser. No. US 89-367751, filed on 21 Jun 1989, now patented, Pat. No. US 5194425

DOCUMENT TYPE: Utility
PRIMARY EXAMINER: Kim, Key K. A.
ASSISTANT EXAMINER: Cunningham, T.
LEGAL REPRESENTATIVE: Townsend and Townsend and Crew
NUMBER OF CLAIMS: 22
EXEMPLARY CLAIM: 1

NUMBER OF DRAWINGS: 35 Drawing Figure(s); 26 Drawing Page(s)
LINE COUNT: 2266
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention is directed to complexes consisting essentially of an isolated MHC component and an autoantigenic peptide associated with the antigen binding site of the MHC component. These complexes are useful in treating autoimmune disease.

L20 ANSWER 25 OF 26 USPATFULL
ACCESSION NUMBER: 94-60237 USPATFULL
TITLE: Interleukin-7
INVENTOR(S): Namen, Anthony E., Seattle, WA, United States
Goodwin, Raymond G., Seattle, WA, United States
Lupton, Stephen D., Seattle, WA, United States
Mochizuki, Diane Y., Seattle, WA, United States
PATENT ASSIGNEE(S): Immunex Corporation, Seattle, WA, United States (U.S. corporation)

NUMBER DATE
PATENT INFORMATION: US 5328988 940712
APPLICATION INFO.: US 92-957649 921006 (7)
RELATED APPL. INFO.: Continuation of Ser. No. US 90-511438, filed on 13 Apr 1990, now abandoned which is a division of Ser. No. US 85-255209, filed on 7 Oct 1989, now patented, Pat. No. US 4965195 And a continuation-in-part of Ser. No. US 87-113566, filed on 26 Oct 1987, now abandoned

DOCUMENT TYPE: Utility
PRIMARY EXAMINER: Draper, Garnette D.
NUMBER OF CLAIMS: 4
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 8 Drawing Figure(s); 8 Drawing Page(s)
LINE COUNT: 1706
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Mammalian Interleukin-7 proteins (IL-7s), "DNAs" and expression vectors "encoding" mammalian IL-7s, and processes for producing mammalian IL-7s as products of cell culture, including recombinant systems, are disclosed.

L20 ANSWER 26 OF 26 USPATFULL
ACCESSION NUMBER: 90-81722 USPATFULL
TITLE: Interleukin-7
INVENTOR(S): Namen, Anthony E., Seattle, WA, United States
Goodwin, Raymond G., Seattle, WA, United States
Lupton, Stephen D., Seattle, WA, United States
Mochizuki, Diane Y., Seattle, WA, United States
PATENT ASSIGNEE(S): Immunex Corp., Seattle, WA, United States (U.S. corporation)

NUMBER DATE
PATENT INFORMATION: US 4965195 901023
APPLICATION INFO.: US 88-255209 881007 (7)
RELATED APPL. INFO.: Continuation-in-part of Ser. No. US 87-113566, filed on 26 Oct 1987

DOCUMENT TYPE: Utility
PRIMARY EXAMINER: Wiseman, Thomas G.
ASSISTANT EXAMINER: Ellis, Joan
NUMBER OF CLAIMS: 17
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 7 Drawing Figure(s); 7 Drawing Page(s)
LINE COUNT: 1714
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Mammalian Interleukin-7 proteins (IL-7s), "DNAs" and expression vectors "encoding" mammalian IL-7s, and processes for producing mammalian IL-7s as products of cell culture, including recombinant systems, are disclosed.

=> s 113 and kit

L21 637 L13 AND KIT
=> s 121 and kit

L22 637 L21 AND KIT

=> s 121 and extracell?

L23 313 L21 AND EXTRACELL?

=> s 113 and vector

L24 92 L 13 AND VECTOR

=> dup rem

ENTER LF LIST OR (END);124

PROCESSING COMPLETED FOR L24
L25 88 DUP REM L24 (4 DUPLICATES REMOVED)

=> d 125 1-88 ibb ab

L25 ANSWER 1 OF 88 USPATFULL
ACCESSION NUMBER: 1998-85817 USPATFULL
TITLE: Cathepsin and methods and compositions for inhibition thereof
INVENTOR(S): Tung, Jay S., 2224 Semeria Ave., Belmont, CA, United States 94002
Sirha, Sukanto, 808 Junipero Serra Blvd., San Francisco, CA, United States 94127
McConlogue, Lisa, 283 Juanita Way, San Francisco, CA, United States 94127
Tatsuno, Gwen, 5910 Pinewood Rd., Oakland, CA, United States 94611
Anderson, John, 21 Bucareli Dr., San Francisco, CA, United States 94132
Chrysler, Susanna, 448-1/2 San Bruno Ave., Brisbane, CA, United States 94005

NUMBER DATE

PATENT INFORMATION: US 5783434 980721
APPLICATION INFO.: US 95-467607 950606 (8)
DOCUMENT TYPE: Utility
PRIMARY EXAMINER: Zitomer, Stephanie W.
ASSISTANT EXAMINER: Whisenant, Ethan
LEGAL REPRESENTATIVE: Burns, Doane, Swecker & Mathis, L.L.P.
NUMBER OF CLAIMS: 2
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 9 Drawing Figure(s); 10 Drawing Page(s)
LINE COUNT: 2303
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Methods for inhibiting the secretion of beta-amyloid peptide (beta AP) from cells comprise administering to the cells certain compounds which inhibit the activity of an approximately 31 kD protease involved in beta AP secretion. The 31 kD protease has been designated Cathepsin Y. Screening methods for beta AP inhibitors rely on determining the activity of test compounds in the presence of Cathepsin Y and a suitable peptide substrate. This invention is also directed to a nucleic acid sequence that encodes Cathepsin Y and the expression and isolation of Cathepsin Y.

L25 ANSWER 2 OF 88 USPATFULL
ACCESSION NUMBER: 1998-76936 USPATFULL
TITLE: Development of a PCR-based method for identification of Tilletia indica, causal agent of Karnal bunt of wheat

INVENTOR(S): Smith, Oney P., Frederick, MD, United States
Peterson, Gary L., Walkersville, MD, United States

Beck, Raymond J., Frederick, MD, United States
Bonde, Morris R., Middletown, MD, United States
Schaad, Norman W., Myersville, MD, United States

PATENT ASSIGNEE(S): The United States of America as represented by the Secretary of Agriculture, Washington, DC, United States (U.S. government)

NUMBER DATE

PATENT INFORMATION: US 5776686 980707
APPLICATION INFO.: US 96-772961 961224 (8)

DOCUMENT TYPE: Utility
PRIMARY EXAMINER: Jones, W. Gary
ASSISTANT EXAMINER: Whisenant, Ethan
LEGAL REPRESENTATIVE: Silverstein, M. Howard; Deck, Randall E.; Fado, John D.
NUMBER OF CLAIMS: 18
EXEMPLARY CLAIM: 13

LINE COUNT: 936
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The polymerase chain reaction (PCR) was used to identify *Tilletia indica*, the causal agent of Karnal bunt of wheat. The method uses two sets of oligonucleotide primers developed by sequence analysis of cloned *Dra* I fragments of mitochondrial DNA of *T. indica*. The primer pair T117M1 (5'-TCCCTTGTGGATCAGAACGTA-3') and T117M2 (5'-AGAAGTCTAACTCCGCCCTCT-3'), derived from clone pTH-MD17, amplified a single 825-bp product from all isolates of *T. indica* and no products for other *Tilletia* species. In addition, the primer pair T157M1 (5'-TTTCCCTCTCTC-CTTTTTC-3') and T157M2 (5'-AGCAAGAAAGAGATGAGCTTCC-3'), derived from clone pTH-MD57, produced a product of 118 bp which was unique to *T. indica*.

L25 ANSWER 3 OF 88 USPATEFULL
ACCESSION NUMBER: 1988:72601 USPATEFULL
TITLE: Pharmaceutical dipeptide compositions and methods of use thereof: systemic toxicity
INVENTOR(S): Morozov, Vyacheslav G., St. Petersburg, Russian Federation
Kharinson, Vladimir Kh., St. Petersburg, Russian Federation
PATENT ASSIGNEE(S): Cytran, Inc., Kirkland, WA, United States (U.S. corporation)

NUMBER DATE
PATENT INFORMATION: US 5770576 980623
APPLICATION INFO.: US 95-452077 950526 (8)
RELATED APPL. INFO.: Continuation of Ser. No. US 94-337341, filed on 10 Nov 1994, now patented, Pat. No. US 5538951 which is a division of Ser. No. US 89-415283, filed on 30 Aug 1989 And a continuation-in-part of Ser. No. US 94-278463, filed on 21 Jul 1994, now abandoned which is a continuation-in-part of Ser. No. US 94-257495, filed on 7 Jun 1994, now abandoned which is a continuation of Ser. No. US 91-783518, filed on 28 Oct 1991, now abandoned which is a continuation-in-part of Ser. No. US 91-678129, filed on 1 Apr 1991, now abandoned which is a continuation-in-part of Ser. No. US 89-415283, filed on 30 Aug 1989, now abandoned
DOCUMENT TYPE: Utility
PRIMARY EXAMINER: Robinson, Douglas W.
ASSISTANT EXAMINER: Harte, Jennifer
NUMBER OF CLAIMS: 13
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 14 Drawing Figure(s); 7 Drawing Page(s)
LINE COUNT: 8823
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Methods of treatment of subjects with systemic toxicity by administering an R'-Glu-Trip-R' pharmaceutical preparation.

L25 ANSWER 4 OF 88 USPATEFULL
ACCESSION NUMBER: 1998:70440 USPATEFULL
TITLE: Tokens-based adaptive video processing arrangement
INVENTOR(S): Wise, Adrian Philip, Bristol, United Kingdom
PATENT ASSIGNEE(S): Discovision Associates, Irvine, CA, United States (U.S. corporation)

NUMBER DATE
PATENT INFORMATION: US 5768561 980616
APPLICATION INFO.: US 95-398998 950307 (8)
RELATED APPL. INFO.: Division of Ser. No. US 95-400397, filed on 7 Mar 1995 which is a continuation-in-part of Ser. No. US 95-382958, filed on 2 Feb 1995, now abandoned which is a continuation of Ser. No. US 93-82291, filed on 24 Jun 1993, now abandoned

PRIORITY INFORMATION: EP 92-306038 920630
GB 94-5914 940324
GB 95-4047 950228
DOCUMENT TYPE: Utility
PRIMARY EXAMINER: Teska, Kevin J.
ASSISTANT EXAMINER: Walker, Tyrone V.
LEGAL REPRESENTATIVE: Clark, Ronald J.; Braun, Robert T.; Bickel, Arthur S.
NUMBER OF CLAIMS: 37
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 189 Drawing Figure(s); 124 Drawing Page(s)
LINE COUNT: 19426
AB A multi-standard video decompression apparatus has a plurality of stages interconnected by a two-wire interface arranged as a pipeline processing machine. Control tokens and DATA Tokens pass over the single two-wire interface for carrying both control and data in token format. A token decode circuit is positioned in certain of the stages for recognizing certain of the tokens as control tokens pertinent to that stage and for passing unrecognized control tokens along the pipeline. Reconfiguration processing circuits are positioned in selected stages and are responsive to a recognized control token for reconfiguring such stage to handle an identified DATA Token. A wide variety of unique supporting subsystem circuitry and processing techniques are disclosed for implementing the system.

L25 ANSWER 5 OF 88 USPATEFULL
ACCESSION NUMBER: 1998:70176 USPATEFULL
TITLE: Memory implemented error detection and correction code capable of detecting errors in fetching data from a wrong address
INVENTOR(S): Chen, Chin-Long, Fishkill, NY, United States
Hsiao, Mu-Yue, Poughkeepsie, NY, United States
Lippner, Walter Heinrich, Ammerbuch, Germany, Federal Republic of
Shen, William Wu, Poughkeepsie, NY, United States
PATENT ASSIGNEE(S): International Business Machines Corporation, Armonk, NY, United States (U.S. corporation)

NUMBER DATE
PATENT INFORMATION: US 5768294 980616
APPLICATION INFO.: US 95-570448 951211 (8)
DOCUMENT TYPE: Utility
PRIMARY EXAMINER: Elmore, Reba I.
ASSISTANT EXAMINER: Marc, McDiemel
LEGAL REPRESENTATIVE: Neff, Lily
NUMBER OF CLAIMS: 21
EXEMPLARY CLAIM: 14
NUMBER OF DRAWINGS: 10 Drawing Figure(s); 7 Drawing Page(s)
LINE COUNT: 1579
AB An apparatus and method is discussed using a parity check matrix in order to achieve correction and detection of errors particularly pertaining to detection data fetched from a wrong address. The code structure enhances utilization of chip reliability by encoding and decoding digital signals through the utilization of a parity check matrix and parity bits generated from system address bits of a computer system with k symbols and b bits per symbol.

L25 ANSWER 6 OF 88 USPATEFULL
ACCESSION NUMBER: 1988:66880 USPATEFULL
TITLE: High efficiency encoding method
INVENTOR(S): Nishiguchi, Masayuki, c/o Sony Corporation, 7-35, Kitashinagawa 6-chome, Shinagawa-ku, Tokyo, Japan
Matsumoto, Jun, c/o Sony Corporation, 7-35, Kitashinagawa 6-chome, Shinagawa-ku, Tokyo, Japan
Ono, Shinobu, c/o Sony Corporation, 7-35, Kitashinagawa 6-chome, Shinagawa-ku, Tokyo, Japan

APPLICATION INFO.: US 93-150082 931206 (8)
WO 93-JP323 930218
931206 PCT 371 date
931206 PCT 102(e) date

NUMBER DATE
PRIORITY INFORMATION: JP 92-91422 920318
JP 92-92259 920318
DOCUMENT TYPE: Utility
PRIMARY EXAMINER: MacDonald, Allen R.
ASSISTANT EXAMINER: Chawen, Vijay B.
LEGAL REPRESENTATIVE: Limbach & Limbach L.L.P.
NUMBER OF CLAIMS: 28
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 73 Drawing Figure(s); 37 Drawing Page(s)
LINE COUNT: 3868
AB A high efficiency encoding method for encoding data on frequency axis obtained by dividing an input audio signal on block-by-block basis and converting the signal onto the frequency axis, wherein V bands are searched for a band B.sub.VH with the highest center frequency if it is decided that there are one or more shift points of voiced (V)/unvoiced (UV) decision data of all bands on the frequency axis, and wherein the number of V bands N.sub.V up to the band B.sub.VH is found, so as to decide whether proportion of the V bands is equal to or higher than a predetermined threshold N.sub.th, thereby deciding one V/UV boundary point. Thus, it is possible to replace the V/UV decision data for each band by information on one demarcation in all bands, thereby to reduce data volume and to reduce bit rate. Also, by using two-stage hierarchical "vector" quantization in quantizing the data on the frequency axis, operation volume for codebook search and memory capacity of the codebook are reduced.

L25 ANSWER 7 OF 88 USPATEFULL
ACCESSION NUMBER: 1998:62822 USPATEFULL
TITLE: Memory implemented error detection and correction code using memory modules
INVENTOR(S): Baat, Klaus Ruediger, Boeblingen, Germany, Federal Republic of
Chen, Chin-Long, Fishkill, NY, United States
Hsiao, Mu-Yue, Poughkeepsie, NY, United States
Lippner, Walter Heinrich, Ammerbuch, Germany, Federal Republic of
Shen, William Wu, Poughkeepsie, NY, United States
PATENT ASSIGNEE(S): International Business Machines Corporation, Armonk, NY, United States (U.S. corporation)

NUMBER DATE
PATENT INFORMATION: US 5761221 980602
APPLICATION INFO.: US 95-570447 951211 (8)
DOCUMENT TYPE: Utility
PRIMARY EXAMINER: Elmore, Reba I.
ASSISTANT EXAMINER: Marc, McDiemel
LEGAL REPRESENTATIVE: Neff, Lily
NUMBER OF CLAIMS: 11
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 10 Drawing Figure(s); 7 Drawing Page(s)
LINE COUNT: 1384
AB A method and apparatus for performing digital signal error detection and correction through the use of a string of received incoming system address bits. The incoming address bits are divided into groups according to whether they contain a high value of "1" or a low value of "0". At least one address parity bit is then generated from each group and used in checking the integrity of data received. Errors are corrected and detected through assignment of data bits to different modules in a memory of a computer system having symbols which are b bits in length.

L25 ANSWER 8 OF 88 USPATEFULL
ACCESSION NUMBER: 1998:53126 USPATEFULL
TITLE: Superscalar microprocessor employing away prediction structure
INVENTOR(S): Roberts, James S., Austin, TX, United States
Pickett, James K., Austin, TX, United States
PATENT ASSIGNEE(S): Advanced Micro Devices, Inc., Sunnyvale, CA

United States (U.S. corporation)

NUMBER DATE

PATENT INFORMATION: US 5752069 980512
APPLICATION INFO.: US 95-521749 950831 (6)
DOCUMENT TYPE: Utility
PRIMARY EXAMINER: Donaghu, Larry D.
LEGAL REPRESENTATIVE: Conley, Rose & Tayan, B. Noel
NUMBER OF CLAIMS: 19
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 66 Drawing Figure(s); 45 Drawing Page(s)
LINE COUNT: 11682
AB A supercircular microprocessor employing a way prediction structure is provided. The way prediction structure predicts a way of an associative cache in which an access will hit, and causes the data bytes from the predicted way to be conveyed as the output of the cache. The typical tag comparisons to the request address are bypassed for data byte selection, causing the access time of the associative cache to be substantially the access time of the direct-mapped way prediction array within the way prediction structure. Also included in the way prediction structure is a way prediction control unit configured to update the way prediction array when an incorrect way prediction is detected. The clock cycle of the supercircular microprocessor including the way prediction structure with its caches may be increased if the cache access time is limiting the clock cycle. Additionally, the associative cache may be retained in the high frequency supercircular microprocessor (which might otherwise employ a direct-mapped cache for access time reasons). Single clock cycle cache access to an associative data cache is maintained for high frequency operation.

L25 ANSWER 9 OF 88 USPATFULL
ACCESSION NUMBER: 1998-42213 USPATFULL
TITLE: DNA cycle sequencing
INVENTOR(S): Fuller, Carl W., Cleveland Heights, OH, United States
PATENT ASSIGNEE(S): Amersham Life Science, Inc., Cleveland, OH, United States (U.S. corporation)

NUMBER DATE

PATENT INFORMATION: US 5741640 980421
APPLICATION INFO.: US 95-443468 950518 (8)
RELATED APPLN INFO.: Division of Ser. No. US 94-227702, filed on 14 Apr 1994. And a continuation-in-part of Ser. No. US 91-767137, filed on 27 Sep 1991

DOCUMENT TYPE: Utility
PRIMARY EXAMINER: Jones, W. Gary
ASSISTANT EXAMINER: Rees, Dianne
LEGAL REPRESENTATIVE: Lyon & Lyon
NUMBER OF CLAIMS: 18
EXEMPLARY CLAIM: 1

NUMBER OF DRAWINGS: 25 Drawing Figure(s); 7 Drawing Page(s)
LINE COUNT: 736
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Method for sequencing DNA which includes the following steps: providing a polynucleotide primer complementary to a region of the DNA to be sequenced providing the DNA to be sequenced, and contacting that primer and DNA together in the presence of a DNA polymerase and between 1 and 3 dNTPs, at least one of the dNTPs being labelled. The primer and DNA are contacted under conditions which allow extension of the primer by addition of one or more of the dNTPs to the primer to form an extended primer. The primer and DNA are then dissociated, generally by heating, and the contacting and dissociating steps repeated a plurality of times (usually 10-200 times). Finally, the extended primer is contacted with the DNA in the presence of a DNA polymerase (which is generally the same polymerase as used in the initial labelling step) all four dNTPs and a chain terminating agent.

L25 ANSWER 10 OF 88 USPATFULL
ACCESSION NUMBER: 1998-36387 USPATFULL
TITLE: Allergenic proteins and peptides from johnson grass pollen
INVENTOR(S): Avjoglou, Asil, Towson, MD, United States

Singh, Mohan Bir, Templestowe, Australia
Knox, Robert Bruce, North Balwyn, Australia
PATENT ASSIGNEE(S): The University of Melbourne, Parkville, Australia (non-U.S. corporation)

NUMBER DATE

PATENT INFORMATION: US 5736149 980407
APPLICATION INFO.: US 95-470165 950606 (8)
RELATED APPLN INFO.: Continuation of Ser. No. US 92-571096, filed on 30 Oct 1992, now patented, Pat. No. US 5460972
DOCUMENT TYPE: Utility
PRIMARY EXAMINER: Chan, Christina Y.
ASSISTANT EXAMINER: Nolan, Patrick T.
LEGAL REPRESENTATIVE: Lahive & Cockfield, LLP; Mandragouras, Amy E.; Remillard, Jane E.

NUMBER OF CLAIMS: 8
EXEMPLARY CLAIM: 1,8
NUMBER OF DRAWINGS: 22 Drawing Figure(s); 12 Drawing Page(s)
LINE COUNT: 1794
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention provides a nucleic acid having a nucleotide sequence coding for Sor h I, a major allergen of Sorghum halepense, and fragments thereof. The present invention also provides purified Sor h I or at least one fragment thereof, produced in a host cell transformed with a nucleic acid sequence coding for Sor h I, or at least one fragment thereof and fragments of Sor h prepared synthetically. Sor h I and fragments thereof are useful for diagnosing, treating, and preventing allergy to Johnson grass pollen.

L25 ANSWER 11 OF 88 USPATFULL
ACCESSION NUMBER: 1998-33759 USPATFULL
TITLE: Peptide library and screening method
INVENTOR(S): Schatz, Peter J., Mountain View, CA, United States
Cull, Millard G., Oakland, CA, United States
Miller, Jeff F., Los Angeles, CA, United States
Stemmer, William Peter Christiaan, Los Gatos, CA, United States
Gates, Christian M., Morgan Hill, CA, United States
States(4)
PATENT ASSIGNEE(S): Affymax Technologies N.V., Greenford, England (non-U.S. corporation)

NUMBER DATE

PATENT INFORMATION: US 5733731 980331
APPLICATION INFO.: US 95-548540 951026 (8)
RELATED APPLN INFO.: Continuation-in-part of Ser. No. US 94-290641, filed on 15 Aug 1994, now patented, Pat. No. US 5495530 which is a continuation of Ser. No. US 92-963321, filed on 15 Oct 1992, now patented, Pat. No. US 5338665 which is a continuation-in-part of Ser. No. US 91-778233, filed on 16 Oct 1991, now patented, Pat. No. US 5270170

DOCUMENT TYPE: Utility
PRIMARY EXAMINER: Ketter, James
LEGAL REPRESENTATIVE: Liebeschuetz, Joe; Stevens, Lauren L.
NUMBER OF CLAIMS: 27
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 12 Drawing Figure(s); 11 Drawing Page(s)
LINE COUNT: 3597
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A random peptide library constructed by transforming host cells with a collection of recombinant "vectors" that encode a fusion protein comprised of a DNA binding protein and a random peptide and also encode a binding site for the DNA binding protein can be used to screen for novel ligands. The screening method results in the formation of a complex comprising the fusion protein bound to a receptor through the random peptide ligand and to the recombinant DNA "vector" through the DNA binding protein.

L25 ANSWER 12 OF 88 USPATFULL
ACCESSION NUMBER: 1998-28061 USPATFULL

TITLE: Methods for normalizing numbers of lymphocytes
INVENTOR(S): Morozov, Vyacheslav G., St. Petersburg, Russian Federation
Khavinson, Vladimir Kh., St. Petersburg, Russian Federation
PATENT ASSIGNEE(S): Cytoven J.V., Kirkland, WA, United States (U.S. corporation)

NUMBER DATE

PATENT INFORMATION: US 5728680 980317
APPLICATION INFO.: US 95-452411 950526 (8)
RELATED APPLN INFO.: Continuation-in-part of Ser. No. US 94-337341, filed on 10 Nov 1994, now patented, Pat. No. US 5538951 And a continuation-in-part of Ser. No. US 94-278463, filed on 21 Jul 1994, now abandoned which is a continuation-in-part of Ser. No. US 94-257495, filed on 7 Jun 1994, now abandoned which is a continuation of Ser. No. US 91-783518, filed on 28 Oct 1991, now abandoned which is a continuation-in-part of Ser. No. US 91-678129, filed on 1 Apr 1991, now abandoned which is a continuation-in-part of Ser. No. US 89-415283, filed on 30 Aug 1989, now abandoned

NUMBER DATE

PATENT INFORMATION: SU 87-4352833871230
DOCUMENT TYPE: Utility
PRIMARY EXAMINER: Feisee, Lila
ASSISTANT EXAMINER: Ungar, Susan
NUMBER OF CLAIMS: 12
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 16 Drawing Figure(s); 8 Drawing Page(s)
LINE COUNT: 8309
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB This invention provides methods for normalizing the numbers of lymphocytes in animals by administering the dipeptide L-Glu-L-Trp.

L25 ANSWER 13 OF 88 USPATFULL
ACCESSION NUMBER: 97-117928 USPATFULL

TITLE: Modular assembly of antibody genes, antibodies prepared thereby and use

INVENTOR(S): Robinson, Randy R., Los Angeles, CA, United States

Liu, Alvin Y., Oceanside, CA, United States
Horwitz, Arnold H., Los Angeles, CA, United States
Better, Marc, Los Angeles, CA, United States
Wall, Randolph, Sherman Oaks, CA, United States
Lei, Shau-Ping, Los Angeles, CA, United States
Wilcox, Gary L., Malibu, CA, United States
PATENT ASSIGNEE(S): Xoma Corporation, Berkeley, CA, United States (U.S. corporation)

NUMBER DATE

PATENT INFORMATION: US 5698435 971216
APPLICATION INFO.: US 95-467140 950606 (8)
RELATED APPLN INFO.: Continuation of Ser. No. US 94-299085, filed on 18 Aug 1994 which is a continuation of Ser. No. US 92-387555, filed on 8 Dec 1992, now abandoned which is a continuation of Ser. No. US 90-501092, filed on 23 Mar 1990, now abandoned which is a continuation-in-part of Ser. No. US 88-142039, filed on 11 Jan 1988, now abandoned And Ser. No. US 87-77528, filed on 24 Jul 1987, now abandoned which is a continuation-in-part of Ser. No. US 85-793980, filed on 1 Nov 1985, now abandoned

DOCUMENT TYPE: Utility

PRIMARY EXAMINER: Ziska, Suzanne E.
LEGAL REPRESENTATIVE: Sterne, Kessler, Goldstein & Fox, P.L.L.C.
NUMBER OF CLAIMS: 20
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 64 Drawing Figure(s); 61 Drawing Page(s)
LINE COUNT: 4071
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention relates to cDNA genetic sequences, vehicles containing same as well as hosts transformed therewith, for the production of chimeric immunoglobulin molecules, functional fragments thereof and immunoglobulin derivatives exhibiting novel functional properties comprising human constant region modules and non-human variable region modules, or for class switching antibody molecules and/or chains. The invention also relates to DNA coding for pectate lyase signal peptide has been cloned on a plasmid to create a secretion ***vector*** which is capable of producing a chosen protein which is transported across the bacterial membrane. The secretion ***vector*** has been used to secrete extracellular thaumatin and extracellular chimeric antibody fragments. The proteins produced by this ***vector*** have biological activity. The thaumatin is properly folded and the antibody fragments are capable of binding antigens on target cancer cells. The invention also relates to the secretion of chimeric antibodies and fragments thereof from yeast in functional form.

RELATED APPLN. INFO.: Division of Ser. No. US 92-971096, filed on 30 Oct 1992, now patented, Pat. No. US 5480972

DOCUMENT TYPE: Utility

PRIMARY EXAMINER: Wax, Robert A

ASSISTANT EXAMINER: Lau, Kewei

LEGAL REPRESENTATIVE: Lahive & Cockfield, LLP; Remillard, Jane E.; Mandragouras, Amy E

INVENTOR(S): Liu, Alvin Y., Oceanside, CA, United States; Horwitz, Arnold H., Los Angeles, CA, United States; Better, Marc, Los Angeles, CA, United States; Wall, Randolph, Sherman Oaks, CA, United States; Lei, Shau-Ping, Los Angeles, CA, United States; Wilcox, Gary L., Malibu, CA, United States

PATENT ASSIGNMENT(S): Xoma Corporation, Berkeley, CA, United States (U.S. corporation)

NUMBER DATE

L25 ANSWER 14 OF 88 USPATFULL

ACCESSION NUMBER: 97:117911 USPATFULL

TITLE: Modular assembly of antibody genes, antibodies prepared thereby and use

INVENTOR(S): Robinson, Randy R., Los Angeles, CA, United States

Liu, Alvin Y., Oceanside, CA, United States

Horwitz, Arnold H., Los Angeles, CA, United States

Better, Marc, Los Angeles, CA, United States

Wall, Randolph, Sherman Oaks, CA, United States

Lei, Shau-Ping, Los Angeles, CA, United States

Wilcox, Gary L., Malibu, CA, United States

PATENT ASSIGNMENT(S): Xoma Corporation, Berkeley, CA, United States (U.S. corporation)

NUMBER DATE

L25 ANSWER 15 OF 88 USPATFULL

ACCESSION NUMBER: 97:112329 USPATFULL

TITLE: Modular assembly of antibody genes, antibodies prepared thereby and use

INVENTOR(S): Robinson, Randy R., Los Angeles, CA, United States

Liu, Alvin Y., Oceanside, CA, United States

Horwitz, Arnold H., Los Angeles, CA, United States

Better, Marc, Los Angeles, CA, United States

Wall, Randolph, Sherman Oaks, CA, United States

Lei, Shau-Ping, Los Angeles, CA, United States

Wilcox, Gary L., Malibu, CA, United States

PATENT ASSIGNMENT(S): Xoma Corporation, Berkeley, CA, United States (U.S. corporation)

NUMBER DATE

L25 ANSWER 16 OF 88 USPATFULL

ACCESSION NUMBER: 97:109731 USPATFULL

TITLE: DNA encoding oligergic proteins and peptides from Johnson grass pollen

INVENTOR(S): Singh, Mohan Bir, Victoria, Australia

Knox, Robert Bruce, Victoria, Australia

(non-U.S. corporation)

ImmuLogic Pharmaceutical Corporation, Wallham, MA, United States (U.S. corporation)

NUMBER DATE

L25 ANSWER 17 OF 88 USPATFULL

ACCESSION NUMBER: 97:97739 USPATFULL

TITLE: Instruction format with sequentially performable operand address extension modification

INVENTOR(S): Sakamura, Ken, Tokyo, Japan

Mitsubishi Denki Kabushiki Kaisha, Tokyo, Japan (part interest) a part interest

NUMBER DATE

L25 ANSWER 18 OF 88 USPATFULL

ACCESSION NUMBER: 97:86430 USPATFULL

TITLE: Diagnostic applications of double D-loop formation

INVENTOR(S): Sena, Elissa P., Palo Alto, CA, United States

Calhoun, Cornelia J., San Francisco, CA, United States

Zarling, David A., Menlo Park, CA, United States

PATENT ASSIGNMENT(S): Daiichi Industries, Ltd., Osaka, Japan (non-U.S. corporation)

NUMBER DATE

PATENT INFORMATION: US 5698417 971216

APPLICATION INFO.: US 95-465203 950606 (8)

RELATED APPLN. INFO.: Continuation of Ser. No. US 95-450731, filed on 25 May 1995 which is a division of Ser. No. US 94-298085, filed on 18 Aug 1994 which is a continuation of Ser. No. US 92-987555, filed on 8 Dec 1992, now abandoned which is a continuation of Ser. No. US 90-501092, now abandoned which is a continuation-in-part of Ser. No. US 87-77528, filed on 24 Jul 1987, now abandoned which is a continuation-in-part of Ser. No. US 85-793980, filed on 1 Nov 1985, now abandoned, said Ser. No. US -501092 which is a continuation-in-part of Ser. No. US 88-142039, filed on 11 Jan 1988, now abandoned

DOCUMENT TYPE: Utility

PRIMARY EXAMINER: Ziska, Suzanne E.

LEGAL REPRESENTATIVE: Sterne, Kessler, Goldstein & Fox P.L.L.C.

NUMBER OF CLAIMS: 9

EXEMPLARY CLAIM: 1

NUMBER OF DRAWINGS: 63 Drawing Figure(s); 61 Drawing Page(s)

LINE COUNT: 4047

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention relates to cDNA genetic sequences, vehicles containing same as well as hosts transformed therewith, for the production of chimeric immunoglobulin molecules, functional fragments thereof and immunoglobulin derivatives exhibiting novel functional properties comprising human constant region modules and non-human variable region modules, or for class switching antibody molecules and/or chains. The invention also relates to DNA coding for pectate lyase signal peptide has been cloned on a plasmid to create a secretion ***vector*** which is capable of producing a chosen protein which is transported across the bacterial membrane. The secretion ***vector*** has been used to secrete extracellular thaumatin and extracellular chimeric antibody fragments. The proteins produced by this ***vector*** have biological activity. The thaumatin is properly folded and the antibody fragments are capable of binding antigens on target cancer cells. The invention also relates to the secretion of chimeric antibodies and fragments thereof from yeast in functional form.

RELATED APPLN. INFO.: Division of Ser. No. US 92-971096, filed on 30 Oct 1992, now patented, Pat. No. US 5480972

DOCUMENT TYPE: Utility

PRIMARY EXAMINER: Kulik, Paul V

LEGAL REPRESENTATIVE: Townsend and Townsend and Crew LLP

NUMBER OF CLAIMS: 19

EXEMPLARY CLAIM: 1

NUMBER OF DRAWINGS: 398 Drawing Figure(s); 211 Drawing Page(s)

LINE COUNT: 11450

AB A data processor which has an operand instruction having an operation code specifying portion to specify the kind of operation and an effective address specifying field showing the effective address of the operand, so that an additional mode specifying field to perform the extension modification of addressing can be added to an addressing mode shown by the effective address specifying field, whereby even when the address modification extension is carried out at multiple levels, the address calculation can sequentially be performed while reading each part of the operand, thereby improving the execution speed of program and facilitating compiler structure.

PATENT INFORMATION: US 5690568 971021

APPLICATION INFO.: US 94-260031 940615 (8)

RELATED APPLN. INFO.: Continuation of Ser. No. US 91-763473, filed on 20 Sep 1991, now abandoned which is a continuation of Ser. No. US 90-563749, filed on 3 Aug 1990, now abandoned which is a continuation of Ser. No. US 88-170972, filed on 21 Mar 1988, now abandoned

DOCUMENT TYPE: Utility

PRIMARY EXAMINER: Kulik, Paul V

LEGAL REPRESENTATIVE: Townsend and Townsend and Crew LLP

NUMBER OF CLAIMS: 19

EXEMPLARY CLAIM: 1

NUMBER OF DRAWINGS: 398 Drawing Figure(s); 211 Drawing Page(s)

LINE COUNT: 11450

AB A data processor which has an operand instruction having an operation code specifying portion to specify the kind of operation and an effective address specifying field showing the effective address of the operand, so that an additional mode specifying field to perform the extension modification of addressing can be added to an addressing mode shown by the effective address specifying field, whereby even when the address modification extension is carried out at multiple levels, the address calculation can sequentially be performed while reading each part of the operand, thereby improving the execution speed of program and facilitating compiler structure.

PATENT INFORMATION: US 5691167 971125

APPLICATION INFO.: US 93-175096 931229 (8)

WO 9305178 930318
APPLICATION INFO.: US 94-199317 940525 (8)
940525 PCT 371 date
940525 PCT 102(e) date
RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 92-910791,
filed on 9 Jul 1992, now abandoned which is a
continuation-in-part of Ser. No. US 91-755462,
filed on 4 Sep 1991, now patented, Pat. No. US
5273881 which is a continuation-in-part of Ser.
No. US 90-520321, filed on 7 May 1990, now
patented, Pat. No. US 5223414

DOCUMENT TYPE: Utility
PRIMARY EXAMINER: Jones, W. Gary
ASSISTANT EXAMINER: Rees, Dianne
LEGAL REPRESENTATIVE: Fabian, Gary R.; Stratford, Carol A.; Dahlinger,
Peter J.
NUMBER OF CLAIMS: 21
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 36 Drawing Figure(s); 17 Drawing Page(s)
LINE COUNT: 2639
AB The present invention describes the formation of RecA protein
catalyzed double-stranded probe:duplex linear target DNA complexes
that are stable to deproteinization. The uses of this stable
probe:target complex in diagnostic/DNA detection systems in
vitro and in situ DNA hybridization reactions is discussed. The
probe:target complexes are also useful for diagnostic application
in RecA protein facilitated DNA amplification reactions.

L25 ANSWER 19 OF 88 USPATFULL
ACCESSION NUMBER: 97:56112 USPATFULL
TITLE: Methods and products for nucleic acid delivery
INVENTOR(S): Isner, Jeffrey M.; Weston, MA, United States
PATENT ASSIGNEE(S): St. Elizabeth's Medical Center of Boston, Inc.,
Boston, MA, United States (U.S. corporation)

NUMBER DATE
PATENT INFORMATION: US 5652225 970729
APPLICATION INFO.: US 96-675523 960703 (8)
RELATED APPLN. INFO.: Continuation of Ser. No. US 94-318045, filed on 4
Oct 1994, now abandoned

DOCUMENT TYPE: Utility
PRIMARY EXAMINER: Low, Christopher S. F.
LEGAL REPRESENTATIVE: Conlin, David G.; Resnick, David S. Dike,
Bronstein, Roberts & Cushman, LLP
NUMBER OF CLAIMS: 6
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 17 Drawing Figure(s); 7 Drawing Page(s)
LINE COUNT: 1314
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention provides a method for the delivery of a
nucleic acid to an arterial cell comprising contacting the cell
with a hydrophilic polymer incorporating the nucleic acid. The
nucleic acid may be any nucleic acid, including antisense DNA or
RNA. The nucleic acid may encode hormones, enzymes, receptors or
drugs of interest. The nucleic acid is selected based upon the
desired therapeutic outcome. For example, in the treatment of
ischemic diseases, one would select a DNA encoding an angiogenic
protein. The nucleic acid may be carried by a microdelivery
vehicle such as cationic liposomes and adenoviral ***vectors***
. DNA encoding different proteins may be used separately or
simultaneously.

L25 ANSWER 20 OF 88 USPATFULL
ACCESSION NUMBER: 97:41486 USPATFULL
TITLE: Speech efficient coding method
INVENTOR(S): Nishiguchi, Masayuki, Kanagawa, Japan
Matsumoto, Jun, Tokyo, Japan
Chan, Joseph, Tokyo, Japan
PATENT ASSIGNEE(S): Sony Corporation, Tokyo, Japan (non-U.S.
corporation)

NUMBER DATE
PATENT INFORMATION: US 5630012 970513

APPLICATION INFO.: US 94-280617 940726 (8)
NUMBER DATE
PRIORITY INFORMATION: JP 93-185324 930727
DOCUMENT TYPE: Utility
PRIMARY EXAMINER: MacDonald, Allen R.
ASSISTANT EXAMINER: Sax, Robert
LEGAL REPRESENTATIVE: Limbach & Limbach L.L.P.
NUMBER OF CLAIMS: 18
EXEMPLARY CLAIM: 10
NUMBER OF DRAWINGS: 14 Drawing Figure(s); 7 Drawing Page(s)
LINE COUNT: 1103

AB There is provided a speech efficient coding method applicable to,
e.g., analysis by a synthesis system such as an MBE vocoder, and
comprising the steps of (a) dividing an input speech signal into
block units on a time base, (b) dividing signals of each of the
respective divided blocks into signals in a plurality of frequency
bands, (c) discriminating whether signals of each of the
respective divided frequency bands which are lower than a first
frequency are voiced sound or unvoiced sound, (d) if the
discrimination results in step (c) for a predetermined number of
frequency bands is voiced sound, assigning a discrimination result
of voiced sound to all frequency bands lower than a second
frequency which is higher than the first frequency to obtain an
ultimate discrimination result of voiced sound/unvoiced sound.
Thus, even in the case where the pitch suddenly changes, or the
harmonics structure is not precisely in correspondence with an
integer multiple of the fundamental pitch period, a stable
judgment of V (Voiced Sound) can be made.

L25 ANSWER 21 OF 88 USPATFULL
ACCESSION NUMBER: 97:39196 USPATFULL
TITLE: Method and apparatus for receiving and
despreading a continuous phase-modulated spread
spectrum signal using self-synchronizing
correlators
INVENTOR(S): Durrant, Randolph L., Colorado Springs, CO,
United States
Burbach, Mark, Peyton, CO, United States
PATENT ASSIGNEE(S): Omnipoint Corporation, Colorado Springs, CO,
United States (U.S. corporation)

NUMBER DATE
PATENT INFORMATION: US 5627856 970506
APPLICATION INFO.: US 95-480442 950607 (8)
RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 94-304091,
filed on 9 Sep 1994

DOCUMENT TYPE: Utility
PRIMARY EXAMINER: Chin, Stephen
ASSISTANT EXAMINER: Gluck, Jeffrey W.
LEGAL REPRESENTATIVE: Lyon & Lyon
NUMBER OF CLAIMS: 21
EXEMPLARY CLAIM: 9
NUMBER OF DRAWINGS: 49 Drawing Figure(s); 35 Drawing Page(s)
LINE COUNT: 3354

AB Apparatus and method for despreading a received continuous phase
modulated spread spectrum signal includes a power divider for
dividing a received spread spectrum signal into a real signal and
an imaginary signal. A real CPM correlator demodulates the real
signal into I and Q components and separately correlates the real
I component and the real Q component without generating a
correlation sequence, thereby performing self-synchronizing
correlation. Likewise, an imaginary CPM correlator demodulates the
imaginary signal into I and Q components and separately correlates
the imaginary I component and the imaginary Q component without
generating a correlation sequence, thereby performing
self-synchronizing correlation. The real I and imaginary I
correlation signals are combined into a final I correlation
signal, and the real Q and imaginary Q correlation signals are
combined into a final Q correlation signal.

L25 ANSWER 22 OF 88 USPATFULL
ACCESSION NUMBER: 97:35678 USPATFULL
TITLE: Variable-pulse dynamic fluid flow controller
INVENTOR(S): Seale, Joseph B., Gorham, ME, United States

PATENT ASSIGNEE(S): FluidSense Corporation, Bedford, NH, United
States (U.S. corporation)

NUMBER DATE
PATENT INFORMATION: US 5624409 970429
APPLICATION INFO.: US 94-257872 940610 (8)
DOCUMENT TYPE: Utility
PRIMARY EXAMINER: Mendez, Manuel
LEGAL REPRESENTATIVE: Caseiro, Chris A.; Bohan, Thomas L.
NUMBER OF CLAIMS: 20
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 16 Drawing Figure(s); 7 Drawing Page(s)
LINE COUNT: 1930

AB A dynamic controller for quantitative rapid-pulse flow control
over a wide dynamic range (1000-to-1) forms a fluid path from a
pressurized source to a sink. The fluid path travels, typically in
a disposable cassette, from the pressure source via a fast (one
millisecond) on-off source control valve into a
volume-displacement interface area, thence to a fast on-off load
control valve and on to the sink. The load control valve may be
replaced by a passive flow restrictor where less dynamic range is
required. From the reusable controller side, fast actuators are
energized to open the normally-closed valves. A volume sensor
mates with the volume-displacement interface area. This sensor
uses an incompressible transfer fluid, typically different than
and isolated from the deliverable fluid by membranes, to transmit
volume displacement change into a transducer area for conversion
from volume to a measurable electrical signal, typically a
frequency. A known pressure/volume curve for the volume sensor
allows pressure monitoring during operation, yielding knowledge of
fluid source and load conditions.

A flow control method relies on a combination of very short,
variable valve-open pulses and design with comparatively
large-diameter fluid passageways into the fluid capacitance of the
volume sensor, to achieve flow limited more by inertia than
viscosity. Distinct high-flow and low-flow control regimes are
used. For high flow, bolus volume is maximized by pulsing for
one-half the fluid oscillation period determined by the volume
sensor fluid capacitance and the flow inertia of the fluid
passageway, shutting off at flow reversal. For low flow, pulses
typically below 10% of the high-flow pulse width yield small bolus
volumes varying as the square of pulse width, providing control
over a wide dynamic range of bolus sizes down to fractions of a
microliter, permitting moderately high pulse frequencies even at
very low average rates, achieving nearly continuous flow. Design
with normally-closed, energize-to-open valves assures flow stop if
power is lost. In this context, the large fluid passageways lead
to a prescribed volume transfer at low valve-open duty cycle,
conserving energy and making battery operation practical.

L25 ANSWER 23 OF 88 USPATFULL
ACCESSION NUMBER: 97:29575 USPATFULL
TITLE: Modular assembly of antibody genes, antibodies
prepared thereby and use

INVENTOR(S): Robinson, Randy R., Los Angeles, CA, United
States
Liu, Alvin Y., Oceanside, CA, United States
Horwitz, Arnold H., Los Angeles, CA, United
States
Better, Marc, Los Angeles, CA, United States
Wail, Randolph, Sherman Oaks, CA, United States
Lei, Shau-Ping, Los Angeles, CA, United States
Wilcox, Gary L., Malibu, CA, United States
PATENT ASSIGNEE(S): Xoma Corporation, Berkeley, CA, United States
(U.S. corporation)

NUMBER DATE
PATENT INFORMATION: US 5618920 970408
APPLICATION INFO.: US 94-235225 940429 (8)
RELATED APPLN. INFO.: Continuation of Ser. No. US 92-870404, filed on
17 Apr 1992, now abandoned which is a division of
Ser. No. US 90-501092, filed on 29 Mar 1990, now
abandoned which is a continuation-in-part of Ser.
No. US 87-77528, filed on 24 Jul 1987, now

abandoned which is a continuation-in-part of Ser. No. US 85-793980, filed on 1 Nov 1985, now abandoned, said Ser. No. US -501092 which is a continuation-in-part of Ser. No. US 88-142039, filed on 11 Jan 1988, now abandoned

DOCUMENT TYPE: Utility
PRIMARY EXAMINER: Budens, Robert D.
ASSISTANT EXAMINER: Reeves, Julie E.
LEGAL REPRESENTATIVE: Sterne, Kessler, Goldstein & Fox, P.L.L.C.
NUMBER OF CLAIMS: 45
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 63 Drawing Figure(s); 61 Drawing Page(s)
LINE COUNT: 3793
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention relates to the secretion of heavy chain immunoglobulin fragments and light chain immunoglobulins from prokaryotic hosts using a prokaryotic secretion signal peptide wherein the heavy chain fragments and light chains are capable of associating to form an antigen binding antibody fragment.

L25 ANSWER 24 OF 88 USPATFULL
ACCESSION NUMBER: 97-27917 USPATFULL
TITLE: System for and method of recognizing and tracking target mark

INVENTOR(S): Hashima, Masayoshi, Kawasaki, Japan
Hasegawa, Fumi, Kawasaki, Japan
Okabayashi, Kei, Kawasaki, Japan
Watanabe, Ichiro, Kawasaki, Japan
Kanda, Shinji, Kawasaki, Japan
Sawasaki, Naoyuki, Kawasaki, Japan
Murasu, Yuichi, Kawasaki, Japan
PATENT ASSIGNEE(S): Fujitsu Limited, Kawasaki, Japan (non-U.S. corporation)

NUMBER DATE
PATENT INFORMATION: US 5617335 970401
APPLICATION INFO.: US 96-586320 960118 (8)
RELATED APPL. INFO.: Division of Ser. No. US 93-119228, filed on 28 Sep 1993, now patented, Pat. No. US 5521843

NUMBER DATE
PRIORITY INFORMATION: JP 92-15557 920130
JP 92-193457 920626
JP 92-219029 920818
JP 92-291628 921029
JP 92-307015 921117

DOCUMENT TYPE: Utility
PRIMARY EXAMINER: Ramirez, Ellis B.
ASSISTANT EXAMINER: Peeso, Thomas
LEGAL REPRESENTATIVE: Armstrong, Westerman, Hutton, McLeland & Naughton

NUMBER OF CLAIMS: 20
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 109 Drawing Figure(s); 47 Drawing Page(s)

LINE COUNT: 2225
AB A system for and a method of recognizing and tracking a target mark with a video camera is disclosed. The system includes a target mark (10) disposed on an object (1) and composed of a black circle and a white triangle mounted centrally on the black circle and three-dimensionally shifted from the black circle, a video camera (20) for imaging the target mark (10), a robot (30) supporting the video camera (20) and movable in directions with six degrees of freedom, an image processor (40) for processing image data of the target mark which is produced by the video camera (20), a shift calculating unit (50) for detecting a shift of the target mark (10) from projected histogram information of the target mark (10) which is produced by the image processor (40), and a robot controller (60) for controlling movement of the robot depending on the shift to enable the video camera (20) to track the target mark (10). The system is capable of tracking the target mark (20) attached to the object (1) on a real-time basis. Mark recognizing apparatus capable of accurately recognizing target marks of other shapes is also disclosed.

L25 ANSWER 25 OF 88 USPATFULL

ACCESSION NUMBER: 97-5879 USPATFULL
TITLE: Modular assembly of antibody genes, antibodies prepared thereby and use
INVENTOR(S): Robinson, Randy R., Los Angeles, CA, United States

Liu, Alvin Y., Oceanside, CA, United States
Horwitz, Arnold H., Los Angeles, CA, United States
Better, Marc, Los Angeles, CA, United States
Wall, Randolph, Sherman Oaks, CA, United States
Lei, Shau-Ping, Los Angeles, CA, United States
Wilcox, Gary L., Malibu, CA, United States
PATENT ASSIGNEE(S): Xoma Corporation, Berkeley, CA, United States (U.S. corporation)

NUMBER DATE

PATENT INFORMATION: US 5595898 970121
APPLICATION INFO.: US 94-239085 940818 (8)
RELATED APPL. INFO.: Continuation of Ser. No. US 92-987555, filed on 8 Dec 1992, now abandoned which is a continuation of Ser. No. US 90-501092, filed on 29 Mar 1990, now abandoned which is a continuation-in-part of Ser. No. US 88-142039, filed on 11 Jan 1988, now abandoned And Ser. No. US 87-77528, filed on 24 Jul 1987, now abandoned which is a continuation-in-part of Ser. No. US 85-793980, filed on 1 Nov 1985, now abandoned

DOCUMENT TYPE: Utility
PRIMARY EXAMINER: Ziska, Suzanne E.
LEGAL REPRESENTATIVE: Sterne, Kessler, Goldstein, & Fox
NUMBER OF CLAIMS: 4
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 64 Drawing Figure(s); 61 Drawing Page(s)
LINE COUNT: 3691

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention relates to cDNA genetic sequences, vehicles containing same as well as hosts transformed therewith, for the production of chimeric immunoglobulin molecules, functional fragments thereof and immunoglobulin derivatives exhibiting novel functional properties comprising human constant region modules and non-human variable region modules, or for class switching antibody molecules and/or chains.

The invention also relates to DNA coding for pectate lyase signal peptide has been cloned on a plasmid to create a secretion ***vector*** which is capable of producing a chosen protein which is transported across the bacterial membrane. The secretion ***vector*** has been used to secrete extracellular thrombin and extracellular chimeric antibody fragments. The proteins produced by this ***vector*** have biological activity. The thrombin is properly folded and the antibody fragments are capable of binding antigens on target cancer cells. The invention also relates to the secretion of chimeric antibodies and fragments thereof from yeast in functional form.

L25 ANSWER 26 OF 88 USPATFULL
ACCESSION NUMBER: 97-3693 USPATFULL
TITLE: Ligand-mediated immunofunctional hormone binding protein assay method
INVENTOR(S): Clark, Ross G., Pacifica, CA, United States
Wong, Wai T., Los Altos, CA, United States
PATENT ASSIGNEE(S): Genentech, Inc., San Francisco, CA, United States (U.S. corporation)

NUMBER DATE
PATENT INFORMATION: US 5593844 970114
APPLICATION INFO.: US 95-441357 950515 (8)
RELATED APPL. INFO.: Continuation of Ser. No. US 95-408094, filed on 21 Mar 1995 which is a continuation of Ser. No. US 93-39093, filed on 9 Apr 1993, now abandoned which is a continuation-in-part of Ser. No. US 90-615538, filed on 19 Nov 1990, now patented, Pat. No. US 5210017
DOCUMENT TYPE: Utility

PRIMARY EXAMINER: Walsh, Stephen G.
ASSISTANT EXAMINER: Gucker, Stephen
LEGAL REPRESENTATIVE: Dreger, Walter H.
NUMBER OF CLAIMS: 7
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 13 Drawing Figure(s); 10 Drawing Page(s)
LINE COUNT: 2317

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A ligand-mediated immunofunctional assay (LIFA) method for detecting the presence and the concentration of polypeptide hormone binding proteins which comprises capturing the binding protein with a solid phase bound first antibody, saturating the bound hormone binding protein with the ligand polypeptide hormone, and detecting the bound ligand polypeptide hormone with a detectably labeled second antibody specific for the ligand polypeptide hormone. In the absence of added saturating polypeptide hormone, the LIFA measures the amount of hormone binding protein bound to the endogenous ligand polypeptide hormone. A growth hormone binding protein assay illustrates the method of the present invention. LIFA assay results indicate that increased binding protein substantially increases growth hormone activity. Methods of use and formulations of growth hormone binding protein, growth hormone, insulin-like growth factor-I and insulin-like growth factor binding protein are disclosed.

L25 ANSWER 27 OF 88 USPATFULL
ACCESSION NUMBER: 96-121716 USPATFULL
TITLE: Optimal parallel processor architecture for real time multitasking
INVENTOR(S): Karalopoulos, Stamatios V., Clinton Township, Hunterdon County, NJ, United States
PATENT ASSIGNEE(S): Lucent Technologies Inc., Murray Hill, NJ, United States (U.S. corporation)

NUMBER DATE
PATENT INFORMATION: US 5590323 961231
APPLICATION INFO.: US 94-242526 940513 (8)
DOCUMENT TYPE: Utility
PRIMARY EXAMINER: Oberley, Alvin E.
ASSISTANT EXAMINER: Banankeh, Majid
NUMBER OF CLAIMS: 3
EXEMPLARY CLAIM: 1
LINE COUNT: 612

AB A process for producing a parallel processor system having the minimum number of microprocessors necessary execute in real time a set of tasks of a multi-tasking application such that execution of an activity of a first task is followed by execution of an activity of a second task. The process includes the step of selecting an initial number of microprocessors for executing the application in real-time. The selecting step includes placing in a first column of a matrix all real-time constrained tasks specific to the application and associating a row of dependent tasks with each task placed in the first column of the matrix to define a plurality of task subsets, each subset incorporating a maximum number of interdependent tasks and a minimum number of interdependent tasks and the number of subsets corresponding to the initial number of microprocessors. The inventive process further includes the steps of listing dependencies between rows in a second column of the matrix, assigning a priority p.sub.i to each task where p.sub.i is between 0 and 1, subdividing at least one of the tasks into discrete activities, each of the activities having a corresponding execution time t.sub.j, estimating the execution time for each activity, reducing the number of rows in the matrix by grouping together tasks having activities that can be executed within a predetermined time window T, and providing a number of microprocessors corresponding to the number of rows obtained from the rows reducing step.

L25 ANSWER 28 OF 88 USPATFULL
ACCESSION NUMBER: 96-112100 USPATFULL
TITLE: Method and apparatus for focus control of transmit and receive beamformer systems
INVENTOR(S): Gee, Albert, Los Altos, CA, United States
Cole, Christopher R., Cupertino, CA, United States

Wright, J. Nelson, Menlo Park, CA, United States
PATENT ASSIGNEE(S): Acuson Corporation, Mountain View, CA, United States (U.S. corporation)

NUMBER DATE
PATENT INFORMATION: US 5581517 961203
APPLICATION INFO.: US 95-432544 950502 (8)
RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 94-286268, filed on 5 Aug 1994, now abandoned
DOCUMENT TYPE: Utility
PRIMARY EXAMINER: Phulic, Daniel T.
LEGAL REPRESENTATIVE: Brinks Hofer Gilson & Lione
NUMBER OF CLAIMS: 182
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 30 Drawing Figure(s); 24 Drawing Page(s)
LINE COUNT: 4642

AB A beamformer control system includes a primary control and secondary controls so that delay and apodization beamformation profiles can be generated on a dynamic and distributed basis with sparsely sampled base delay and apodization data sets first expanded to the final values by the primary control and then further expanded in the secondary controls associated with multi-processing channels of the beamformer systems. The beamformer control system coordinates the transmit and receive beamformer systems preferably using data sets common to all beamformer systems, and by advantageously specifying to all beamformer systems, processing mode trade-offs among the signal nominal center frequency, the range spatial resolution, and the number of beams. The beamformer control system supports multiple simultaneous beam operation, as well as beam-to-beam adjustable frequency and synthetic aperture operations. Further, the present beamformer control system maintains beam-to-beam coherent receive beamformation and supports adaptive beamformation.

L25 ANSWER 29 OF 88 USPATFULL
ACCESSION NUMBER: 96:106368 USPATFULL
TITLE: ***Vectors*** with pectate lyase signal sequence

INVENTOR(S): Robinson, Randy R., Walnut Creek, CA, United States
Belter, Marc, Los Angeles, CA, United States
Lei, Shau-Ping, Los Angeles, CA, United States
Wilcox, Gary L., Mill Creek, WA, United States
PATENT ASSIGNEE(S): Xoma Corporation, Berkeley, CA, United States (U.S. corporation)

NUMBER DATE
PATENT INFORMATION: US 5576195 961119
APPLICATION INFO.: US 94-357234 941209 (8)
RELATED APPLN. INFO.: Continuation of Ser. No. US 93-20671, filed on 22 Feb 1993, now abandoned which is a division of Ser. No. US 92-987555, filed on 8 Dec 1992, now abandoned which is a continuation of Ser. No. US 90-501092, filed on 29 Mar 1990, now abandoned which is a continuation-in-part of Ser. No. US 87-77528, filed on 24 Jul 1987, now abandoned which is a continuation-in-part of Ser. No. US 85-793980, filed on 1 Nov 1985, now abandoned, said Ser. No. US 90-501092, filed on 29 Mar 1990 which is a continuation-in-part of Ser. No. US 88-142039, filed on 11 Jan 1988, now abandoned
DOCUMENT TYPE: Utility
PRIMARY EXAMINER: Mosher, Mary E
LEGAL REPRESENTATIVE: Sterne, Kassler, Goldstein & Fox P.L.L.C.
NUMBER OF CLAIMS: 35
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 58 Drawing Figure(s); 50 Drawing Page(s)
LINE COUNT: 3860

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention relates to DNA coding for a pectate lyase signal peptide which has been inserted into plasmids to create secretion ***vectors*** which are capable of producing a chosen protein by directing transport across the bacterial membrane. The secretion ***vectors*** have been used to secrete extracellular thrombin and extracellular antibody fragments. The proteins produced by

these ***vectors*** have biological activity. The thrombin is properly folded and the antibody fragments are capable of binding antigens on target cancer cells.

L25 ANSWER 30 OF 88 USPATFULL
ACCESSION NUMBER: 96:102489 USPATFULL
TITLE: Method and system for process expression and resolution including a general method of direct association
INVENTOR(S): Fant, Karl M., Minneapolis, MN, United States
Brandt, Scott A., Minneapolis, MN, United States
PATENT ASSIGNEE(S): Thesaur Research, Inc., Minneapolis, MN, United States (U.S. corporation)

NUMBER DATE
PATENT INFORMATION: US 5572732 961105
APPLICATION INFO.: US 94-296809 940826 (8)
RELATED APPLN. INFO.: Continuation of Ser. No. US 92-837641, filed on 14 Feb 1992, now patented, Pat. No. US 5355496
DOCUMENT TYPE: Utility
PRIMARY EXAMINER: Kulik, Paul V.
LEGAL REPRESENTATIVE: Merchant, Gould, Smith, Edell, Welter & Schmidt, P.A.

NUMBER OF CLAIMS: 8
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 68 Drawing Figure(s); 27 Drawing Page(s)
LINE COUNT: 6077
AB A method and system for process expression and resolution including a general method of direct association and resolution first language structure including a named result reference which is a destination for a result string for a directly associated correspondingly named resultant is provided. In addition, a second language structure including a result link is provided. A first end of the result link is located within a formal list of a definition. A second end of the result link is directly associated by list position and is located within an actual list of an invocation. A third language structure including the resultant is provided. The resultant is associated with one or more language elements, including: the correspondingly named result reference and/or the correspondingly named result link. A resolution mechanism replaces the named result reference associated with the correspondingly named resultant with the resultant result string such that a language expression is resolved.

L25 ANSWER 31 OF 88 USPATFULL
ACCESSION NUMBER: 96:70309 USPATFULL
TITLE: Co-factor activated recombinant adenovirus proteases
INVENTOR(S): Anderson, Carl W., Stony Brook, NY, United States
Mangel, Walter F., Shoreham, NY, United States
PATENT ASSIGNEE(S): Associated Universities, Inc., Washington, DC, United States (U.S. corporation)

NUMBER DATE
PATENT INFORMATION: US 5543264 960806
APPLICATION INFO.: US 93-155171 931119 (8)
RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 92-851217, filed on 13 Mar 1992, now abandoned which is a continuation-in-part of Ser. No. US 90-545595, filed on 29 Jun 1990, now abandoned
DOCUMENT TYPE: Utility
PRIMARY EXAMINER: Wax, Robert A.
ASSISTANT EXAMINER: Moore, William W.
LEGAL REPRESENTATIVE: Bogosian, Margaret C.
NUMBER OF CLAIMS: 19
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 29 Drawing Figure(s); 25 Drawing Page(s)
LINE COUNT: 3005

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB This application describes methods and expression constructs for producing recombinant recombinant adenovirus proteases. Purified activatable recombinant adenovirus proteases and methods of purification are described. Activated adenovirus proteases and methods for obtaining activated adenovirus proteases are further included. Isolated peptide cofactors of adenovirus proteinase

activity, methods of purifying and identifying said peptide cofactors are also described. Antibodies immunoreactive with adenovirus proteinases, immunospecific antibodies, and methods for preparing them are also described. Other related methods and materials are also described.

L25 ANSWER 32 OF 88 USPATFULL
ACCESSION NUMBER: 96:53275 USPATFULL
TITLE: Process for the protection of plant seeds and apparatus to carry out said process
INVENTOR(S): Rensing, Cornelis W., Oisssel, France
Sainsard, Hubert, Louviers, France
PATENT ASSIGNEE(S): Ciba-Geigy Corporation, Tarrytown, NY, United States (U.S. corporation)

NUMBER DATE
PATENT INFORMATION: US 5527760 960618
APPLICATION INFO.: US 95-410645 950324 (8)
RELATED APPLN. INFO.: Continuation of Ser. No. US 94-182075, filed on 13 Jan 1994, now abandoned

NUMBER DATE
PRIORITY INFORMATION: FR 91-9035 910717
DOCUMENT TYPE: Utility
PRIMARY EXAMINER: Clardy, S. Mark
LEGAL REPRESENTATIVE: Roberts, Edward McC.
NUMBER OF CLAIMS: 19
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 2 Drawing Figure(s); 1 Drawing Page(s)
LINE COUNT: 652
AB An improved process for the phytoprotection of plant seeds, wherein there is simultaneously applied to the seeds, on the one hand, at least one first liquid composition containing at least one phytoprotection product, and on the other hand, a foam formed from a second composition, containing at least one nonphytotoxic foaming agent.

L25 ANSWER 33 OF 88 USPATFULL
ACCESSION NUMBER: 96:51341 USPATFULL
TITLE: Methods and apparatus for concurrently acquiring video data from multiple video data sources
INVENTOR(S): King, David R., Norfolk, MA, United States
Wolff, Robert, Sherborn, MA, United States
PATENT ASSIGNEE(S): Cognex Corporation, Natick, MA, United States (U.S. corporation)

NUMBER DATE
PATENT INFORMATION: US 5526050 960611
APPLICATION INFO.: US 94-220555 940331 (8)
DOCUMENT TYPE: Utility
PRIMARY EXAMINER: Kostak, Victor R.
LEGAL REPRESENTATIVE: Choate, Hall & Stewart
NUMBER OF CLAIMS: 11
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 12 Drawing Figure(s); 8 Drawing Page(s)
LINE COUNT: 4057
AB The invention provides apparatus and methods for concurrently acquiring video data from multiple video data sources. The invention comprises an asynchronous interface that collects pixel data from multiple video data sources. A packet manager collects the pixel data and generates a packet data signal that represents the pixel data collected from the multiple video data sources. The packet manager transmits the packet data signal to a pixel buffer memory that includes an address generator that separates out the pixel data associated with each of the video data sources and that stores the pixel data in a video memory in a manner suitable for video display.

L25 ANSWER 34 OF 88 USPATFULL
ACCESSION NUMBER: 96:46694 USPATFULL
TITLE: System for and method of recognizing and tracking target mark
INVENTOR(S): Hashima, Masayoshi, Kawasaki, Japan
Hasegawa, Fumi, Kawasaki, Japan

Okabayashi, Keiju, Kawasaki, Japan
Watanabe, Ichiro, Kawasaki, Japan
Kanda, Shinji, Kawasaki, Japan
Sawasaki, Naoyuki, Kawasaki, Japan
Murasu, Yuichi, Kawasaki, Japan
PATENT ASSIGNEE(S): Fujitsu Limited, Kawasaki, Japan (non-U.S. corporation)

NUMBER DATE
PRIORITY INFORMATION: US 5521843 960528
WO 9315376 930805
APPLICATION INFO.: US 93-119228 930928 (8)
WO 93-JP107 930129
930928 PCT 371 date
930928 PCT 102(e) date

NUMBER DATE
PRIORITY INFORMATION: JP 92-15557 920130
JP 92-193457 920626
JP 92-219029 920818
JP 92-291628 921029
JP 92-307015 921117
DOCUMENT TYPE: Utility
PRIMARY EXAMINER: Voeltz, Emanuel T.
ASSISTANT EXAMINER: Pessio, Thomas
LEGAL REPRESENTATIVE: Armstrong, Westerman, Hattori, McLeiland & Naughton

NUMBER OF CLAIMS: 14
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 109 Drawing Figure(s); 47 Drawing Page(s)
LINE COUNT: 2186

AB A system for and a method of recognizing and tracking a target mark with a video camera is disclosed. The system includes a target mark (10) disposed on an object (1) and composed of a black circle and a white triangle mounted centrally on the black circle and three-dimensionally shifted from the black circle, a video camera (20) for imaging the target mark (10), a robot (30) supporting the video camera (20) and movable in directions with six degrees of freedom, an image processor (40) for processing image data of the target mark which is produced by the video camera (20), a shift calculating unit (50) for detecting a shift of the target mark (10) from projected histogram information of the target mark (10) which is produced by the image processor (40), and a robot controller (60) for controlling movement of the robot depending on the shift to enable the video camera (20) to track the target mark (10). The system is capable of tracking the target mark (20) attached to the object (1) on a real-time basis. Mark recognizing apparatus capable of accurately recognizing target marks of other shapes is also disclosed.

25 ANSWER 35 OF 88 USPSTFULL
ACCESSION NUMBER: 96:37207 USPSTFULL
TITLE: High speed simulcast data system using adaptive compensation

INVENTOR(S): Marchetto, Robert F., Burnaby, Canada
Stewart, Todd A., West Vancouver, Canada
Ho, Paul K., Surrey, Canada

PATENT ASSIGNEE(S): Glenayre Electronics, Inc., Charlotte, NC, United States (U.S. corporation)

NUMBER DATE
PRIORITY INFORMATION: US 5513215 960430
APPLICATION INFO.: US 93-124155 930920 (8)
DOCUMENT TYPE: Utility
PRIMARY EXAMINER: Colles, Sr., Edward L.
ASSISTANT EXAMINER: Nguyen, Madeline AV
LEGAL REPRESENTATIVE: Christensen O'Connor Johnson & Kindness
NUMBER OF CLAIMS: 15
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 23 Drawing Figure(s); 19 Drawing Page(s)
LINE COUNT: 1644
AB In a simulcast communication system, a method and apparatus for compensating differences in propagation time, lack of synchronization in transmitters, and multipath fading to recover

data transmitted to a receiving device. In a simulcast communication system(26) that comprises a plurality of transmitters (32), a receiver (36) includes a digital signal processor (DSP) (86) that processes a demodulated received signal to adaptively compensate for changes in the channel through which a multipath signal is propagated from the transmitters to the receiver. In one embodiment, the DSP comprises a decision feedback equalizer. An error signal is produced by the equalizer through a comparison of the estimated symbols with symbols most likely transmitted, for use in updating filter coefficients used by the equalizer in processing the received signal. Alternatively, in a linear adaptive equalizer, references or pilot symbols transmitted with the data symbols are used to determine the error signal. Another embodiment implements a Viterbi algorithm to make decisions of the most likely data symbols in response to estimates of the channel impulse response. Further, a hybrid embodiment combines the Viterbi decoder with a bi-directional decision feedback equalizer that produces forward and reverse estimates of the sequence of data symbols. The Viterbi decoder selects between the forward and reverse sequences based upon channel impulse response estimates to dynamically compensate for varying channel conditions. Using any one of these embodiments, a linear modulated signal can be decoded to recover the data transmitted, even though the received signal has been degraded by propagation in a multipath fading channel. The same techniques are also disclosed as applicable to constant envelope modulated transmissions in a simulcast system.

L25 ANSWER 36 OF 88 USPSTFULL
ACCESSION NUMBER: 96:13003 USPSTFULL
TITLE: BRC/ABL transgenic animals as models for Philadelphia chromosome positive chronic myelogenous and acute lymphoblastic leukemia
INVENTOR(S): Grotfin, John, Los Angeles, CA, United States
Heisterkamp, Nora, Los Angeles, CA, United States
Pattengale, Paul K., Los Angeles, CA, United States

PATENT ASSIGNEE(S): Childrens Hospital of Los Angeles, Los Angeles, CA, United States (U.S. corporation)

NUMBER DATE
PRIORITY INFORMATION: US 5491283 960213
APPLICATION INFO.: US 93-3951 930114 (8)
RELATED APPL. INFO.: Continuation of Ser. No. US 89-440062, filed on 22 Nov 1989, now abandoned
DOCUMENT TYPE: Utility
PRIMARY EXAMINER: Chambers, Jasmine C.
LEGAL REPRESENTATIVE: Pernie & Edmonds
NUMBER OF CLAIMS: 15
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 17 Drawing Figure(s); 11 Drawing Page(s)
LINE COUNT: 1016
CAS INDEXING IS AVAILABLE FOR THIS PATENT

AB The present invention relates to non-human transgenic animals which contain a transgene comprising a BCR/ABL gene fusion and which develop leukemia. In a preferred embodiment of the present invention, the transgenic animals exhibit a rapid induction of acute leukemia.

The present invention offers the advantage of providing, for the first time, a non-human transgenic animal model system which carries the BCR/ABL gene fusion characteristic of the Philadelphia chromosome and which develops leukemia in a manner directly analogous to the clinical progression of chronic myelogenous leukemia (CML) and/or acute lymphoblastic leukemia (ALL) in humans. This model system for human leukemia may be valuable in obtaining a better understanding of CML and ALL and in developing effective therapeutic regimens.

L25 ANSWER 37 OF 88 USPSTFULL
ACCESSION NUMBER: 96:1933 USPSTFULL
TITLE: Positional deviation detecting method
INVENTOR(S): Matsugu, Masakazu, Tokyo, Japan
Saitoh, Kenji, Yokohama, Japan
Hattori, Jun, Zama, Japan
Houryu, Sakae, Hachioji, Japan

PATENT ASSIGNEE(S): Canon Kabushiki Kaisha, Tokyo, Japan (non-U.S. corporation)

NUMBER DATE
PRIORITY INFORMATION: US 5481363 960102
APPLICATION INFO.: US 94-242066 940513 (8)
RELATED APPL. INFO.: Continuation of Ser. No. US 91-693708, filed on 30 Apr 1991, now abandoned

NUMBER DATE
PRIORITY INFORMATION: JP 90-115445 900501
JP 90-272926 901011
JP 90-272927 901011
JP 90-272928 901011
JP 90-272929 901011

DOCUMENT TYPE: Utility
PRIMARY EXAMINER: Rosenberger, Richard A.
ASSISTANT EXAMINER: Hanits, K. P.
LEGAL REPRESENTATIVE: Fitzpatrick, Cella, Harper & Scinto
NUMBER OF CLAIMS: 29
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 23 Drawing Figure(s); 18 Drawing Page(s)
LINE COUNT: 2665

AB A method of detecting a relative positional deviation of a first object having a first grating mark with an optical power and a second object having a second grating mark with an optical power, is disclosed, wherein a projected radiation beam is diffracted by the first and second grating marks in sequence and, on the basis of a position of convergence on a light receiving surface of the plural diffraction beams produced by the diffraction through the first and second grating marks and including a signal beam having been diffracted at a predetermined order by each of the first and second grating marks, the relative positional deviation is determined, a detection zone is defined on the light receiving surface, the signal beam is converged upon the detection zone, and a predetermined diffraction beam of the plural diffraction beams which, for a relative positional deviation of the first and second objects, shows displacement different from that of the signal beam is substantially prevented from being converged upon the detection zone.

L25 ANSWER 38 OF 88 USPSTFULL
ACCESSION NUMBER: 96:1548 USPSTFULL
TITLE: Allergenic proteins from Johnson grass pollen
INVENTOR(S): Avigloglu, Asil, Towson, MD, United States
Singh, Mohan B., Templestowe, Australia
Knox, Robert B., North Balwyn, Australia
PATENT ASSIGNEE(S): The University of Melbourne, Parkville, Australia (non-U.S. corporation)
ImmuLogic Pharmaceutical Corporation, Waltham, MA, United States (U.S. corporation)

NUMBER DATE
PRIORITY INFORMATION: US 5480972 960102
APPLICATION INFO.: US 92-971096 921030 (7)
DOCUMENT TYPE: Utility
PRIMARY EXAMINER: Fleisher, Mindy B.
ASSISTANT EXAMINER: Schmickel, David
LEGAL REPRESENTATIVE: Lahive & Cockfield
NUMBER OF CLAIMS: 9
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 22 Drawing Figure(s); 12 Drawing Page(s)
LINE COUNT: 1775

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention provides a nucleic acid having a nucleotide sequence coding for Sor h I, a major allergen of Sorghum halepense, and fragments thereof. The present invention also provides purified Sor h I or at least one fragment thereof produced in a host cell transformed with a nucleic acid sequence coding for Sor h I, or at least one fragment thereof and fragments of Sor h prepared synthetically. Sor h I and fragments thereof are useful for diagnosing, treating, and preventing allergy to Johnson grass pollen.

L25 ANSWER 39 OF 88 SCISEARCH COPYRIGHT 1998 ISI (R) DUPLICATE
1
ACCESSION NUMBER: 96:427530 SCISEARCH
THE GENUINE ARTICLE: UN548
IDENTIFICATION OF A COMMON FILARIAL LARVA IN
SIMULIUM-DAMNOSUM S-L (TYPE-D, DUKE, 1967) AS
ONCHOCERCA-RAMACHANDRINI FROM THE WART HOG
AUTHOR: WAHL, G (Reprint)
CORPORATE SOURCE: UNIV TUBINGEN, INST TROP MED, WILHELMSTR
27, D-72074
TUBINGEN, GERMANY (Reprint)
COUNTRY OF AUTHOR: GERMANY
SOURCE: JOURNAL OF PARASITOLOGY, (JUN 1996) Vol. 82, No. 3,
pp. 520-524.
ISSN: 0022-3395.
DOCUMENT TYPE: Article; Journal
FILE SEGMENT: LIFE: AGRI
LANGUAGE: ENGLISH
REFERENCE COUNT: 6
ABSTRACT IS AVAILABLE IN THE ALL AND ALL FORMATS
AB Filarial larvae resembling Type D (Duke, 1967), which are common
in the Simulium damnosum s.l. ***vectors*** of human
onchocerciasis ("river blindness") in several parts of West Africa,
were dissected from wild-caught flies in north Cameroon and examined
morphologically. This was done in order to establish a possible
synonymy with infective larvae (L3) of 2 recently discovered
Onchocerca species of wart hogs (Onchocerca ramachandrini Bain,
Wahl, and Renz, 1993 and Onchocerca sp. Wahl and Bain, 1995), which
has been found to resemble Type D. After dissection of approximately
1,700 S. damnosum s. ***vectors*** Type D-like larvae
were recovered from 12 infected flies. Their morphology corresponded
to O. ramachandrini.

L25 ANSWER 40 OF 88 USPATFULL
ACCESSION NUMBER: 95:111065 USPATFULL
TITLE: Ultrasonic measuring system
INVENTOR(S): Kuzuya, Keiji, Kariya, Japan
Nakahara, Naoki, Nagoya, Japan
Aoki, Yasuyuki, Owarinashi, Japan
PATENT ASSIGNEE(S): Aisin Seiki Kabushiki Kaisha, Kariya, Japan
(non-U.S. corporation)

NUMBER DATE

PATENT INFORMATION: US 5475620 951212
APPLICATION INFO.: US 94-248730 940525 (6)

NUMBER DATE

PRIORITY INFORMATION: JP 93-122987 930525

DOCUMENT TYPE: Utility

PRIMARY EXAMINER: Ramirez, Ellis B.

ASSISTANT EXAMINER: Peeso, Thomas

LEGAL REPRESENTATIVE: Sughrue, Mion, Zinn, Macpeak & Seas

NUMBER OF CLAIMS: 8

EXEMPLARY CLAIM: 1

NUMBER OF DRAWINGS: 15 Drawing Figure(s); 13 Drawing Page(s)

LINE COUNT: 982

AB An ultrasonic measuring system for a vehicle is composed of first and second ultrasonic transducing assemblies TR1 and TR2. Each transducing assembly TR1, TR2 has three ultrasonic transducers TR11, TR12, TR13, TR21, TR22, TR23 which are separated from each other at an angle of 120 degrees in a horizontal plane about axis disposed at a front and a rear of the vehicle, respectively. Each transducer transmits ultrasonic waves to a road surface at a predefined down-angle relative to the road surface and receives reflected waves from the road surface. Each of the transducers TR21, TR22, TR23 transmits ultrasonic waves to the road surface and receiving reflected waves from the road surface in an opposite direction to a corresponding one of the transducers TR11, TR12, TR13. A two dimensional speed, a yaw rate and a yawing center are obtained by differences of first three speed ***vectors*** in three directions obtained by the first ultrasonic transducing assembly, TR1 and second three speed ***vectors*** in second three directions, corresponding to the first three directions, obtained by the second ultrasonic transducing assembly TR2.

L25 ANSWER 41 OF 88 USPATFULL
ACCESSION NUMBER: 95:85031 USPATFULL
TITLE: Method for solving geometric constraint systems
INVENTOR(S): Kramer, Glenn A., Austin, TX, United States
Keyrouz, Walid T., Austin, TX, United States
Pabon, Jahir A., Austin, TX, United States
PATENT ASSIGNEE(S): Schlumberger Technology Corporation, Austin, TX, United States (U.S. corporation)

NUMBER DATE

PATENT INFORMATION: US 5452238 950919

APPLICATION INFO.: US 92-979143 921120 (7)

DISCLAIMER DATE: 20080827

RELATED APPL. INFO.: Continuation-in-part of Ser. No. US 89-365586, filed on 13 Jun 1989, now patented, Pat. No. US 5253189

DOCUMENT TYPE: Utility

PRIMARY EXAMINER: Voeltz, Emanuel T.

ASSISTANT EXAMINER: Tran, Alan

LEGAL REPRESENTATIVE: Huston, Charles D.

NUMBER OF CLAIMS: 25

EXEMPLARY CLAIM: 1

NUMBER OF DRAWINGS: 17 Drawing Figure(s); 16 Drawing Page(s)

LINE COUNT: 1577

AB A method, useful in computer-aided design, for finding possible configurations of a system having a collection of geometric entities and constraints. The method represents the geometric entities in terms of degrees of freedom and systematically satisfies the constraints reducing the degrees of freedom of the geometric entities. The method uses a number of specialized routines, called plan fragments, which satisfy a particular constraint relating to a particular geometric entity. Each plan fragment changes the configuration of a geometric entity in space--i.e. the location and orientation--satisfying a constraint and reducing a degree of freedom. The series of plan fragments which reduce the degrees of freedom and satisfy the constraints comprise an assembly plan for possible configurations of the system. The method identifies unconstrained, fully constrained, and unconstrained systems to the user and assists in finding possible configurations if the constraints are changed, added, or deleted. The method is useful in solving any geometric constraint problem, such as describing mechanical assemblies constraint-based sketching and design, geometric modeling for CAD, and kinematic analysis of robots and linkage mechanisms. By reasoning symbolically about the geometry of the system, the method provides faster solutions, numerical stability, user feedback, and the ability to handle redundant constraints.

L25 ANSWER 42 OF 88 USPATFULL

ACCESSION NUMBER: 95:50083 USPATFULL

TITLE: Decomposition of ethylenically unsaturated carboxylic esters

INVENTOR(S): Nicks, Peter F., Maidenhead, Great Britain

Carber, Mark A., Stockton on Tees, Great Britain

Ratton, Julian M., Darlington, Great Britain

PATENT ASSIGNEE(S): Imperial Chemical Industries plc, London, United Kingdom (non-U.S. corporation)

NUMBER DATE

PATENT INFORMATION: US 5422269 950606

WO 9115520 911017

APPLICATION INFO.: US 92-930560 921130 (7)

WO 91-GB483 910328

921130 PCT 371 date

921130 PCT 102(e) date

NUMBER DATE

PRIORITY INFORMATION: GB 90-7140 900330

DOCUMENT TYPE: Utility

PRIMARY EXAMINER: Schiefer, Joseph L.

ASSISTANT EXAMINER: Weber, Tom

LEGAL REPRESENTATIVE: Cushman Darby & Cushman

NUMBER OF CLAIMS: 6

EXEMPLARY CLAIM: 1

NUMBER OF DRAWINGS: 3 Drawing Figure(s); 3 Drawing Page(s)
LINE COUNT: 429
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Residual levels of monomeric ethylenically unsaturated carboxylic acid esters such as allyl acrylate and methacrylates, especially ethyl, butyl and "iso-hexyl" acrylates and methacrylates, in surfactant stabilised dispersions of polymers of the monomer(s) such as latices or products formulated from latices, are reduced by treatment with a hydrolytic enzyme, particularly a lipase or esterase. The treatment reduces and can obviate the perceived bad odour of the dispersions arising from the presence of the monomers.

L25 ANSWER 43 OF 88 USPATFULL

ACCESSION NUMBER: 95:23410 USPATFULL

TITLE: Edge detecting apparatus

INVENTOR(S): Aoyama, Chiaki, Wako, Japan

PATENT ASSIGNEE(S): Honda Giken Kogyo Kabushiki Kaisha, Tokyo, Japan (non-U.S. corporation)

NUMBER DATE

PATENT INFORMATION: US 5398292 950314

APPLICATION INFO.: US 93-49524 930420 (6)

NUMBER DATE

PRIORITY INFORMATION: JP 92-103244 920422

DOCUMENT TYPE: Utility

PRIMARY EXAMINER: Boudreau, Leo H.

ASSISTANT EXAMINER: Cammarata, Michael R.

LEGAL REPRESENTATIVE: Lyon & Lyon

NUMBER OF CLAIMS: 5

EXEMPLARY CLAIM: 1

NUMBER OF DRAWINGS: 12 Drawing Figure(s); 8 Drawing Page(s)

LINE COUNT: 394

AB Edge detecting masks each having a sensing directivity to a specific direction are arranged with each directivity direction shifted by a given angular interval from the neighboring masks. A sum-of-products computation is performed between weighting elements in each of the so-arranged masks and image data indicating the brightness or tint of respective pixels. A selecting device selects a mask which exhibits the maximum sum-of-products output value among others and also selects two or three more masks before and behind the selected mask according to the interpolation method employed. An estimate computing device performs interpolation using the angles and output values of the selected edge detecting masks to estimate a true edge direction.

L25 ANSWER 44 OF 88 USPATFULL

ACCESSION NUMBER: 94:113648 USPATFULL

TITLE: Wavelength converting optical device

INVENTOR(S): Hatakeuchi, Genichi, Yokohama, Japan

Okajima, Masaki, Kawasaki, Japan

Terashima, Kazutaka, Ebina, Japan

Uematsu, Yutaka, Yokohama, Japan

PATENT ASSIGNEE(S): Kabushiki Kaisha Toshiba, Kawasaki, Japan (non-U.S. corporation)

NUMBER DATE

PATENT INFORMATION: US 5377291 941227

APPLICATION INFO.: US 89-451234 891215 (7)

NUMBER DATE

PRIORITY INFORMATION: JP 89-16224 890113

JP 89-196831 890731

DOCUMENT TYPE: Utility

LEGAL REPRESENTATIVE: Lee, John D.

LEGAL REPRESENTATIVE: Oblon, Spivak, McClelland, Maier, & Neustadt

NUMBER OF CLAIMS: 23

EXEMPLARY CLAIM: 12

NUMBER OF DRAWINGS: 43 Drawing Figure(s); 15 Drawing Page(s)

LINE COUNT: 1462

AB A wavelength converting optical device includes an optical waveguide which has a waveguide portion and a cladding portion, at

AB The invention relates to a nonlinear optical material. A least one of which is formed of a nonlinear optical material. A fundamental wave, incident on the waveguide portion from an input end face of the waveguide, is converted into an optical second harmonic wave by Cerenkov radiation and is radiated into the cladding portion. The radiated second harmonic wave is output from an output end face of the waveguide. A reflecting film is provided on the emerging end face of the waveguide. The reflecting film includes a high reflectivity with respect to the fundamental wave of a guide mode and a low reflectivity with respect to the optical second harmonic wave. A wave front converting element is arranged to oppose the reflecting film. A wave front converting element has a diffraction grating for converting the second harmonic wave, emerging from the output end face of the waveguide, into a plane wave.

L25 ANSWER 45 OF 88 USPATFULL
ACCESSION NUMBER: 94-97932 USPATFULL
TITLE: Method and apparatus for encoding-decoding a digital signal
INVENTOR(S): Duhamel, Pierre, Issy les Moulineaux, France
PATENT ASSIGNEE(S): Mahieux, Yannick, Begard, France
corporate(S): France Telecom, Paris, France (non-U.S. corporation)

NUMBER DATE
PATENT INFORMATION: US 5363096 941108
APPLICATION INFO.: US 92-871543 920421 (7)

NUMBER DATE
PRIORITY INFORMATION: FR 91-5064 910424
DOCUMENT TYPE: Utility
PRIMARY EXAMINER: Logan, Sharon D.
LEGAL REPRESENTATIVE: Larson & Taylor
NUMBER OF CLAIMS: 16
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 7 Drawing Figure(s); 7 Drawing Page(s)
LINE COUNT: 1131
AB After a windowing operation $h(n)$ performed by space-time weighting of the samples, a method and an apparatus for encoding-decoding a digital signal comprising a sequence of samples $x(n)$ consists in performing a modified discrete cosine transform of the samples to calculate the even order transformation coefficients: $\#EQU1\#$ for $k = \text{epision}[0, \dots, N/2-1]$ with $YN-k = Yk-1$ The coefficient $Y2k$ are expressed in the form of an invertible complex transformation: $\#EQU2\#$ for $k=0, \dots, N/4-1$ with $Yn=2n, h2n, y'n$
 $xN-2n-1, hN-2N-1$

$WN = \cos(2\pi \cdot \text{pl}/4N) \cdot \sin(2\pi \cdot \text{pl}/4N)$ The invertible complex transformation is calculated using an auxiliary calculation equation: $\#EQU3\#$ with: $zn = (Y2n - YN/2 - 1 - 2n) \cdot (YN - 1 - 2n + YN/2 - 2n)$ The invention is applicable to encoding and decoding digital audio or video signals.

L25 ANSWER 46 OF 88 USPATFULL
ACCESSION NUMBER: 94-90955 USPATFULL
TITLE: Membrane expression of heterologous genes
INVENTOR(S): Niesel, David W., League City, TX, United States
Moncrief, J. Scott, Galveston, TX, United States
Phillips, Linda H., Galveston, TX, United States
PATENT ASSIGNEE(S): Board of Regents, The University of Texas, Austin, TX, United States (U.S. corporation)

NUMBER DATE
PATENT INFORMATION: US 5356797 941018
APPLICATION INFO.: US 91-792525 911115 (7)
DOCUMENT TYPE: Utility
PRIMARY EXAMINER: Schwartz, Richard A.
ASSISTANT EXAMINER: Guzo, David
LEGAL REPRESENTATIVE: Arnold, White & Durkee
NUMBER OF CLAIMS: 24
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 12 Drawing Figure(s); 11 Drawing Page(s)
LINE COUNT: 1390
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention relates to nucleic acid segments useful in the construction of expression "vectors" for expression of heterologous polypeptides directed to particular areas of the host cell. Selected constructs direct production of polypeptides to the outer membrane surface of the cell. Other constructs direct expression of heterologous polypeptides to the inner membrane/periplasm of the host cell. Transformed host cells are potentially useful for the production of vaccines or immunogens elicited in response to antigens expressed on the outer membranes of the host cells.

L25 ANSWER 47 OF 88 USPATFULL
ACCESSION NUMBER: 94-89434 USPATFULL
TITLE: Method and system for process expression and resolution including a generally and inherently concurrent computer language
INVENTOR(S): Fant, Karl M., Minneapolis, MN, United States
Brandt, Scott A., Minneapolis, MN, United States
PATENT ASSIGNEE(S): Thesius Research, Inc., Minneapolis, MN, United States (U.S. corporation)

NUMBER DATE
PATENT INFORMATION: US 5355496 941011
APPLICATION INFO.: US 92-837641 920214 (7)
DOCUMENT TYPE: Utility
PRIMARY EXAMINER: Kulik, Paul V.
LEGAL REPRESENTATIVE: Merchant, Gould, Smith, Edell, Welter & Schmidt
NUMBER OF CLAIMS: 20
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 68 Drawing Figure(s); 27 Drawing Page(s)
LINE COUNT: 6080
AB A method and system for process expression and resolution is described. A first language structure comprising a possibility expression having at least one definition which is inherently and generally concurrent is provided. Further, a second language structure comprising an actuality expression including a fully formed input data name to be resolved is provided. Furthermore, a third language structure comprising an active expression initially having at least one invocation, the invocation comprising an association with a particular definition and the fully formed input data name of the actuality expression is provided. Subsequently, the process of resolving invocations begins in the active expression with fully formed input data names in relation to their associated definition to produce at least one or both of the following: (1) an invocation with a fully formed input data name and (2) a result data name.

L25 ANSWER 48 OF 88 USPATFULL
ACCESSION NUMBER: 94-81066 USPATFULL
TITLE: Lens periphery processing apparatus, method for obtaining processing data, and lens periphery processing method
INVENTOR(S): Shibata, Ryoji, Toyokawa, Japan
Kobayashi, Masahiko, Aichi, Japan
Ban, Yukinobu, Nishio, Japan
Obayashi, Hirokatsu, Aichi, Japan
PATENT ASSIGNEE(S): Nidek Co., Ltd., Gamagori, Japan (non-U.S. corporation)

NUMBER DATE
PATENT INFORMATION: US 5347762 940920
APPLICATION INFO.: US 93-11759 930201 (8)
PRIORITY INFORMATION: JP 92-54214 920204
DOCUMENT TYPE: Utility
PRIMARY EXAMINER: Rachuba, M.
LEGAL REPRESENTATIVE: Nikaido, Marmalstein, Murray & Oram
NUMBER OF CLAIMS: 6
EXEMPLARY CLAIM: 6
NUMBER OF DRAWINGS: 29 Drawing Figure(s); 22 Drawing Page(s)
LINE COUNT: 1150
AB An apparatus and a method for processing lens peripheries which allow lenses to be properly fitted in a frame, i.e., which

processes lenses with high dimensional accuracy. For this purpose, the lens periphery processing apparatus and method are designed to comprise an input device for inputting the configuration of lens frame portions of the eyeglasses frame which is a result of three-dimensional measurement, a calculation device for deriving peripheral lengths of the lens frame portions from the three-dimensional lens frame portion configuration inputted by the input device, a tapered edge curve determining device for determining a curve value defined by the locus of the tapered edge of each lens, and a computing device for computing the locus of the tapered edge of each lens which substantially coincides with the peripheral length of the associated lens frame portion which is obtained by the calculation device.

L25 ANSWER 49 OF 88 USPATFULL
ACCESSION NUMBER: 94-51887 USPATFULL
TITLE: Measuring method and measuring apparatus
INVENTOR(S): Matsumoto, Takahiro, Atsugi, Japan
Yoshii, Minoru, Tokyo, Japan
Saito, Kenji, Yokohama, Japan
Nose, Hiroyasu, Zama, Japan
Sentoku, Koichi, Atsugi, Japan
Takeuchi, Seiji, Atsugi, Japan
PATENT ASSIGNEE(S): Canon Kabushiki Kaisha, Tokyo, Japan (non-U.S. corporation)

NUMBER DATE
PATENT INFORMATION: US 5321502 940614
APPLICATION INFO.: US 92-910457 920708 (7)

NUMBER DATE
PRIORITY INFORMATION: JP 91-171285 910711
JP 92-16519 920131
DOCUMENT TYPE: Utility
PRIMARY EXAMINER: Warden, Robert J.
ASSISTANT EXAMINER: Carpenter, Robert
LEGAL REPRESENTATIVE: Fitzpatrick, Cella, Harper & Scinto
NUMBER OF CLAIMS: 9
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 20 Drawing Figure(s); 18 Drawing Page(s)
LINE COUNT: 1786
AB A measuring arrangement includes forming first and second pairs of light beams each having a low frequency light beam and a high frequency light beam. Both pairs of light beams generate beat signals of the same frequency. The low frequency light beam of either pair and the high frequency of the other pair pass through a predetermined optical path to cause phase changes in the same direction. Beat signals are generated by superposing the first and second beam pair to provide measurement information on the phase changes.

L25 ANSWER 50 OF 88 USPATFULL
ACCESSION NUMBER: 93-59484 USPATFULL
TITLE: Process and device for real-time spectral analysis of complex unsteady signals
INVENTOR(S): Demont, Guy, Orsay, France
Herment, Alain, Paris, France
Arcle, Claude, Igny, France
Moutapa, Indira, Paris, France
Houacine, Amrane, Bab Essouar, Algeria
Peronneau, Pierre, Paris, France
PATENT ASSIGNEE(S): Institut National de la Sante et de la Recherche Medicale, France (non-U.S. government)

NUMBER DATE
PATENT INFORMATION: US 5229716 930720
WO 9011494 901004
APPLICATION INFO.: US 91-776400 911121 (7)
WO 90-FR163 900322
911121 PCT 371 date
911121 PCT 102(e) date
NUMBER DATE

PRIORITY INFORMATION: FR 89-3761 890322
DOCUMENT TYPE: Utility
PRIMARY EXAMINER: Tokar, Michael J.
LEGAL REPRESENTATIVE: Larson and Taylor
NUMBER OF CLAIMS: 6
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 5 Drawing Figure(s); 2 Drawing Page(s)
LINE COUNT: 610
AB The invention includes a real time spectral analysis of unsteady signals with complex values representatives of a physical phenomenon. Successive sections of a sample signal are modelled by a high order self-regressive process by estimating parameters characterizing the model by rapid Kalman filtering using an algorithm.

L25 ANSWER 51 OF 88 USPATFULL
ACCESSION NUMBER: 93-55204 USPATFULL
TITLE: Positional deviation detecting method
INVENTOR(S): Matsugu, Masakazu, Atsugi, Japan
Saito, Kenji, Yokohama, Japan
Hattori, Jun, Zama, Japan
PATENT ASSIGNEE(S): Canon Kabushiki Kaisha, Tokyo, Japan (non-U.S. corporation)

NUMBER DATE
PATENT INFORMATION: US 5225892 930706
APPLICATION INFO.: US 92-939429 920904 (7)
RELATED APPLN. INFO.: Continuation of Ser. No. US 91-650863, filed on 5 Feb 1991, now abandoned

NUMBER DATE
PRIORITY INFORMATION: JP 90-25489 900205
DOCUMENT TYPE: Utility
PRIMARY EXAMINER: Evans, F. L.
LEGAL REPRESENTATIVE: Fitzpatrick, Cella, Harper & Scinto
NUMBER OF CLAIMS: 72
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 7 Drawing Figure(s); 6 Drawing Page(s)
LINE COUNT: 1628
AB Disclosed is a method of detecting relative positional deviation of a first object with a first grating pattern having an optical power and a second object with a second grating mark having an optical power. Light diffracted by both the first and second grating marks forms a light pattern on a predetermined plane; wherein different diffraction beams of the light diffracted by both the first and second grating marks are displaceable along the predetermined plane in accordance with the relative positional deviation of the first and second objects, in the same direction and by substantially the same quantity; and the relative positional deviation of the first and second objects is detected on the basis of the position of the light pattern on the predetermined plane.

L25 ANSWER 52 OF 88 USPATFULL
ACCESSION NUMBER: 93-27726 USPATFULL
TITLE: Multiple address-space data processor with addressable register and context switching
INVENTOR(S): Sakamura, Ken, Tokyo, Japan
PATENT ASSIGNEE(S): Mitsubishi Denki Kabushiki Kaisha, Tokyo, Japan (non-U.S. corporation)

NUMBER DATE
PATENT INFORMATION: US 5201039 930406
APPLICATION INFO.: US 90-569758 900820 (7)
RELATED APPLN. INFO.: Continuation of Ser. No. US 88-173501, filed on 24 Mar 1988, now abandoned

NUMBER DATE
PRIORITY INFORMATION: JP 87-247418 870930
DOCUMENT TYPE: Utility
PRIMARY EXAMINER: Lee, Thomas C.
ASSISTANT EXAMINER: Hanly, Paul
LEGAL REPRESENTATIVE: Townsend and Townsend

NUMBER OF CLAIMS: 16
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 397 Drawing Figure(s); 213 Drawing Page(s)
LINE COUNT: 10991
AB Two or more address spaces are provided in a data processor. One of the address spaces comprises control registers so that the control registers can be accessed using instructions having an address in the second address space. High-speed context switching can be accomplished by allocating the context-saving area to the second address space. The context can be saved in various formats specified by a context format register.

L25 ANSWER 53 OF 88 USPATFULL
ACCESSION NUMBER: 93-15237 USPATFULL
TITLE: Dynamic pattern matcher using incomplete data
INVENTOR(S): Wang, Lui, Houston, TX, United States
Johnson, Gordon G., Princeton, NJ, United States
PATENT ASSIGNEE(S): The United States of America as represented by the United States National Aeronautics and Space Administration, Washington, DC, United States (U.S. government)

NUMBER DATE
PATENT INFORMATION: US 5189709 930223
APPLICATION INFO.: US 91-749819 910826 (7)
DOCUMENT TYPE: Utility
PRIMARY EXAMINER: Couso, Jose L.
LEGAL REPRESENTATIVE: Barr, Hardie R.; Miller, Guy M.; Fein, Edward K.
NUMBER OF CLAIMS: 20
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 7 Drawing Figure(s); 3 Drawing Page(s)
LINE COUNT: 865
AB A method of matching a first query pattern with a plurality of stored data is disclosed. For each stored data pattern, the number of components are counted which are identical to corresponding components in the first query pattern, thereby forming a set of match numbers equals the number of components in any stored pattern, that stored data pattern is displayed as an output pattern set indicating a match. If no match exists then a second query pattern is determined by modifying the first query pattern, component by component, in dependence upon both a first, global influence of all stored patterns on all components of the first query pattern and a second, particular influence of all stored patterns on each respective component of the first query pattern. The first two method steps are then repeated using the second query pattern in place of the first query pattern. If no match a third query pattern similarly is determined by modifying the second query pattern. Finally, the output pattern is displayed, component by component, with those respective components of the third query pattern that have been modified at most once from the first query pattern.

L25 ANSWER 54 OF 88 USPATFULL
ACCESSION NUMBER: 93-7639 USPATFULL
TITLE: Exception, interrupt, and trap handling apparatus which fetches addressing and context data using a single instruction following an interrupt
INVENTOR(S): Sakamura, Ken, Tokyo, Japan
PATENT ASSIGNEE(S): Mitsubishi Denki Kabushiki Kaisha, Tokyo, Japan (non-U.S. corporation)

NUMBER DATE
PATENT INFORMATION: US 5182811 930126
APPLICATION INFO.: US 90-554945 900710 (7)
RELATED APPLN. INFO.: Continuation of Ser. No. US 88-172035, filed on 23 Mar 1988, now abandoned

NUMBER DATE
PRIORITY INFORMATION: JP 87-250216 871002
DOCUMENT TYPE: Utility
PRIMARY EXAMINER: Lee, Thomas C.
ASSISTANT EXAMINER: Treat, William M.
LEGAL REPRESENTATIVE: Townsend and Townsend
NUMBER OF CLAIMS: 20

EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 397 Drawing Figure(s); 212 Drawing Page(s)
LINE COUNT: 10251
AB A data processor executes the exception process, interrupt process and the trap instruction of internal interrupt instructions in a unified manner. The data processor is adapted to read an internal state variable simultaneously with reading the head address of an EIT process handler from an external memory when an EIT process is started so that it enables the internal state to be set on the basis of the information of the variable when the EIT process handler starts. The data processor is provided with multiple EIT process means which, when a plurality of EIT process requests are generated, decides the process order on the basis of priority from the content of the request. The data processor is also provided with means which specially treats the EIT process acceptance condition after returning from one EIT process handler, and thereby is generously free in programming.

L25 ANSWER 55 OF 88 USPATFULL
ACCESSION NUMBER: 93-5881 USPATFULL
TITLE: Receiver for a DSSS signal
INVENTOR(S): Neeser, Fredy D., Zurich, Switzerland
Hufschmid, Markus D., Zurich, Switzerland
Ruprecht, Jurg P., Muri, Switzerland
PATENT ASSIGNEE(S): Ascom Tech. AG., Bern, Switzerland (non-U.S. corporation)

NUMBER DATE
PATENT INFORMATION: US 5181225 930119
APPLICATION INFO.: US 91-795477 911121 (7)

NUMBER DATE
PRIORITY INFORMATION: CH 90-3701 901122
DOCUMENT TYPE: Utility
PRIMARY EXAMINER: Barron, Jr., Gilberto
LEGAL REPRESENTATIVE: Brady, O'Boyle & Gates
NUMBER OF CLAIMS: 10
EXEMPLARY CLAIM: 2
NUMBER OF DRAWINGS: 9 Drawing Figure(s); 3 Drawing Page(s)
LINE COUNT: 522
AB In a receiver (3) for a DSSS signal (DSSS=direct sequence spread spectrum), an inverse filter (12) is utilized in place of a matched filter for detecting the symbols (8 sub.m). The inverse filter (12) is distinguished in that it responds to the predetermined pulse sequence as such with a pure Kronecker delta sequence. Preferably, the DSSS signal is generated with a pulse sequence realizing a maximum process gain.

L25 ANSWER 56 OF 88 BIOSIS COPYRIGHT 1998 BIOSIS
ACCESSION NUMBER: 94/82397 BIOSIS
DOCUMENT NUMBER: 97095397
TITLE: Potato leafroll virus in solanaceous weeds in absence of known potato donor sources.
AUTHOR(S): Souza-Dias J A C; Costa A; Nardin A M
CORPORATE SOURCE: Instituto Agronomico Campinas, Caixa Postal 28, 13020-900-Campinas SP, BRZ
SOURCE: Summa Phytopathologica 19 (2), 1993, 80-85, ISSN: 0100-5405
LANGUAGE: English

AB Outbreaks of potato leafroll virus (PLRV) in Brazil occur quite frequently in most of the main potato planting states. In the states of Sao Paulo and Parana, which hold the largest potato cultivated areas of the country, high grade seed potato lots, containing less than 1% of PLRV, may reach 20-50% of the virus in one or two multiplications only. Such a high inoculum pressure has been explained as due to outside inoculum sources, present among weeds and cultivated species other than potato. In this paper we report results from a survey conducted in the states of Sao Paulo and Parana in which natural infection of PLRV was demonstrated, by immuno (ELISA) and bio-assay, in 5 out of 8 solanaceous weeds sampled from the border or within potato plantations containing PLRV primarily infected plants. No known PLRV donor plants were present to be associated with such infection. Negative PLRV results were observed for samplings of the same species collected from non-potato planting

areas. The following species were randomly sampled and identified as PLRV alternative hosts: *Solanum aculeatissimum* Jacq. (9 positive/ 48 tested), *S. lycocarpum* St. Hil. (9/26), *S. paniculatum* L. (14/56), *S. variable* L. (1/1) (***13*** /47), and *S. elaeagnifolium* Dun. (1/1). Recovery tests via aphid ***vector*** *Myzus persicae* showed a range of 22-66% of transmission to indicator plants of Physalis and 11-33% to potato 'Bintje'. Although in this survey negative tests for PLRV were recorded for other solanaceous weeds (*S. sisymbrium* L. 0/6; *S. pseudocapsicum* L. 0/4; and *Datura stramonium* L. 0/10), they are not excluded as potential PLRV hosts. The results sustain previous evidences regarding PLRV dissemination as being mainly from outside of the potato field in areas with records of high seed potato degeneration levels.

L25 ANSWER 57 OF 88 USPATFULL
ACCESSION NUMBER: 92-93220 USPATFULL
TITLE: System for detecting nuclear magnetic resonance signals from small samples
INVENTOR(S): Sidles, John A., Seattle, WA, United States
PATENT ASSIGNEE(S): The Board of Regents of the University of Washington, Seattle, WA, United States (U.S. corporation)

NUMBER DATE
PATENT INFORMATION: US 5166815 921124
APPLICATION INFO.: US 91-654961 910211 (7)
DOCUMENT TYPE: Utility
PRIMARY EXAMINER: Tokar, Michael J.
LEGAL REPRESENTATIVE: Christensen, O'Connor, Johnson & Kindness
NUMBER OF CLAIMS: 22
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 5 Drawing Figure(s); 4 Drawing Page(s)
LINE COUNT: 1515

AB Apparatus and methods for detecting NMR signals from small samples using mechanical oscillators. In one embodiment, the sample is affixed to the mechanical oscillator, and immersed in a magnetic field. Magnetic resonance is detected by monitoring the mechanical excitation of the oscillator. The greatest excitation occurs when there is a three-fold resonance between the spin precession frequency of the sample, the natural frequency of the oscillator, and the oscillation frequency of the applied time dependent magnetic field. Samples as small as a single atomic nucleus can generate a detectable signal. In a second embodiment, the sample is affixed to a mechanically vibrating substrate, and a magnetic source is affixed to the mechanical oscillator.

L25 ANSWER 58 OF 88 USPATFULL
ACCESSION NUMBER: 92-89695 USPATFULL
TITLE: Multi-slot call relocation control method and system
INVENTOR(S): Hamaguchi, Naohisa, Yokohama, Japan
Komura, Kazushi, Yokohama, Japan
Suezaki, Eiichi, Yokohama, Japan
PATENT ASSIGNEE(S): Hitachi, Ltd., Tokyo, Japan (non-U.S. corporation)

NUMBER DATE
PATENT INFORMATION: US 5159590 921027
APPLICATION INFO.: US 90-584118 900918 (7)
PRIORITY INFORMATION: JP 89-239954 890918
DOCUMENT TYPE: Utility
PRIMARY EXAMINER: Safourek, Benedict V.
ASSISTANT EXAMINER: Samuel, T.
LEGAL REPRESENTATIVE: Antonelli, Terry, Stout & Kraus
NUMBER OF CLAIMS: 23
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 27 Drawing Figure(s); 19 Drawing Page(s)
LINE COUNT: 1108

AB A multi-slot call relocation control method and system having a multi-slot call switching system and/or transmission equipment constituted by an address control memory, address controller and address location changing circuit whereby address write and read

information for a channel memory is controlled. Where unoccupied circuits are 2.sup.N (N: natural number) times the basic switching unit, incoming calls with a maximum of 2.sup.N basic switching units in capacity may not be switched or transmitted by the unoccupied circuits depending on their status involving the presence of other calls. In that case, calls are relocated within a frame using the fewest steps possible. This is achieved by a neural network in the address control memory of multi-slot call switching system A, the neural network learning to output a call allocation pattern such that the number of times calls are relocated becomes minimal. The information from the network makes it possible to relocate the least number of times the calls whose capacity is not more than 2.sup.N basic switching unit in the channel memory. The relocation information is transmitted from switching system A to another system B, connected oppositely to system A. Using the relocation information received, system B relocates calls within a channel memory of its own.

L25 ANSWER 59 OF 88 USPATFULL
ACCESSION NUMBER: 92-82890 USPATFULL
TITLE: IL-2 analogs containing N-linked glycosylation sites
INVENTOR(S): Mitchell, Kenneth F., Media, PA, United States
Vallone, Carol A., Media, PA, United States
PATENT ASSIGNEE(S): Du Pont Merck Pharmaceutical Company, Wilmington, DE, United States (U.S. corporation)

NUMBER DATE
PATENT INFORMATION: US 5153310 921006
APPLICATION INFO.: US 89-317177 890228 (7)
DOCUMENT TYPE: Utility
PRIMARY EXAMINER: Lacey, David L.
ASSISTANT EXAMINER: Guest, Shelly J.
LEGAL REPRESENTATIVE: Ferguson, Blair O., Kerr, Don M.
NUMBER OF CLAIMS: 12
EXEMPLARY CLAIM: 1
LINE COUNT: 660
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Biologically active analogs of human IL2, which differ from natural IL2 by the substitution of amino acid residues to form N-linked glycosylation sites in the molecule, are prepared by recombinant DNA techniques. Such analogs of IL2 are N-linked glycosylated when expressed in eukaryotic cells. Natural IL2 is not N-linked glycosylated.

L25 ANSWER 60 OF 88 USPATFULL
ACCESSION NUMBER: 92-80754 USPATFULL
TITLE: Fermentation processes using amylolytic enzyme producing microorganisms
INVENTOR(S): Strasser, Alexander, Chopinstr 7, Dusseldorf, Germany, Federal Republic of
Martens, Feodor B., Chopinstr 7, HE Leiden, Germany, Federal Republic of
Dohnen, Jurgen, Chopinstr 7, Meerbusch, Germany, Federal Republic of
Hollenberg, Cornelius P., Chopinstr 7, D-4000 Dusseldorf, Germany, Federal Republic of
PATENT ASSIGNEE(S): Hollenberg, Cornelius, Dusseldorf, Germany, Federal Republic of (non-U.S. individual)

NUMBER DATE
PATENT INFORMATION: US 5151354 920929
APPLICATION INFO.: US 91-748161 910821 (7)
RELATED APPLN. INFO.: Division of Ser. No. US 87-85107, filed on 13 Aug 1987 which is a continuation-in-part of Ser. No. US 87-62943, filed on 16 Jun 1987, now abandoned

NUMBER DATE
PRIORITY INFORMATION: EP 86-111586 860821
DOCUMENT TYPE: Utility
PRIMARY EXAMINER: Schwartz, Richard A.
ASSISTANT EXAMINER: Johnson, Michelle

LEGAL REPRESENTATIVE: Cooper, Iver P.
NUMBER OF CLAIMS: 14
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 17 Drawing Figure(s); 42 Drawing Page(s)
LINE COUNT: 1887
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB This invention provides a method for producing amylolytic enzymes by culturing a microorganism, having received as a result of recombinant DNA technology DNA sequences from a donor yeast comprising the coding sequences for the amylolytic enzymes wherein the host microorganism is capable of expressing said amylolytic enzymes. Furthermore, this invention provides microorganisms genetically engineered as to being able to produce and express the amylolytic enzymes, a ***vector*** containing the DNA sequences, coding for the amylolytic enzymes and the respective DNA sequences. The said host microorganisms are useful in the production of biomass and many fermentation processes, preferably in the production of special beers.

L25 ANSWER 61 OF 88 USPATFULL
ACCESSION NUMBER: 92-25257 USPATFULL
TITLE: Amylolytic enzymes producing microorganisms, constructed by recombinant DNA technology and their use for fermentation processes

INVENTOR(S): Strasser, Alexander, Zonser Str. 6, Dusseldorf, Germany, Federal Republic of
Martens, Feodor B., Hogenwoerd 13, HE Leiden, Netherlands
Dohnen, Jurgen, Breitenstr. 20, Meerbusch, Germany, Federal Republic of
Hollenberg, Cornelius P., Chopinstr 7, Dusseldorf, Germany, Federal Republic of

NUMBER DATE
PATENT INFORMATION: US 5100794 920331
APPLICATION INFO.: US 87-85107 870813 (7)
RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 87-62943, filed on 16 Jun 1987, now abandoned

NUMBER DATE
PRIORITY INFORMATION: EP 86-111586 860821
DOCUMENT TYPE: Utility
PRIMARY EXAMINER: Teskin, Robin L.
LEGAL REPRESENTATIVE: Cooper, Iver P.
NUMBER OF CLAIMS: 41
EXEMPLARY CLAIM: 12
NUMBER OF DRAWINGS: 17 Drawing Figure(s); 40 Drawing Page(s)
LINE COUNT: 1911
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The cloning of Schwannomyces glucanmylase and alpha-amylase genes is taught. The genes are expressed in recombinant host cells.

L25 ANSWER 62 OF 88 USPATFULL
ACCESSION NUMBER: 92-18081 USPATFULL
TITLE: Adaptive control system for vehicles
INVENTOR(S): Ishida, Akira, Sakai, Japan
Takada, Masahiro, Hirakata, Japan
Narazaki, Kazushige, Neyagawa, Japan
Ito, Osamu, Kodoma, Japan
PATENT ASSIGNEE(S): Matsushita Electric Industrial Co., Ltd., Osaka, Japan (non-U.S. corporation)

NUMBER DATE
PATENT INFORMATION: US 5094127 920310
APPLICATION INFO.: US 90-614514 901116 (7)

NUMBER DATE
PRIORITY INFORMATION: JP 89-302901 891121
DOCUMENT TYPE: Utility
PRIMARY EXAMINER: Diehl, Dwight
LEGAL REPRESENTATIVE: Stevens, Davis, Miller & Mosher
NUMBER OF CLAIMS: 5

EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 11 Drawing Figure(s); 10 Drawing Page(s)
LINE COUNT: 626
AB An adaptive control system for vehicles using a time delay control method which applies a reference model for giving desired response characteristics, assumes that terms of an unknown section such as for variations of plant dynamics are constant for a minute time period, and estimates this variation of the unknown section to calculate a control input that follows said reference model.

L25 ANSWER 63 OF 88 USPATFULL
ACCESSION NUMBER: 91:24767 USPATFULL
TITLE: DNA coding for antigen protein of rinderpest virus
INVENTOR(S): Yamanouchi, Kazuya, Fuchu, Japan
Yoshikawa, Yasuhiro, Hoya, Japan
Sugimoto, Masanobu, Shiki, Japan
PATENT ASSIGNEE(S): Toa Nanyo Kogyo Kabushiki Kaisha, Tokyo, Japan
(non-U.S. corporation)

NUMBER DATE
PRIORITY INFORMATION: US 5003058 910326
APPLICATION INFO.: US 87-90550 870828 (7)

NUMBER DATE
PRIORITY INFORMATION: JP 86-201765 860829
JP 87-70413 870326
DOCUMENT TYPE: Utility
PRIMARY EXAMINER: Schwartz, Richard A.
ASSISTANT EXAMINER: Mosher, M.
LEGAL REPRESENTATIVE: Wegner, Centor, Mueller & Player
NUMBER OF CLAIMS: 4
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 4 Drawing Figure(s); 11 Drawing Page(s)
LINE COUNT: 356

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A DNA coding for an entire or a part of an antigen protein of the rinderpest virus; a protein for the production of the DNA comprising the steps of preparing an mRNA from the rinderpest virus, preparing a cDNA library from the mRNA, selecting a cDNA coding for the target protein from the cDNA library, and cloning the selected cDNA in a cloning "vector"; and a protein for the production of the antigen protein of the rinderpest virus comprising the steps of transfecting a "vector" containing the DNA coding for the target protein into animal cells, culturing the animal cells to produce the antigen protein, and recovering the target protein from the cell culture.

L25 ANSWER 64 OF 88 USPATFULL
ACCESSION NUMBER: 90:97062 USPATFULL
TITLE: Magnetic field screens
INVENTOR(S): Mansfield, Peter, Nottingham, England
Chapman, Barry L. W., Nottingham, England
Turner, Robert, Nottingham, England
Bowley, Roger M., Nottingham, England
PATENT ASSIGNEE(S): National Research Development Corporation, London, England (non-U.S. corporation)

NUMBER DATE
PRIORITY INFORMATION: US 497820 901218
APPLICATION INFO.: US 89-338392 890414 (7)
RELATED APPL. INFO.: Continuation of Ser. No. US 86-909292, filed on 19 Sep 1986, now abandoned

NUMBER DATE
PRIORITY INFORMATION: GB 85-23326 850920
GB 86-2911 860206
GB 86-14912 860619
DOCUMENT TYPE: Utility
PRIMARY EXAMINER: Tokar, Michael J.
LEGAL REPRESENTATIVE: Cushman, Darby & Cushman
NUMBER OF CLAIMS: 37
EXEMPLARY CLAIM: 1

NUMBER OF DRAWINGS: 40 Drawing Figure(s); 13 Drawing Page(s)
LINE COUNT: 1056
AB The screen is provided by surrounding the coil producing the magnetic field with a set of electrical conductors the currents within the conductors being controlled in such a manner that the field is neutralized in a specific region of space, the current distribution within the conductors being determined by calculating the current within a hypothetical superconductive shield which would have the effect of neutralizing the field, the current through the conductors thereby being a substitute for the superconductive shield.

L25 ANSWER 65 OF 88 USPATFULL
ACCESSION NUMBER: 90:66124 USPATFULL
TITLE: Direct digital synthesizer with selectively randomized accumulator
INVENTOR(S): Essenwanger, Kenneth A., Walnut, CA, United States
PATENT ASSIGNEE(S): Hughes Aircraft Company, Los Angeles, CA, United States (U.S. corporation)

NUMBER DATE
PRIORITY INFORMATION: US 4951237 900821
APPLICATION INFO.: US 88-184642 880422 (7)
DOCUMENT TYPE: Utility
PRIMARY EXAMINER: Malzahn, David H.
LEGAL REPRESENTATIVE: Denson-Low, Wanda K.
NUMBER OF CLAIMS: 21
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 4 Drawing Figure(s); 4 Drawing Page(s)
LINE COUNT: 647

AB A direct digital synthesizer (DDS) accumulator circuit is disclosed wherein a selected few of the low order accumulator bits are dithered by a pseudorandom number generator in order to introduce flat frequency deviation density to suppress spurious signals including those close-in to the output or fundamental frequency. The accumulator circuit may advantageously be sectioned into a lower order accumulator and higher order accumulator in a pipelined combination with a sine approximation output circuit in order to construct a DDS circuit wherein such spur suppression is achieved without decreasing system throughput.

L25 ANSWER 66 OF 88 USPATFULL
ACCESSION NUMBER: 90:8151 USPATFULL
TITLE: Key management system for open communication environments
INVENTOR(S): Pollard, Alan J., Winnipeg, Canada
Lemire, James R., Winnipeg, Canada
PATENT ASSIGNEE(S): The Manitoba Telephone System, Winnipeg, Canada
(non-U.S. corporation)

NUMBER DATE
PRIORITY INFORMATION: US 4897875 900130
APPLICATION INFO.: US 87-92625 870903 (7)
RELATED APPL. INFO.: Continuation of Ser. No. US 85-710429, filed on 11 Mar 1985, now abandoned

NUMBER DATE
PRIORITY INFORMATION: GB 86-21333 860904
DOCUMENT TYPE: Utility
PRIMARY EXAMINER: Buczynski, Stephen C.
ASSISTANT EXAMINER: Gregory, Bernarr Earl
LEGAL REPRESENTATIVE: Battison, Adrian D., Ade, Stanley G.; Thrift, Murray E.
NUMBER OF CLAIMS: 22
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 8 Drawing Figure(s); 6 Drawing Page(s)
LINE COUNT: 1354

AB A telecommunications security device for use on the communication medium includes a first and a second security unit each arranged to be inserted into for example the telephone line adjacent a user device. The units are identical and therefore either can act as a central unit for example for a computer access port with the other

providing one of a set of remote units. Each unit includes a separable memory module with all the modules having a memory storing identical information. The information stored includes a plurality of pairs of random signals one of each pair providing a request signal and the other the security code. The central unit on receipt of a telephone call provides a signal requesting an ID code from the remote unit and on receipt of the ID code issues from one of the pairs the security code request signal. On matching the received code with the expected code a transmission gate is opened. The pairs are used in turn until all of the pairs have been used whereupon an indicator shows this condition. The modules can be removed and the memory re-written with fresh pairs of codes. The key includes a security logic circuit which controls access to the numbers to a fixed set of access rules allowing authentication and/or encryption and providing security against unauthorized access.

L25 ANSWER 67 OF 88 USPATFULL
ACCESSION NUMBER: 89:49670 USPATFULL
TITLE: Position control system including a quick response control
INVENTOR(S): Itoh, Hiroshi, Numazu, Japan
PATENT ASSIGNEE(S): Toshiba Kikai Kabushiki Kaisha, Tokyo, Japan
(non-U.S. corporation)

NUMBER DATE
PRIORITY INFORMATION: US 4841208 890620
APPLICATION INFO.: US 87-95110 870911 (7)

NUMBER DATE
PRIORITY INFORMATION: JP 85-214741 850911
JP 87-98649 870407
DOCUMENT TYPE: Utility
PRIMARY EXAMINER: Ro, Bentsu
LEGAL REPRESENTATIVE: Birch, Stewart, Kolasch & Birch
NUMBER OF CLAIMS: 4
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 9 Drawing Figure(s); 9 Drawing Page(s)
LINE COUNT: 534

AB A position control system comprises a position command generator for generating a position command at a prescribed sampling time k for a time k+M which is at least one sampling cycle M ahead of the prescribed sampling time. A controlled object includes a speed control loop, and a control unit for generating a control input value determined by determining a weight coefficient of each of position commands at sampling times k+1, 2, ..., M and a weight coefficient for the position and speed which are outputs of the controlled object in order to minimize the value of an evaluation function so that the position command at the prescribed sampling time k and the position of the controlled object will be equalized, while the position commands produced by the position command generator at the sampling times k+1, 2, ..., M, the position and speed of the controlled object, and a control input to be applied to the controlled object are being used as variables.

L25 ANSWER 68 OF 88 USPATFULL
ACCESSION NUMBER: 88-47604 USPATFULL
TITLE: Target tracking system
INVENTOR(S): Piccolinuz, Heinz, Regensdorf, Switzerland
PATENT ASSIGNEE(S): Contraves AG, Zurich, Switzerland (non-U.S. corporation)

NUMBER DATE
PRIORITY INFORMATION: US 4760397 880726
APPLICATION INFO.: US 87-134751 871218 (7)

NUMBER DATE
PRIORITY INFORMATION: CH 86-5216 861222
DOCUMENT TYPE: Utility
PRIMARY EXAMINER: Tubbsing, T. H.
ASSISTANT EXAMINER: Barron, Jr., Gilberto
LEGAL REPRESENTATIVE: Kleeman, Werner W.

NUMBER OF CLAIMS: 14
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 4 Drawing Figure(s); 3 Drawing Page(s)
LINE COUNT: 1657
AB The target tracking system has high tracking reliability at small servo load and comprises a plural number of groups of target sensors having tracking signal travelling times which vary from one group to the other and defining respective lines of sight, a servo system causing the lines of sight to track the target, a target estimator for estimating the movement of the target, a servo estimator for estimating the movement of the servo system, and a regulator which identically controls the servo system and the servo estimator such that the vectorial difference between the estimate of the target movement and the estimate of the servo movement is caused to approach zero. During the target tracking operation, vectorial target deviation signals which are generated by groups of angle sensors, are processed by multipliers using respective matrices in order to produce related combined target deviation signals. The thus processed vectorial target deviation signals are directly applied to the servo system and the servo estimator in a manner as if there would be present only one respective angle sensor producing the combined target deviation signal.

25 ANSWER 69 OF 88 USPATEFULL
ACCESSION NUMBER: 88-39471 USPATEFULL
TITLE: Precision platform pointing controller for a dual-spin spacecraft
INVENTOR(S): Stafer, Loren I., Los Angeles, CA, United States
Bender, Douglas J., Santa Barbara, CA, United States
Yocum, John F., Rancho Palos Verdes, CA, United States
PATENT ASSIGNEE(S): Hughes Aircraft Company, Los Angeles, CA, United States (U.S. corporation)

NUMBER DATE
PATENT INFORMATION: US 4752884 880621
APPLICATION INFO.: US 85-756867 850718 (6)
DOCUMENT TYPE: Utility
PRIMARY EXAMINER: Chin, Gary
LEGAL REPRESENTATIVE: Mitchell, S. M.; Meltzer, M. J.; Karambelas, A. W.
NUMBER OF CLAIMS: 8
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 32 Drawing Figure(s); 27 Drawing Page(s)
LINE COUNT: 1753
AB A pointing apparatus for a dual-spin spacecraft utilizing a first sensor for sensing the time of arrival of an inertial attitude reference as the spinning portion of the spacecraft rotates, and a second sensor for sensing the time of arrival of an index reference which relates the position of the despun portion with the spinning portion. A digital processor estimates the spin rate and phase of the spinning portion from the inertial attitude reference time of arrival, estimates the relative spin rate and phase between the spinning portion and the despun portion from the index reference time of arrival, and estimates the bearing friction bias torque on the motor means which controls the pointing direction of the despun portion of the spacecraft. The spinning portion spin rate and phase estimates are added with the relative spin rate and phase estimates to produce an estimate of the despun portion spin rate and phase, and the despun portion spin rate and phase estimates and the friction bias torque estimates are subtracted from commanded despun portion spin rate, phase and friction bias torque states. A torque command is generated for controlling the motor means from the subtracted estimates.

L25 ANSWER 70 OF 88 USPATEFULL
ACCESSION NUMBER: 88-34433 USPATEFULL
TITLE: Process for recovering refractile bodies containing heterologous proteins from microbial hosts
INVENTOR(S): Dorin, Glenn, San Rafael, CA, United States
Hanisch, Wolfgang H., Balmoral Heights, Australia
Lin, Leo S., Walnut Creek, CA, United States

PATENT ASSIGNEE(S): Cetus Corporation, Emeryville, CA, United States (U.S. corporation)
NUMBER DATE
PATENT INFORMATION: US 4748234 880531
APPLICATION INFO.: US 86-843997 860325 (6)
RELATED APPL. INFO.: Continuation-in-part of Ser. No. US 85-749951, filed on 26 Jun 1985, now abandoned
DOCUMENT TYPE: Utility
PRIMARY EXAMINER: Kight, John
ASSISTANT EXAMINER: Draper, Garnetta D.
LEGAL REPRESENTATIVE: Halluin, Albert P.; Lauder, Leona L.; McLaughlin, Jane R.
NUMBER OF CLAIMS: 46
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 6 Drawing Figure(s); 6 Drawing Page(s)
LINE COUNT: 1655
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A refractile material containing a heterologous protein is recovered from a host microorganism cell culture transformed to produce the protein. One recovery process involves disrupting the cell wall and membrane of the host cell, removing greater than 99% by weight of the salts from the disruptate, redispersing the desalted disruptate, adding a material to the disruptate to create a density or viscosity gradient in the liquid within the disruptate, and separating the refractile material from the cellular debris by high-speed centrifugation. Another version of such a recovery process comprises the further steps of solubilizing the refractile material under reducing conditions, organically extracting the solubilized refractile material, and isolating said refractile material from the extractant.

Preferably the protein is recombinant IL-2 or IFN-beta, and the salt removal step is carried out by diafiltration.

L25 ANSWER 71 OF 88 USPATEFULL
ACCESSION NUMBER: 88-31125 USPATEFULL
TITLE: sup.59 Valine insulin-like growth factor I and process for production thereof
INVENTOR(S): Ueda, Ikuo, Toyonaka, Japan
Niwa, Mineo, Mukoo, Japan
Saito, Yoshimasa, Osaka, Japan
Sato, Susumu, Osaka, Japan
Ono, Hiroki, Osaka, Japan
Kikaguchi, Tadashi, Amagasaki, Japan
PATENT ASSIGNEE(S): Fujisawa Pharmaceutical Co., Ltd., Osaka, Japan (non-U.S. corporation)
NUMBER DATE
PATENT INFORMATION: US 4745179 880517
APPLICATION INFO.: US 85-713828 850320 (6)

PRIORITY INFORMATION: GB 84-8473 840402
GB 84-13989 840601
GB 84-24157 840925
DOCUMENT TYPE: Utility
PRIMARY EXAMINER: Kight, John
ASSISTANT EXAMINER: Chan, Christina
LEGAL REPRESENTATIVE: Oblon, Fisher, Spivak, McClelland & Maier
NUMBER OF CLAIMS: 3
EXEMPLARY CLAIM: 1
LINE COUNT: 1480
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to a sup.59 Valine insulin-like growth factor I (sup.59 Val-IGF-I), to a sup.59 Val-IGF-I fused to a protective peptide, to a gene coding for sup.59 Val-IGF-I, to a gene coding for fused sup.59 Val-IGF-I, to a plasmid containing the sup.59 Val-IGF-I gene, to a host organism containing a plasmid containing the sup.59 Val-IGF-I gene, to a host organism containing a plasmid containing the fused sup.59 Val-IGF-I gene, and to processes for the production of these.

L25 ANSWER 72 OF 88 USPATEFULL

ACCESSION NUMBER: 88-17913 USPATEFULL
TITLE: Active site modified protease .alpha.-1-antitrypsin inhibitors
INVENTOR(S): Barr, Philip J., Orinda, CA, United States
Hallewell, Robert A., San Francisco, CA, United States
Rosenberg, Steven, Oakland, CA, United States
PATENT ASSIGNEE(S): Chiron Corporation, Emeryville, CA, United States (U.S. corporation)
NUMBER DATE
PATENT INFORMATION: US 4732973 880322
APPLICATION INFO.: US 84-620408 840614 (6)
DOCUMENT TYPE: Utility
PRIMARY EXAMINER: Phillips, Delbert R.
LEGAL REPRESENTATIVE: Ciotti & Murashige, Irell & Manella
NUMBER OF CLAIMS: 4
EXEMPLARY CLAIM: 1
LINE COUNT: 691
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Proteinaceous composition are provided which inhibit naturally occurring serine proteases. Particularly, an amino acid sequence analogous to human .alpha.-sub.1-antitrypsin is modified at the active site while maintaining protease inhibition. The methionine at the active site is substituted with an oxidatively stable amino acid, while other amino acids may also be changed, added or deleted, particularly at the termini.

The yeast strains AB103.1 (pCUPH05AT(Val) and AB110 (pCUP1GAPAT(Val) were deposited at the A.T.C.C. on June 18, 1984 and given Accession Nos. 20711 and 20712, respectively.

L25 ANSWER 73 OF 88 MEDLINE MEDLINE DUPLICATE 2
ACCESSION NUMBER: 88149037
DOCUMENT NUMBER: 88149037
TITLE: Transformation of Clostridium perfringens L forms with shuttle plasmid DNA

AUTHOR: Mahony D E; Mader J A; Dubel J R
CORPORATE SOURCE: Department of Microbiology, Faculty of Medicine, Dalhousie University, Halifax, Nova Scotia, Canada.
SOURCE: APPLIED AND ENVIRONMENTAL MICROBIOLOGY, (1988 Jan) 54
(1) 264-7.

Journal code: 6K6 ISSN: 0099-2240.
PUB. COUNTRY: United States
Journal: Article: (JOURNAL ARTICLE)

LANGUAGE: English
FILE SEGMENT: Priority Journals
ENTRY MONTH: 198806

AB L-form (L-phase) cultures of Clostridium perfringens were tested for their transformability with plasmid DNA. Three L-form strains were transformable, but one, strain ***1*** - ***13***, was superior to the others. This strain was easily and reproducibly transformed with previously described shuttle vectors*** which were derived from either C. perfringens or Escherichia coli. Strain ***1*** - ***13*** was transformable by a variety of methods, and a new micromethod worked well under both aerobic and anaerobic conditions. The maximal number of transformants was attained after strain ***1*** - ***13*** was exposed for 4 h to the transforming DNA and polyethylene glycol. Viable counts determined in tubes of semisolid brain heart infusion medium containing 10% sucrose, with or without 2 micrograms of tetracycline per ml, showed a transformation rate of 3.9 X 10(-5) (transformants per viable cells).

L25 ANSWER 74 OF 88 USPATEFULL
ACCESSION NUMBER: 87-47495 USPATEFULL
TITLE: Process and system for programming robot movements

INVENTOR(S): Artber, Klaus, Moorenweis, Germany, Federal Republic of
PATENT ASSIGNEE(S): Deutsche Forschungs- und Versuchsanstalt fur Luft- und Raumfahrt e.V., Cologne, Germany, Federal Republic of (non-U.S. corporation)

NUMBER DATE

S(b),e1,e2) and overflow (OF) and underflow (UF) criteria are delivered. Parallel, serial and word organized summing units (ALU) and accumulator registers (ACR) are usable and in another embodiment, the multiplication of the factors (pi, q) is performed using a table of multiples store.

L25 ANSWER 78 OF 88 USPATFULL
ACCESSION NUMBER: 86:57264 USPATFULL
TITLE: Coil construction for electromagnetic treatment of an afflicted body region
INVENTOR(S): Moore, John S., Upper Montclair, NJ, United States
PATENT ASSIGNEE(S): Electro-Biology, Inc., Fairfield, NJ, United States (U.S. corporation)

NUMBER DATE
PATENT INFORMATION: US 4616629 861014
APPLICATION INFO.: US 85-737433 850524 (6)
DOCUMENT TYPE: Utility
PRIMARY EXAMINER: Kamm, William E.
LEGAL REPRESENTATIVE: Hoppgood, Calimafide, Kallil, Blaustein & Judlowe
NUMBER OF CLAIMS: 8
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 12 Drawing Figure(s); 2 Drawing Page(s)
LINE COUNT: 274
AB The invention contemplates a single-coil configuration adapted for embedment in an orthopedic cast, for use in applying electromagnetic signals for osteogenic therapy. An otherwise flat circular multiple-turn coil is so permanently deformed as to establish a first generally U-shaped projection of the coil in a first viewing aspect which is normal to the coil axis, the deformation being further such as to establish a second generally U-shaped projection of the coil in a second viewing aspect which is normal to the coil axis, said viewing aspects being orthogonally related. The depth of the deformation is common to each of the U-shapes and is approximately one fourth of the combined span of the two U-shapes.

L25 ANSWER 79 OF 88 USPATFULL
ACCESSION NUMBER: 86:8274 USPATFULL
TITLE: Man machine interface
INVENTOR(S): Allen, Bruce S., Willow St., East Kingston, NH, United States 03827
Dunaivey, Michael R., 276 Harris Ave., Needham, MA, United States 02192
King, Bruce A., R.F.D. 2, Bolton, MA, United States 01740
DuPrie, Harold J., 57 High St., Apt. 1B, Andover, MA, United States 01810
Hudhall, Richard E., 15 Juniper La., Nashua, NH, United States 03063
Lapidus, Stanley N., 44 Elk Dr., Bedford, NH, United States 03102
Gilbert, Daniel R., 103 Horseshoe Rd., Dracut, MA, United States 01826
Carlson, Anne M., 31 Avon St., Wakefield, MA, United States 01880
Thakrar, Kiran, 13 Tiffany Rd., Apt. 7 King's Cl., Salem, NH, United States 03079
Doig, Robert C., 9 Lancelot Ct., Apt. 12, Salem, NH, United States 03079
Kinner, Brian S., 66 John Carver Rd., Reading, MA, United States 01867
Sirois, Andrew F., 20 Easton St., Lawrence, MA, United States 01843
Poirer, Bruce A., 5 Belgreen Ct., Bradford, MA, United States 01830
Hunt, Philip G., 3 Silvestri Cir., Apt. 17, Derry, NH, United States 03038
Dziesanowski, Joseph J., 59 Strahmore Rd., Brighton, MA, United States 02146
Bromberg, Michael A., 120 Hampshire Dr., Nashua, NH, United States 03063
Brown, Michael, 1 Lancelot Ct., Apt. #16, Salem, NH, United States 03079
Friedel, Seymour A., Bean Rd., Merrimack, NH,

volulus, and other filariae, in Simulium sandcipauli s.l. and S. yahense in a rain-forest area of Liberia. Garms R
Tropenkrankheiten, Hamburg, Department of Entomology.
SOURCE: TROPICAL MEDICINE AND PARASITOLOGY, (1987 Sep) 38 (3)
Journal code: TRP ISSN: 0177-2392.
PUB. COUNTRY: GERMANY, WEST: Germany, Federal Republic of
Journal: Article; (JOURNAL ARTICLE)
LANGUAGE: English
FILE SEGMENT: Priority Journals
ENTRY MONTH: 198805
AB Simulium sandcipauli s.l. and S. yahense are common and widespread in the rain-forest zone of Liberia, but differ with regard to their biting densities and contribution to the transmission of Onchocerca volvulus. Although, in a study area on the St. Pauli River, S. sandcipauli s.l. (presumably S. soursense in the sense of Post) was the predominant ma-biting species (74.3% of 30 855 females examined), S. yahense was shown to be the important ***vector***. While 1000 biting females of S. yahense carried 96 3rd stage larvae indistinguishable from O. volvulus, only 14 were found per 1000 females of S. sandcipauli s.l. Of the perous females (3135 S. sandcipauli s.l./1621 S. yahense) 23.939.9% harboured 1st and/or 2nd stage filarial larvae and 1.99.4% 3rd stage larvae of O. volvulus. Animal filariae of unknown origin, indicative of zoophily, were very common in S. sandcipauli s. ***i*** (***13***.8%) but practically absent from S. yahense (0.5%). In spite of its poorer vectorial performance S. sandcipauli s.l. cannot be neglected as a ***vector*** because it may occur in high biting densities and contribute considerably to the transmission, in particular in the vicinity of the St. Paul River. The interplay of two ***vector*** species, which develop in different types of water-courses explains the overall high endemicity of onchocerciasis in the study area.

L25 ANSWER 77 OF 88 USPATFULL
ACCESSION NUMBER: 86:63810 USPATFULL
TITLE: Circuitry for generating scalar products and sums of floating point numbers with maximum accuracy
INVENTOR(S): Kulisch, Ulrich, Im Eichbaumle 37, 7500 Karlsruhe, Germany, Federal Republic of

NUMBER DATE
PATENT INFORMATION: US 4622650 861111
APPLICATION INFO.: US 85-764517 850809 (6)
RELATED APPL. INFO.: Continuation of Ser. No. US 82-438561, filed on 2 Nov 1982, now abandoned

NUMBER DATE
PRIORITY INFORMATION: DE 81-3144015811105
DOCUMENT TYPE: Utility
PRIMARY EXAMINER: Thomas, James D.
ASSISTANT EXAMINER: Shaw, Dale M.
LEGAL REPRESENTATIVE: Sprung Horn Kramer & Woods
NUMBER OF CLAIMS: 12
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 16 Drawing Figure(s); 9 Drawing Page(s)
LINE COUNT: 1352
AB Circuitry for generating scalar products and sums of floating point numbers with maximum accuracy and circuitry and a method for electronic computers by which scalar products of floating point numbers of the type pi, qi, ES(b,i,e1,e2) are summed with full precision in a fixed point representation by means of a summing unit (ALU) and one or more accumulator registers (ARC1, ARC2) with cells (Ai, j) for storing of codes of a base b having a length (2i+ 2 e1+ 2e2) for fixed point representation and certain overflow positions. By control means (SHR, E, Contr) the mantissas of products are delivered depending on the value of the respective exponents into the summing unit (ALU). By control means (RO, Control), rounding operations (circle, . . . ,gradient, increment) demanded by the higher level computer are performed, and a rounded floating point number (quadrature, c, epsilon,

patent information: US 4677568 870630
application info.: US 85-731831 850508 (6)
number date
priority information: DE 84-3417668840514
document type: Utility
primary examiner: Ruggiero, Joseph
legal representative: Collard, Roe & Galgano
number of claims: 2
exemplary claim: 1
number of drawings: 4 Drawing Figure(s); 2 Drawing Page(s)
line count: 386
ab There is provided a process and system for the memory-saving programming of a robot wherein a reference course is recorded first in the form of samples, which are then stored. For reducing the storage space, the recorded and stored samples are transformed into a Fourier matrix. sub 0 C by means of a Fourier analysis. Said matrix is then filed in a memory. From this Fourier matrix. sub 0 C, it is possible to derive Fourier matrices for courses with the same configuration, but with any desired position and orientation solely by a linear transformation of the coordinates in the form of a Fourier matrix. sub 1 C. With the help of the dynamical model of the robot used, the derived Fourier matrix. sub 1 C can be modified with adjustment to the desired speed, so as to compensate for the dynamical errors in the motional actions of the robot. For creating the course coordinates which the robot can then follow when performing its movements, the modified Fourier matrix C is subjected to a final Fourier synthesis with predetermination of an arc length (s) conforming to the desired course speed (v). In this way, not only is memory-saving programming achieved, but the dynamics of the robot can be compensated for within the spectral range irrespective of speed if the dynamics of the robot used can be represented by a transmission function.

L25 ANSWER 75 OF 88 USPATFULL
ACCESSION NUMBER: 87:24817 USPATFULL
TITLE: Superconducting filter coils for high homogeneity magnetic field
INVENTOR(S): Keim, Thomas A., Clifton Park, NY, United States
Mayegovz, Isak D., Rockville, MD, United States
PATENT ASSIGNEE(S): General Electric Company, Schenectady, NY, United States (U.S. corporation)

NUMBER DATE
PATENT INFORMATION: US 4656447 870407
APPLICATION INFO.: US 84-625076 840627 (6)
DOCUMENT TYPE: Utility
PRIMARY EXAMINER: Harris, George
LEGAL REPRESENTATIVE: Cutter, Lawrence D.; Davis, James C.; Snyder, Marvin
NUMBER OF CLAIMS: 16
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 5 Drawing Figure(s); 2 Drawing Page(s)
LINE COUNT: 725
AB When a closed circuit is formed by joining superconducting wires with superconducting joints, the current in that circuit adjusts itself as required to maintain whatever total flux linkage the circuit had at the instant superconductivity was achieved. In particular, a closed circuit which first becomes superconducting under conditions of zero net flux linkage maintains zero net flux linkage as long as the circuit remains superconducting. By appropriately configuring a set of short-circuited superconducting coils, a field inside a volume described by the coils is kept substantially more uniform than it would be if the same volume were magnetized by the same source in the absence of the short-circuited coils. This property is used to insure that the volume within the coils exhibits improved magnetic field homogeneity.

L25 ANSWER 76 OF 88 MEDLINE
ACCESSION NUMBER: 88126759 MEDLINE
DOCUMENT NUMBER: 88126759
TITLE: Infection rates and parasitic loads of Onchocerca

United States 03054

NUMBER DATE

PATENT INFORMATION: US 4570217 860211
APPLICATION INFO.: US 83-479191 830328 (6)
RELATED APPL. INFO.: Continuation-in-part of Ser. No. US 82-363404,
filed on 29 Mar 1982, now abandoned

DOCUMENT TYPE: Utility

PRIMARY EXAMINER: Ruggiero, Joseph
LEGAL REPRESENTATIVE: Ware, Robert H.; Stoltz, Melvin I.; Fressola,
Alfred A.

NUMBER OF CLAIMS: 43

EXEMPLARY CLAIM: 35

NUMBER OF DRAWINGS: 119 Drawing Figure(s); 105 Drawing Page(s)
LINE COUNT: 17226

AB A man-machine interface for use with industrial processes is disclosed having the capability of design and configuration of the interrelationship of components forming an overall industrial process. The man-machine interface further provides operator use, including process monitoring and control, as well as alarm annunciation. Most user interaction with the man-machine interface is performed through a color CRT monitor having a touch panel on the surface of the CRT screen. Operator use may be limited to touch panel interaction while configurator and designer use normally further includes use of a keyboard.

The man-machine interface utilizes distributed processing and incorporates a high level graphic language. The graphic language facilitates real time graphic display implementation through use of dynamic and static variables. Variable types are dynamically associated with variable values so that variables can undergo type changes without detrimental effect. Video bit bangers and shifters further enhance the versatility and ease of implementing rapid modifications of graphic displays. The man-machine interface further incorporates a new bus structure including a new bus arbitration technique, a unidirectional memory boundary protection mechanism, an improved interrupt system, and an improved watchdog timer circuit.

L25 ANSWER 80 OF 88 USPATFULL

ACCESSION NUMBER: 85:59807 USPATFULL

TITLE: Voltage stabilizing transformer

INVENTOR(S): Spain

Pacho, Angel R., Paseo de la Habana 40, Madrid,

Spain

NUMBER DATE

PATENT INFORMATION: US 4546306 851008

APPLICATION INFO.: US 80-161448 800620 (6)

NUMBER DATE

PRIORITY INFORMATION: ES 79-482374 790710

DOCUMENT TYPE: Utility

PRIMARY EXAMINER: Beha, Jr., William H.

LEGAL REPRESENTATIVE: Pennie & Edmonds

NUMBER OF CLAIMS: 6

EXEMPLARY CLAIM: 1

NUMBER OF DRAWINGS: 13 Drawing Figure(s); 8 Drawing Page(s)
LINE COUNT: 367

AB An improved magnetic core transformer for use as a voltage stabilizer in gas discharge lamps and tube circuits. The transformer has a magnetic stack length greater than either side of the magnetic cross-section and a floating shunt assembly constructed from stacks of magnetic strips. The stack length is optimized technically and as a function of the cost of iron and copper utilized in the transformer and when conformed with an optimum shunt a greater leakage inductance variation is achieved.

L25 ANSWER 81 OF 88 BIOSIS COPYRIGHT 1988 BIOSIS

ACCESSION NUMBER: 85:314948 BIOSIS

DOCUMENT NUMBER: BA79:94944

TITLE: CLONING AND NUCLEOTIDE SEQUENCING OF THE GENES

FOR

RIBOSOMAL PROTEINS S-9 RPS-1 AND ***L***

13 RPL-M OF ESCHERICHIA-COLI

AUTHOR(S): ISONO S.; THAMM S.; KITAKAWA M.; ISONO K
CORPORATE SOURCE: DEP. OF BIOLOGY, FACULTY OF SCIENCE,
KOBE

SOURCE: UNIVERSITY, ROKKODAI, KOBE 657 JAPAN,

MOL GEN GENET 198 (2). 1985. 279-282. CODEN:

MGGEAE ISSN: 0026-8925

LANGUAGE: English

AB The genes for the ribosomal proteins S9 (rpsl) and L13 (rplM) of E. coli were cloned into a lambda, phage ***vector*** learned L47.1. The 2 genes were identified by infecting UV-light irradiated cells with the resultant phages and analyzing the protein products by 2-dimensional gel electrophoresis. Suitable DNA fragments of the isolate were cloned subsequently into M13 phage ***vectors*** and their nucleotide sequence was determined by the dideoxy method. The 2 genes form a transcriptional unit, the rplM gene being promoter-proximal. There is a typical signal sequence for transcriptional termination after the rpsl gene. The codon usage pattern in the 2 genes is similar to other ribosomal protein genes of E. coli.

L25 ANSWER 82 OF 88 USPATFULL

ACCESSION NUMBER: 79:52469 USPATFULL

TITLE: Programmable calculator having string variable

editing capability

INVENTOR(S): Walden, Jack M., Loveland, CO, United States

Eads, William D., Loveland, CO, United States

Cozzens, Ray J., Loveland, CO, United States

Bigwell, John L., Loveland, CO, United States

Jewett, Robert A., Loveland, CO, United States

Wilson, Martin S., Loveland, CO, United States

Griffin, Daniel J., Loveland, CO, United States

Kuski, Robert E., Loveland, CO, United States

Schulte, Louis T., Loveland, CO, United States

PATENT ASSIGNEE(S): Hewlett-Packard Company, Palo Alto, CA, United States (U.S. corporation)

NUMBER DATE

PATENT INFORMATION: US 4180854 791225

APPLICATION INFO.: US 77-837771 770929 (5)

DOCUMENT TYPE: Utility

PRIMARY EXAMINER: Springborn, Harvey E.

LEGAL REPRESENTATIVE: Hein, William E.

NUMBER OF CLAIMS: 2

EXEMPLARY CLAIM: 1

NUMBER OF DRAWINGS: 470 Drawing Figure(s); 454 Drawing Page(s)
LINE COUNT: 12193

AB A programmable calculator employs modular read-write and read-only memories separately expandable to provide additional program and data storage functions within the calculator oriented toward the environment of the user and two sixteen bit LSI NMOS central processing units. One of the central processing units (LPU) is employed to perform language syntaxing, arithmetic, and general supervision of program execution. The second central processing unit (PPU) is employed for managing input/output operations. Communication between the two central processing units is accomplished by an arrangement through which the two central processing units share a common portion of memory. The calculator also includes a keyboard having a full complement of alphanumeric keys for entering programs and data into the calculator and for otherwise allowing the user to control operation of the calculator. The calculator further includes a CRT that can be operated in either an alphanumeric mode or a graphics mode, two magnetic tape transports that permit the user to store information into and to retrieve information from the user portion of the calculator read-write memory, and an 80-column thermal printer utilizing a print head that includes 560 thermal print resistors arranged in a single horizontal row.

L25 ANSWER 83 OF 88 USPATFULL

ACCESSION NUMBER: 78:29700 USPATFULL

TITLE: Slope feature detection system

INVENTOR(S): Bryan, Larry Wayne, Arlington, TX, United States

Himmel, David Paul, Dallas, TX, United States

Woster, Jr., George William, Dallas, TX, United States

States

PATENT ASSIGNEE(S): Recognition Equipment Incorporated, Dallas, TX,
United States (U.S. corporation)

NUMBER DATE

PATENT INFORMATION: US 4093941 780606

APPLICATION INFO.: US 78-749200 761209 (5)

DOCUMENT TYPE: Utility

PRIMARY EXAMINER: Boudreau, Leo H.

LEGAL REPRESENTATIVE: Vandigrieff, John E.; DeMond, Thomas W.

NUMBER OF CLAIMS: 14

EXEMPLARY CLAIM: 1

NUMBER OF DRAWINGS: 120 Drawing Figure(s); 45 Drawing Page(s)
LINE COUNT: 5886

AB A character feature detection system is provided for reliably reading non-touching hand printed and multi-font machine printed alphanumeric characters. An information field is scanned by a sensor array, and the sensor responses are digitized to form a binary character image. The image is thinned in one-cell layers as the image boundary and loops internal to the image are traced from boundary point to boundary point. A transition from one boundary point to another is defined by one of eight equally divergent ***vectors*** which are indicative of the local slope of a boundary between connected points. The sequence of ***vectors*** and their x-ray locations are recorded, and boundary slopes are indicated by a running average of four ***vectors*** representative of cell to cell transitions. Character features are set including circumference counts, maximum and minimum image boundary limits, inflection points and loops. The image boundary is thinned to a one-cell stroke width, and character stops and nodes are located. Each stop arm is traced to identify valid stops, and the slope of each valid stop is determined to complete the feature set. The feature set is formatted and stored in a memory unit for character identification.

L25 ANSWER 84 OF 88 USPATFULL

ACCESSION NUMBER: 78:2645 USPATFULL

TITLE: Information storage and retrieval system

INVENTOR(S): Dechant, Thomas Edward, Burton, OH, United States

Glaser, Edward Lewis, Cleveland Heights, OH,

Pitt, Paul Eldred, Malibu, CA, United States

Way, III, Frederick, Cleveland Heights, OH,

United States

PATENT ASSIGNEE(S): Systems Development Corporation, Santa Monica,

CA, United States (U.S. corporation)

NUMBER DATE

PATENT INFORMATION: US 4068298 780110

APPLICATION INFO.: US 75-637511 751203 (5)

DOCUMENT TYPE: Utility

PRIMARY EXAMINER: Zache, Raulife B.

LEGAL REPRESENTATIVE: Christie, Parker & Hale

NUMBER OF CLAIMS: 393

EXEMPLARY CLAIM: 1

NUMBER OF DRAWINGS: 160 Drawing Figure(s); 144 Drawing Page(s)
LINE COUNT: 28817

AB Data processing information storage and retrieval system having a memory. A number of modules are interconnected with the memory. Encode and decode modules operate in conjunction with the memory for compacting and expanding data. A revolve module in association with a delta module and a memory enable coded signals to be transferred into a number of unique but equivalent and related signals. A seed module enables the shortest of the equivalent signals to be located. A change module enables any one of the equivalent signals to be updated. An output module causes an equivalent signal to be converted back to the original signal representation. Pipe and brightness modules perform a discrimination function on stored information. The data processor includes programs which by unique means and methods structure and retrieve data from the data base. The retrieval may be based on an indexed match between events and entries of a request and the structured data base.

L25 ANSWER 85 OF 88 USPATFULL
ACCESSION NUMBER: 76:5143 USPATFULL
TITLE: Pulse generator for television for generating at least one pulse series having pulses of different duration and repetition period
INVENTOR(S): Kaptein, Eugenius Martinus, Eindhoven, Netherlands
PATENT ASSIGNEE(S): U.S. Philips Corporation, New York, NY, United States (U.S. corporation)

NUMBER DATE
PRIORITY INFORMATION: NL 70-3669 700314
NL 70-7169 700516
NL 70-14894 701010
DOCUMENT TYPE: Utility
PRIMARY EXAMINER: Griffin, Robert L.
ASSISTANT EXAMINER: Stellar, George G.
LEGAL REPRESENTATIVE: Trifan, Frank R.; Steckler, Henry I.
NUMBER OF CLAIMS: 21
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 27 Drawing Figure(s); 22 Drawing Page(s)
LINE COUNT: 2589
AB A TV pulse generator for generating television synchronizing and blanking signals and a chrominance subcarrier gating signal. The switchable generator is formed with a clock pulse generator having a frequency which, for the CCIR and the RTMA standards, is 80 times the line frequency. In addition to auxiliary pulses of field frequency, circuits of frequency dividers formed with JK flip-flops and pulse generators also generate auxiliary pulses of line frequency and of double the line frequency. The edges in the synchronizing and blanking signals and in the PAL or NTSC chrominance subcarrier gating signal generated by signal generators are accurately determined by trigger signals derived from the clock pulses.

L25 ANSWER 86 OF 88 USPATFULL
ACCESSION NUMBER: 75:13464 USPATFULL
TITLE: COMPOSITE THIN FILM OPTICAL DEVICE
INVENTOR(S): Kaminow, Ivan Paul, New Shrewbury, NJ, United States
Kogelnik, Herwig Werner, Fair Haven, NJ, United States
PATENT ASSIGNEE(S): Bell Telephone Laboratories, Incorporated, Murray Hill, Berkeley Heights, NJ, United States (U.S. corporation)

NUMBER DATE
PRIORITY INFORMATION: NL 70-3669 700314
NL 70-7169 700516
NL 70-14894 701010
DOCUMENT TYPE: Utility
PRIMARY EXAMINER: Griffin, Robert L.
ASSISTANT EXAMINER: Stellar, George G.
LEGAL REPRESENTATIVE: Trifan, Frank R.; Steckler, Henry I.
NUMBER OF CLAIMS: 21
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 27 Drawing Figure(s); 22 Drawing Page(s)
LINE COUNT: 2589
AB A TV pulse generator for generating television synchronizing and blanking signals and a chrominance subcarrier gating signal. The switchable generator is formed with a clock pulse generator having a frequency which, for the CCIR and the RTMA standards, is 80 times the line frequency. In addition to auxiliary pulses of field frequency, circuits of frequency dividers formed with JK flip-flops and pulse generators also generate auxiliary pulses of line frequency and of double the line frequency. The edges in the synchronizing and blanking signals and in the PAL or NTSC chrominance subcarrier gating signal generated by signal generators are accurately determined by trigger signals derived from the clock pulses.

L25 ANSWER 87 OF 88 USPATFULL
ACCESSION NUMBER: 75:13464 USPATFULL
TITLE: COMPOSITE THIN FILM OPTICAL DEVICE
INVENTOR(S): Kaminow, Ivan Paul, New Shrewbury, NJ, United States
Kogelnik, Herwig Werner, Fair Haven, NJ, United States
PATENT ASSIGNEE(S): Bell Telephone Laboratories, Incorporated, Murray Hill, Berkeley Heights, NJ, United States (U.S. corporation)

NUMBER DATE
PRIORITY INFORMATION: NL 70-3669 700314
NL 70-7169 700516
NL 70-14894 701010
DOCUMENT TYPE: Utility
PRIMARY EXAMINER: Griffin, Robert L.
ASSISTANT EXAMINER: Stellar, George G.
LEGAL REPRESENTATIVE: Trifan, Frank R.; Steckler, Henry I.
NUMBER OF CLAIMS: 21
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 27 Drawing Figure(s); 22 Drawing Page(s)
LINE COUNT: 2589
AB A TV pulse generator for generating television synchronizing and blanking signals and a chrominance subcarrier gating signal. The switchable generator is formed with a clock pulse generator having a frequency which, for the CCIR and the RTMA standards, is 80 times the line frequency. In addition to auxiliary pulses of field frequency, circuits of frequency dividers formed with JK flip-flops and pulse generators also generate auxiliary pulses of line frequency and of double the line frequency. The edges in the synchronizing and blanking signals and in the PAL or NTSC chrominance subcarrier gating signal generated by signal generators are accurately determined by trigger signals derived from the clock pulses.

L25 ANSWER 87 OF 88 USPATFULL

ACCESSION NUMBER: 73:46795 USPATFULL
TITLE: ELECTROMAGNETIC THICKNESS GAUGING USING A TRANSMITTING COIL SHAPED TO PROVIDE A CONSTANT FIELD OVER A RANGE OF MEASURING DISTANCES
INVENTOR(S): Greenwood, Ivan A., Stamford, CT, United States
PATENT ASSIGNEE(S): The Singer Company, Little Falls, NJ, United States (U.S. corporation)

NUMBER DATE
PRIORITY INFORMATION: US 3764897 731009
APPLICATION INFO.: US 71-212899 711228 (5)
DOCUMENT TYPE: Utility
PRIMARY EXAMINER: Corcoran, Robert J.
LEGAL REPRESENTATIVE: S. A. Giarratana et al.
NUMBER OF CLAIMS: 18
NUMBER OF DRAWINGS: 8 Drawing Figure(s); 2 Drawing Page(s)
LINE COUNT: 1005
AB In an electromagnetic thickness gauge a transmitting coil induces eddy currents in a conducting sheet the thickness of which is to be measured. The phase angle of the magnetic field generated by the eddy currents relative to the field generated directly by the transmitting coil provides the measure of thickness. The magnetic field generated by the transmitting coil is shaped so that the phase angle measurement is substantially constant as the distance between the sheet and the transmitting coil changes. This constant phase angle is achieved by designing the coil to produce an electromagnetic field in which the scalar magnetic potential varies as a single exponential over a selected range of distances from the transmitting coil. Two eddy current measurements in which the phase angles are different functions of the thickness and conductivity are taken so that both the thickness and conductivity can be determined from the two measurements by solving simultaneous equations.

L25 ANSWER 88 OF 88 USPATFULL
ACCESSION NUMBER: 73:8257 USPATFULL
TITLE: METHOD AND APPARATUS FOR EVALUATING RAILROAD TRACK STRUCTURE AND CAR PERFORMANCE
INVENTOR(S): Freeman, William H., Port Cartier, Quebec, Canada
Peterson, Leavitt A., Glenshaw, PA, United States
Wandrisco, Joseph M., Lower Burrell, PA, United States
PATENT ASSIGNEE(S): Bessemer and Lake Erie Railway Company, BY SAID
Peterson, United States (U.S. corporation)
Quebec Cartier Mining, BY SAID Freeman, United States (non-U.S. corporation)
United States Steel Corporation, BY SAID Wandrisco, United States (U.S. corporation)

NUMBER DATE
PRIORITY INFORMATION: US 3718040 730227
APPLICATION INFO.: US 71-178131 710907 (5)
DOCUMENT TYPE: Utility
PRIMARY EXAMINER: Woodiel, Donald O.
LEGAL REPRESENTATIVE: Helm, Rea C.
NUMBER OF CLAIMS: 43
NUMBER OF DRAWINGS: 21 Drawing Figure(s); 11 Drawing Page(s)
LINE COUNT: 791
AB Method and apparatus for determining dynamic lateral and vertical wheel-rail forces. Axle bending sensors and axle load cells provide signals to a computer programmed to calculate lateral and vertical wheel-rail forces. These forces are used as the basis for comparing the effects of a variety of car truck design criteria and track conditions. Comparison of forces developed by the same equipment on different runs over the same trackage discloses track condition changes between runs.

L25 ANSWER 89 OF 88 USPATFULL
ACCESSION NUMBER: 73:8257 USPATFULL
TITLE: METHOD AND APPARATUS FOR EVALUATING RAILROAD TRACK STRUCTURE AND CAR PERFORMANCE
INVENTOR(S): Freeman, William H., Port Cartier, Quebec, Canada
Peterson, Leavitt A., Glenshaw, PA, United States
Wandrisco, Joseph M., Lower Burrell, PA, United States
PATENT ASSIGNEE(S): Bessemer and Lake Erie Railway Company, BY SAID
Peterson, United States (U.S. corporation)
Quebec Cartier Mining, BY SAID Freeman, United States (non-U.S. corporation)
United States Steel Corporation, BY SAID Wandrisco, United States (U.S. corporation)

NUMBER DATE
PRIORITY INFORMATION: US 3718040 730227
APPLICATION INFO.: US 71-178131 710907 (5)
DOCUMENT TYPE: Utility
PRIMARY EXAMINER: Woodiel, Donald O.
LEGAL REPRESENTATIVE: Helm, Rea C.
NUMBER OF CLAIMS: 43
NUMBER OF DRAWINGS: 21 Drawing Figure(s); 11 Drawing Page(s)
LINE COUNT: 791
AB Method and apparatus for determining dynamic lateral and vertical wheel-rail forces. Axle bending sensors and axle load cells provide signals to a computer programmed to calculate lateral and vertical wheel-rail forces. These forces are used as the basis for comparing the effects of a variety of car truck design criteria and track conditions. Comparison of forces developed by the same equipment on different runs over the same trackage discloses track condition changes between runs.

=> d his

(FILE 'HOME' ENTERED AT 10:01:40 ON 28 AUG 1998)
SET PLURALS ON

FILE 'MEDLINE, CANCERLIT, SCISEARCH, BIOSIS, WPIDS, USPATFULL'

ENTERED AT 10:02:37 ON 28 AUG 1998
FILE 'MEDLINE, CANCERLIT, SCISEARCH, BIOSIS, EMBASE, WPIDS, USPATFULL' ENTERED AT 10:02:54 ON 28 AUG 1998

L1 1 S 312C2
L2 397502 S T(T)CELL OR T(W)LYMPHOCYTE OR THYMOCYTE
L3 1875287 S RECEPTOR
L4 4810 S CO-STIMULAT?
L5 1185 S L2 AND L3 AND L4
L6 5520103 S PROLIFERAT? OR ACTIVAT? OR DIVID? OR GROWTH
L7 1080 S L5 AND L6
L8 194581 S ANTIGEN(8A)SPECIF? OR ANTIGEN(8A)TARGET?
L9 234 S L7 AND L8
L10 148 DUP REM L9 (88 DUPLICATES REMOVED)
L11 52 S L10 AND ((NUCLEIC(W)ACID OR DNA OR CDNA OR GENE OR POLY
L12 4465 S (L2 AND L6) AND ((NUCLEIC(W)ACID OR DNA OR CDNA OR GE
L13 2656 DUP REM L12 (1809 DUPLICATES REMOVED)
L14 696 S L13 AND EXTRACELL?
L15 53 S L0 AND EXTRACELL?
L16 46 DUP REM L15 (7 DUPLICATES REMOVED)
L17 41 S L11 AND EXTRACELL?
L18 48 S L11 AND (INTRACELL? OR CYTOPLASM?)
L19 44 S L11 AND LABEL?
L20 26 S L11 AND KIT
L21 637 S L13 AND KIT
L22 313 S L21 AND KIT
L23 313 S L21 AND EXTRACELL?
L24 92 S L13 AND VECTOR
L25 88 DUP REM L24 (4 DUPLICATES REMOVED)

=> logoff

ALL L# QUERIES AND ANSWER SETS ARE DELETED AT LOGOFF LOGOFF? (Y)N/HOLD.Y

STN INTERNATIONAL LOGOFF AT 11:28:12 ON 28 AUG 1998